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I	  
Summary 
Epstein-Barr virus is a herpesvirus that efficiently infects B cells. During infection, 
EBV takes advantage of the normal B cell differentiation processes to establish a 
persistent infection within the host. The present study investigates how EBV infection 
modifies and controls the immunogenicity of the infected B cells in order to minimize 
attack by immune cells. 
To understand the effects of EBV infection on B cells, the immunophenotype of EBV-
infected B cells was analyzed through a detailed investigation of the modulation of the 
surface expression of molecules serving as agonistic or antagonistic ligands for 
important receptors on antiviral immune cells. Expression of these ligands was 
analyzed during the early onset of infection and on established lymphoblastoid cell 
lines (LCLs), which stably carry the virus. To identify the specific aspects modulated 
by infection with EBV, these findings were compared to those observed during normal 
B cell activation in the absence of EBV.  
LMP2A is one of the few EBV antigens that can be expressed in three out of the four 
latency types that are part of the life cycle of EBV, and is expressed in most types of 
EBV-associated cancer. Given its frequent expression in EBV-infected B cells, LMP2A 
was identified as a good candidate for a possible mediator of immunoevasive functions 
during latency of EBV. LMP2A immunomodulatory functions were especially 
investigated under the light of CD8+ T cell recognition of infected cells. LMP2A was 
shown to interfere with the recognition of EBV-infected cells by CD8+ T cells of 
different EBV antigen specificities. LMP2A variably modulated the expression of other 
viral antigens and moderately affected the surface expression of MHC class I 
molecules. Moreover, LMP2A altered the surface expression of several 
immunomodulatory molecules. In particular, LMP2A downregulated the surface 
expression of the ligands for the co-activatory receptor NKG2D, which I showed to be 
involved in the recognition of infected cells by EBV-specific CD8+ T cells. 
In addition, the immune response to EBV by γδ T cells was investigated. To this end, 
reactivity to EBV-infected cells of both short-term polyclonal γδ T cell lines and single 
γδ T cell clones was investigated. This led to the identification of a subpopulation of 
these cells, presenting a TCR with a δ1+ chain, showing an EBV-specific reactivity. 
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II	  
One of the EBV-specific δ1+ T cell clones showed an HLA-A2-restricted recognition 
of EBV-infected cells. Interestingly, while LMP2A hampered recognition of infected 
cells by EBV-specific CD8+ T cells, it increased recognition of infected cells by γδ T 
cells. These data suggest that the evolutionary pressure on EBV by the immune system 
specifically prompted the virus to develop immunoevasive strategies against detection 
by CD8+ T cells in the latent phase. Taken together, I have discovered the first example 
of an EBV latent protein that interferes with T cell recognition, have identified γδ T 
cells that are specifically active against EBV-infected cells, and have shown that 
complementary responses by CD8+ and γδ T cells shape EBV immunoevasion.  
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1 Introduction 
1.1 The immune system 
Every day of our lives, we are in contact with microorganisms. With some of them, 
such as the bacterial flora in the gut or bacteria on the skin, we have established 
beneficial interactions. Others instead can be dangerous to humans and cause a variety 
of diseases. Four broad categories of pathogenic microorganisms are recognized: 
viruses, bacteria, fungi and parasites. In order to prevent the development of diseases, 
higher organisms are equipped with a complex network of tissues, organs, cells and 
molecules able to confront these pathogens. Tissues, such as the skin and the mucosae, 
protect the internal environment from the external environment. Organs, such as the 
lymphoid organs, generate cells responsible for the counteraction against pathogens, 
called immune response, and are the regions where this reaction is initiated. Immune 
cells, called lymphocytes, and molecules taking part in the immune response are the 
direct mediators of the immune response and divided into two groups, innate and 
adaptive immunity, according to their mechanism of action and the speed of reactivity 
to a pathogen. 
Innate immunity serves as a first defense line. It occurs rapidly, but it is either 
unspecific or targets only a limited set of conserved microbial structures. Adaptive 
immunity takes more time for its formation and activation, but it is capable of 
eliminating infections more efficiently because of its high specificity and versatility. 
Clonal expansion ensures that immune responses with exactly the specificity required 
to combat the pathogens at hand are selected and amplified from a large pool of 
available specificities. Adaptive immunity can also lead to the development of a 
lifelong protective immunity, called immunological memory. This property of the 
adaptive immune response is of extreme importance because it allows a faster and 
stronger reactivity in case a pathogen is encountered again at later times. To mount a 
proper immune reaction against pathogens, both of these compartments can efficiently 
distinguish between self and nonself, but they differ in how they do it (Murphy 2011). 
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1.2 Innate immunity 
Most of the microorganisms encountered daily are promptly detected and destroyed by 
innate immunity. This line of defense relies on preexisting mechanisms common to all 
individuals. The first barriers against infections are the epithelia and the mucosal 
epithelia. On top of conferring a physical barrier between the internal and the external 
environment, these tissues present numerous mechanical, chemical and microbiological 
properties to protect from infections. For example, epithelial cells are joined together 
by tight junctions and mucosal epithelia are often coated in mucus, preventing the 
adhesion of microorganisms to the surface. Epithelia produce antimicrobial peptides, 
which disrupt the cell membrane of microbes, and on some surfaces, enzymes attacking 
specific features of the bacterial cell wall are released. In addition, the commensal 
microbial flora inhabiting some epithelia competes with pathogens for nutrients and for 
attachment sites on epithelial cells, providing another layer of defense. 
Once pathogens pass through these barriers, they encounter a molecular mechanism of 
defense, called the complement system, and the first cell defense line, the phagocytes. 
Complement is a system of plasma proteins and activation of these proteins leads to the 
generation of protein products binding covalently to the surface of the pathogen that 
can (i) directly induce the lysis of certain pathogens or (ii) be recognized by phagocytic 
cells that eliminate the pathogen. Phagocytic cells, such as granulocytes, macrophages 
and dendritic cells (DCs), lie beneath the epithelial barriers and monitor these tissues 
for invading microorganisms. Phagocytes recognize, engulf and destroy pathogens 
coated with complement proteins through the binding of the activated complement 
components to specific receptors present on the phagocytes’ surface. Receptors for the 
complement proteins or for microbial molecular structures are called pattern 
recognition receptors (PRRs). Activation of phagocytes through these receptors induces 
the secretion of cytokines (chemokines, interleukins and TNF family molecules), which 
(i) recruit other immune cells to the site of infection, (ii) deliver modulatory signals to 
other innate and adaptive immune cells, and (iii) mobilize antigen-presenting cells 
(APCs) that induce the adaptive immune response. Other cells associated to innate 
immunity are natural killer (NK) cells. These cells are cytotoxic lymphocytes involved 
in non-specific viral and tumor immune surveillance. NK cells distinguish between 
healthy and infected or transformed cells by recognizing changes in the expression of 
cell-surface molecules on these cells (Murphy 2011). 
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1.3 Adaptive immunity 
B and T lymphocytes are the major players in the adaptive immune response. These 
cells present highly specific antigen receptors generally referred to as B-cell receptor 
(BCR) and T-cell receptor (TCR). BCRs and TCRs recognize a small part (called 
epitope) of the molecular structure of a pathogen’s complex macromolecule (usually 
referred to as antigen). An adaptive immune response is initiated when APCs take up 
antigens and present them to B and T cells. After this specific encounter, B cells 
differentiate to plasma cells, highly proliferating cells that produce a soluble version of 
the BCR, the antibodies. These molecules bind to the pathogens’ surface, supporting 
the phagocytosis of the pathogens. After antigen encounter, T cells support clearance of 
the infection by coordinating the immune response of other cells or by directly killing 
infected cells. Characteristics of the adaptive immunity common to both B and T cells 
are: (i) production of highly specific lymphocyte antigen receptors by somatic DNA 
recombination, (ii) presentation on the cell surface of these highly specific receptors 
(iii) clonal expansion upon activation, (iv) 
establishment of immunological memory (Murphy 
2011).  
 
1.4 Antigen presentation to T cells 
T cells can only recognize antigens when these are 
presented by highly polymorphic surface glycoproteins 
encoded by genes in the major histocompatibility 
complex (MHC). In the human system, the MHC 
proteins are also called human leukocyte antigens 
(HLAs). Surface MHC molecules associate to small 
peptides derived by degradation of pathogens’ 
macromolecules. MHC molecules are highly unstable 
when peptides are not bound, and T cell recognition of 
antigenic peptides is possible only when these are 
loaded on a MHC molecule because the TCR binds and 
interacts directly with both the peptide and the MHC 
molecule. There are two types of MHC molecules. 
Figure 1.1.  Cartoon showing the 
molecular structure of an αβ  TCR 
and a peptide:MHC-I complex, and 
the  interaction between them. The 
TCR molecule interacts with both the 
peptide and the MHC molecule. 
Thereby, TCR specificity is determined 
by both the antigenic peptide and the 
MHC molecule. Figure modified after 
(Reboul et al. 2012) 
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MHC class I (MHC-I) are expressed virtually by all cells and present peptides that 
originate from antigens located in the cytosol (both self and nonself antigens). MHC 
class II (MHC-II) expression is restricted to thymic epithelial cells and professional 
APCs and presented peptides originate in the vesicular endosomal system.  
MHC-I molecules consist of two polypeptide chains: a polymorphic α chain (heavy 
chain, 44 kDa) encoded by the genes in the MHC, and β2-microglobulin (β2m, light 
chain, 12 kDa) a smaller nonpolymorphic chain not encoded by the MHC. The α chain 
consists of three extracellular α domains (α1-α3), a transmembrane domain and a 
cytosolic tail. The β2m is noncovalently associated to the α3 domain of the α chain. The 
MHC locus is located on chromosome 6 and contains more than 200 genes, many of 
them involved in immune response, while the β2m gene locates to chromosome 15. The 
MHC-I α chains are encoded by HLA-A, -B and –C, highly polymorphic genes, 
referred to as “classical” MHC-class I molecules, and by HLA-E, -F and –G genes, 
which are less polymorphic and constitute the “non-classical” MHC-class I molecules.  
The α1 and the α2 domains form the peptide-binding groove, where the peptide is 
presented for T cell recognition. MHC-I molecules usually bind 8-10 amino acids long 
peptides. Major differences between MHC-I molecules are found in the peptide-binding 
groove. This influences the peptides that the MHC-I molecule will bind, thus 
influencing the recognition by T cells.  
MHC-II molecules consist of two chains, α and β, both anchoring to the plasma 
membrane. They are approximately equal in size (30 kDa) and each chain contains two 
extracellular domains (α1/α2 and β1/β2), a transmembrane domain and a cytosolic tail. 
The α1 and β1 domains of the two chains form the groove accommodating the peptide. 
Genes coding for MHC-class II molecules in humans are called HLA-DR, -DP, and –
DQ. Each MHC-II molecule comprises of a α and β chain, which are encoded by 
separate genes in the HLA-II region that are designated as A and B, respectively (e.g. 
HLA-DQA1, HLA-DQB1). The overall structure of the MHC-II and MHC-I molecules 
is similar, but the binding groove is not capped at the sides in the MHC-II molecules, 
which permits them the binding of longer peptides, 13-25 amino acids long (Germain 
1994).  
Before MHC class I and II molecules reach the cell surface, they are loaded with 
peptides coming from the degradation of pathogens’ antigens or from self antigens. 
Peptides loaded on MHC-I molecules derive from cytosolic degradation performed by 
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the proteasome, a multicatalytic protease, and cytosolic proteases. The peptides are 
transported into the endoplasmatic reticulum (ER) by the transporter associated with 
antigen processing (TAP) (Del Val et al. 2011). Here, they are further processed and 
trimmed by ER aminopeptidases (ERAPs) to produce peptides of the right length to fit 
into the binding groove of the MHC-I molecules (Serwold et al. 2002). MHC-I 
molecules are translocated during their synthesis into the ER, where they are joined 
with the β2 subunit and loaded with the peptide. Peptide binding occurs before the 
MHC-I molecule completes its folding and is coordinated by the peptide-loading 
complex. Highly hydrophobic peptides or peptides generated in the ER or in the Golgi 
compartment reach the MHC-I molecules in a TAP-independent manner (Lautscham et 
al. 2003). Once the peptide:MHC-I complex is formed, it is transported to the cell 
surface, ready for interaction with CD8+ T cells. 
MHC class II molecules bind peptides generated by acidic endosomal compartments. 
Upon synthesis in the ER and before acquiring their ligands, MHC-II molecules are 
associated with the invariant chain (Ii), which binds the peptide groove, preventing the 
binding of peptides. Once MHC-II reaches the endosomal compartment, proteases here 
located release Ii, allowing the loading and binding of other peptides, a reaction 
catalyzed by the chaperone-like molecule HLA-DM. Afterwards, the peptide:MHC-II 
complex is transported to the cell surface for interaction with CD4+ T cells (Murphy 
2011). 
Another class of antigen presenting molecules belongs to the CD1 gene group. CD1 
molecules, called CD1a to CD1e, are specialized in binding glycolipids, and are 
expressed by DCs, monocytes and some thymocytes. These molecules are divided into 
two groups. Group 1, which is lacking in the mouse, contains the human molecules 
CD1a, CD1b, CD1c; Group 2 consists of CD1d, which is present in mice and humans. 
The molecule CD1e functions as a lipid chaperone. Since CD1 molecules can present 
cellular and microbial glycolipids, their probable task is to alert T cells to a 
pathogenically altered lipid repertoire, just as MHC molecules inform T cells about 
abnormal alterations in the protein repertoire of a cell. T cells recognizing Group 1 
CD1 molecules do express neither CD4 nor CD8, and most of these T cells have a 
diverse repertoire of αβ TCRs. The majority of CD1d-restricted T cells are less diverse, 
express a limited set of TCRα chains, and express NK receptors. For this reason they 
have been called invariant NKT (iNKT) cells. Interestingly, CD1 molecules have been 
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found to be ligands for populations from both αβ and γδ T cells (Murphy 2011; Adams 
2014). 
 
1.5 NK cells and NK coreceptors 
Natural killer (NK) cells represent 5-15% of circulating lymphocytes. They are 
phenotypically characterized by lack of CD3, a component of the T cell receptor 
complex that is present in all T cells, and by the presence of CD56 (NCAM) (Cooper et 
al. 2001). They differ from T and B cells in that they do not present a receptor with 
somatic DNA rearrangement, but their function is coordinated by a combination of 
activating and inhibitory receptors specific for conserved molecules. These receptors 
  Inhibitory Receptor Ligand 
KIR family 
2DL1 HLA-C*02, 04, 05, 06 
2DL2/3 HLA-C*01, 03, 07, 08 
2DL5 Unknown 
3DL1 HLA-A/B with Bw4 motif 
3DL2 HLA-A*03, 11 
KLR family 
CD94:NKG2A HLA-E 
NKR-P1A LLT1 
LIR/ILT family LILRB1/ILT2/LIR1 HLA-A/B/C 
  Activatory Receptor Ligand 
NCR family 
NKp30 BAT-3 
NKp44 Viral haemagglutinin 
NKp46 Viral haemagglutinin 
KLR family  
CD94:NKG2C HLA-E 
CD94:NKG2E HLA-E 
NKG2D MICA/B, ULBPs 
KIR family 
2DS1 HLA-C*02, 04, 05, 06 
2DS2 HLA-C*01, 03, 07, 08 
3DS1 HLA-A/B with Bw4 motif 
2DS3 Unknown 
2DS4 HLA-C*04 
2DS5 Unknown 
2DL4 HLA-G 
Others 
CD244 (2B4) CD48 
CD16 IgG 
Table 1.1. Inhibitory and activatory receptors on NK cells and their ligands. Modified after 
(Cheent & Khakoo 2009). 
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allow the recognition of “altered” or “missing” self. Upon activation, NK cells mediate 
direct cytotoxicity of the targeted cell. The balance between inhibitory and activatory 
receptors plays a critical role in governing the functions of this cell type. 
Inhibitory NK receptors allow the cell to detect “missing self”. Killer cell 
immunoglobulin-like receptors (KIRs), killer C-type lectin-like receptors (KLRs) and 
the receptor of the leucocyte immunoglobulin-like receptor/immunoglobulin-like 
transcript family (LIR/ILT) form the inhibitory receptor repertoire of NK cells. The 
majority of these receptors detect changes in the surface levels of MHC-I molecules. 
Malignant or virally infected cells often downregulate the surface expression of MHC-
I. The decreased expression of MHC-I releases the inhibitory signal induced by the 
inhibitory receptors, and permits activation of the NK cell.  
Activating receptors mediate the activation of NK cells. Some of them recognize MHC-
I molecules, a viral component (viral haemagglutinin), or the up-regulation of 
immunomodulatory molecules. Activating receptors include molecules from different 
families, KIRs, KLRs, and natural cytotoxicity receptors (NCRs), and unrelated 
receptors, such as the SLAM family member CD244 (2B4) or the antibody-binding Fc 
receptor CD16 (Cheent & Khakoo 2009; Murphy 2011).  
Interestingly, NK cells in the same individual express variable numbers and different 
combinations of KIRs (Valiante et al. 1997). The distribution of KIRs in the NK 
population appears to be stochastically determined, and maintenance of an NK cell’s 
KIR repertoire appears to be guided by the methylation state of the KIR gene loci 
(Chan et al. 2003). 
 
1.6 T lymphocytes 
Immune cells originate in the bone marrow from hematopoietic stem cells. To complete 
their development, the precursors of T cells migrate from the bone marrow to the 
thymus, where they acquire their antigen specificity by recombining their T-cell 
receptor genes. This results in two broad T cell subsets, αβ T cells and γδ T cells, 
distinguished by the type of TCR chain expressed (αβ or γδ TCR). Each type of TCR is 
the result of somatic rearrangement of the genes encoding for the two constituent 
chains, occurring during T cell development in the thymic cortex (Murphy 2011). 
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1.6.1 αβ  T cells 
The majority of circulating T cells express an αβ TCR that has the potential to 
recognize a peptide:MHC complex. Both the α and the β chains of the TCR contain a 
variable amino-terminal region and a constant region, largely encoded by a V and a C 
gene segment, respectively. In between the larger V and C gene segments, smaller gene 
segments and non-templated nucleotides are inserted during TCR recombination. The 
additional segments are a J (joining) segment for the α chain, and a J and D (diversity) 
segment for the β chain. The TCR chain loci contain sets of several alternative gene 
segments, from which one is chosen during TCR recombination. The sequences of 
alternative V and J segments show large differences, and thus the choice of segments 
has a large impact on the specificity of the resulting TCR. The TCRα locus consists of 
70-80 Vα gene segments, 61 Jα gene segments and a single Cα gene. The TCRβ locus 
consists of 52 Vβ gene segments and two separate clusters, each containing a single Dβ 
gene segment together with 6 or 7 Jβ gene segments and a single Cβ gene. The V gene 
segments encode for the complementary-determining region (CDR) 1 and 2 of each 
chain, while the junctions between the V(D)J form the CDR3. The highly variable 
CDR3 domains of the two chains form the center of the antigen-binding site of the T 
cell receptor (Figure 1.2). 
Once the TCR is engaged in the recognition of the peptide-MHC complex, the complex 
Figure 1.2. Cartoon showing V(D)J gene recombination. During T cell development, gene 
rearrangement leads to the combination of randomly selected V, (D), and J segments. The junctions 
between the different segments can be further modified by deletion and insertion of nucleotides, resulting 
in the creation of the hypervariable region CDR3, which determines the antigen-specific recognition of 
the T cells. Figure modified after (Bonarius et al. 2006) 
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of the cluster of differentiation 3 (CD3) mediates transmission of the signal. The CD3 
complex is closely associated to the TCR and is formed of one CD3γ, one CD3δ and 
two CD3ε chains and the homodimeric ζ chain. These chains carry immune-receptor 
tyrosine-based activation motifs (ITAMs). Each ITAM contains two tyrosine residues 
that, once phosphorylated, function as docking sites for other signaling molecules 
leading as a final result to T cell activation. The CD3 complex does not participate in 
the recognition and in the binding of the antigen. 
After maturation, naive T cells leave the thymus, enter the blood and lymphatic streams 
and regularly pass secondary lymphoid organs such as lymph nodes or the spleen. In 
lymphoid organs, they can make numerous contacts with DCs to screen the 
peptide:MHC complexes presented by these cells. By sampling the DCs, T cells have a 
high probability of encountering antigens derived from pathogens present in whatever 
location in the body. The activatory signals induced by the engagement of the TCR 
with the peptide:MHC complex is referred to as signal 1. Full activation of naive T 
cells needs additional stimulatory signals mediated by the interaction of coreceptors 
with their ligand counterparts on the APCs (signal 2) and by cytokines controlling the 
differentiation of the T cells (signal 3). Activation, proliferation (clonal expansion) and 
differentiation of a naive T cell after antigen recognition is called priming.  
Mature αβ T cells can be further distinguished by the presence of either the CD8 or the 
CD4 coreceptors. These molecules recognize and bind the nonpolymorphic domains of 
the MHC-I (α3 domain) or of the MHC-II (β2 domain) molecules respectively, which 
increases the affinity of antigen recognition by T cell. Therefore, CD8+ T cells 
recognize antigens coming from the cytoplasm and presented on MHC-I molecules, 
while CD4+ T cells recognize antigens coming from the cellular vesicles and presented 
by MHC-II. Most CD8+ T cells differentiate to cytotoxic lymphocytes (CTLs), which 
kill their target cells. In contrast to CD8+ T cells, CD4+ T cells can differentiate into 
several functional classes: TH1, TH2, TH17, regulatory T cells (Treg) and T follicular 
helper cell (TFH). Differentiation into the different subsets of CD4+ T cells is mediated 
by different cytokines produced by the priming APCs. TH1 cells, for which the 
signature cytokine is IFN-γ, are important for activation of macrophages to destroy 
phagocyted bacteria, for induction of cytotoxic T cell proliferation, and for inducing B 
cells to produce IgG or IgA antibodies. Some TH1 cells can directly kill virus-infected 
cells in the manner of CD8+ T cells, as shown in the EBV system (Adhikary et al. 
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2006). TH2 cells, producing IL-4, IL-5, IL-10 and IL-13, promote B cells to produce 
antibodies with isotypes including IgE, and direct the immune response toward an anti-
parasitic or allergic type of immunity. TH17 release IL-17, IL-21 and IL-22 and recruit 
acute inflammatory cells to the site of infection. Treg produce inhibitory molecules such 
as IL-10 and TGF-β, suppressing immune function. These cells are important to 
prevent excessive reactions and to maintain tolerance to self-antigens. TFH cells 
produce IL-4 and IL-21 and are specialized in promoting T cell help to B cells. After 
priming, the naive T cells develop to effector and memory T cells of the same 
specificity. At a subsequent encounter with the same antigen, these cells can react and 
expand rapidly, without the need of undergoing the priming step (Palmer & Weaver 
2010; Murphy 2011). 
 
1.6.2 γδ  T cells 
As mentioned, T cells can be divided into two large groups, according to the type of T 
cell receptor (TCR) they express. Classical CD8+ killer and CD4+ helper T cells 
generally carry an αβ TCR. In contrast, γδ T cells usually do not express CD8 or CD4. 
They generally represent between 2 to 10% of lymphocytes in peripheral blood, but can 
be more strongly expanded in the blood in response to infection, and constitute a 
considerable lymphocyte population in epithelial tissues (Vantourout & Hayday 2013). 
These cells are often considered to be the link between innate and adaptive immunity, 
because they present features identified with either type of immune response. There are 
distinct subgroups among γδ T cells that are distinguished by the subclass of γδ TCR 
they express, and such subgroups specifically accumulate in different tissues (Itohara et 
al. 1990). Interestingly, in some tissues γδ T cells are almost monoclonal. This permits 
to have a large number of cells ready to promptly counteract pathogens, without the 
dependence on clonal expansion for an efficient immune response. This feature recalls 
a principle of innate immunity. On the other hand, like αβ T cells, the TCR of γδ T 
cells derives from somatic V(D)J recombination. Compared to the α and β loci, γ and δ 
chains derive from a more limited repertoire of V and J segments (Chien & 
Konigshofer 2007). The TCRδ locus is embedded in the TCRα locus and it contains 
three Dδ gene segments, four Jδ gene segments, and a single Cδ gene segment. The 
δ locus codes for three δ-specific V gene segments but shares five more V segments 
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that can also be part of a TCRα chain. The γ TCR locus has twelve Vγ gene segments, 
and resemble the TCRβ locus in having two C genes, each with its own set of J genes 
(three in one set, two in the second one). Even though the number of available gene 
segments is smaller, the CDR3 region of both γ and δ chains can have a higher degree 
of variation compared to the α and β chains because (i) during rearrangement it can 
incorporate multiple D gene segments, (ii) all D gene segments can be read in all three 
open reading frames, and (iii) N-nucleotides can be inserted into junctions of the J gene 
segments (Chien & Konigshofer 2007).  This leads to a contrast between the limited 
diversity of the CDR1 and CDR2 loops of the γδ TCR, determined only by the small 
choice of possible V gene segments, and the CDR3 that has high potential for diversity 
(Rock et al. 1994). Another interesting feature of the γδ TCRs is that CDR3 regions of 
both γ and δ chains are more variable in length than αβ TCRs. The high variability of 
the CDR3, both in length and in sequence, might reflect the target variability or 
different affinities to the target of γδ T cells.  
 
1.6.2.1 γδ  T cell subsets 
In humans, γδ T cells expressing a δ1 chain are enriched in epithelial tissues, while T 
cells with a δ2 chain are mostly found in peripheral blood and the δ2 chain is usually 
paired to a γ9 chain (γ9δ2 T cells). Cells with the γ9δ2 TCR are known to recognize 
phosphoantigens (Gober et al. 2003), while several antigens have been proposed as 
targets for cells expressing the δ1 chain (Vantourout & Hayday 2013).  
γ9δ2 cells represent the most abundant subpopulation of γδ T cells in peripheral blood. 
These cells were shown to recognize phosphoantigens such as isopentenyl 
pyrophosphate (IPP), an ubiquitous intermediate of isoprenoid and steroid biosynthesis, 
and hydromethyl-but-2-enyl-pyrophosphate (HMBPP), a bacterial metabolite (Morita et 
al. 2007). In mammalian cells, phosphoantigens such as IPP are produced as 
intermediates of the mevalonate pathway, which is essential for the synthesis of 
cholesterol, steroid hormones and other molecules. Most bacteria make use of an 
alternative pathway, the methylerythritol 4-phosphate (MEP) pathway, of which 
HMBPP is an intermediate. Interestingly, γ9δ2 cells can be activated by both IPP and 
HMBPP, but the bacterial counterpart is much more potent (Hintz et al. 2001). In 
human cells, phosphoantigens are quickly turned over. However, during tumor 
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transformation, these molecules can accumulate, allowing the recognition of malignant 
cells by the γ9δ2 T cells (Morita et al. 2007). Recognition of phosphoantigens by γ9δ2 
T cells is dependent on cell-cell contact (Morita et al. 1995). Phosphoantigens need to 
be presented by particular cell types in order to be recognized by γ9δ2 T cells (Allison 
et al. 2001). These data suggest that phosphoantigens need to be presented by an 
antigen-presenting molecule. In particular, γ9δ2 T cell activation was shown to be 
greatly enhanced by monocytes (Eberl & Moser 2009). To date, several proteins have 
been linked to recognition by γ9δ2 T cells: the chaperone GroEL (Fisch et al. 1990), the 
F1-ATPase (Mookerjee-Basu et al. 2010), an aminoacyl-tRNA synthetase (Monkkonen 
et al. 2006) and, most recently and convincingly, butyrophilin 3A1 (Vavassori et al. 
2013).  
T cells with a δ1 cells are less frequent in peripheral blood (between 0.1 and 3% of 
lymphocytes). They are often associated with mucosal surfaces. Various evidence 
suggests that circulating δ1 T cells are different from the ones in epithelia, suggesting a 
correlation between localization, function and phenotype. There are various suggestions 
as to which antigens are recognized by these T cells. The NKG2D ligands MICA and 
MICB have been proposed to be recognized directly by the δ1 TCR (Groh et al. 1998; 
Das et al. 2001). In addition, subpopulations of δ1 T cells were shown to recognize the 
CD1c (Spada et al. 2000) and sulfatide-loaded CD1d molecule (Bai et al. 2012). 
Interestingly, CD1d was also found to be recognized by peripheral δ3+ T cells (Mangan 
et al. 2013). Most likely, the δ1 T cell population is highly heterogeneous, which would 
explain the identification of such various molecules as targets. Possibly, different 
populations might have different targets, different properties and different roles. In 
contrast to γ9δ2 T cells, δ1 T cells appears to be more closely involved in control of 
viral infections, as they were shown to strongly expand after HIV, HCMV and HSV 
infections (Hinz et al. 1994; Boullier et al. 1995; Maccario et al. 1995; Lafarge et al. 
2001; Pitard et al. 2008).  
 
1.6.3 T cell coreceptors 
Specific engagement of the TCR with the peptide:MHC complex activates the T cells. 
However, intensity and quality of antigen recognition may depend on their interaction 
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with costimulatory or coinhibitory receptors. To date, various classes of coreceptors 
have been identified. Here, I will discuss some of those that were relevant for my work.  
The B7 family consists of structurally related cell-surface proteins, and comprises 
stimulatory and inhibitory members. B7 molecules include CD86 (B7.1), ICOS-L (B7-
H2), and PD-L1 (B7-H1). CD86 is a molecule constitutively expressed on APCs at low 
levels, but activation of APCs leads to its upregulation. CD86 can bind to the co-
stimulatory receptor CD28 or to the inhibitory receptor CTLA-4 on T cells, but it was 
shown to be bound by CD28 more effectively (Collins et al. 2002). CD28 is 
constitutively expressed on naive CD8+ and CD4+ T cells, serving as positive 
stimulator of cell growth and cell survival. CTLA-4 is induced on the surface of T cells 
upon T cell activation and it suppresses T cell responses (Chen & Flies 2013). ICOS-L 
is constitutively expressed on DCs and monocytes, but also on non-lymphoid cells 
(Collins et al. 2005). It interacts with the receptor ICOS (Inducible COStimulator), 
which is upregulated on activated T cells. ICOS is particularly important for CD4+ T 
cell helper functions to B cells (Greaves & Gribben 2013). PD-L1 is constitutively 
expressed and upregulated upon activation on APCs, but it can also be expressed on 
non-lymphoid cells. Its receptor, PD-1, is expressed during the effector phase of T cells 
and limit the responses of both CD4+ and CD8+ T cells. In the context of viral 
infection, PD-1 may play a role in contraction of the response after acute infection 
(Brown et al. 2010), but it has also been associated with T cell dysfunction, especially 
in the context of tumor immunity (Greaves & Gribben 2013). 
The activatory receptor NKG2D was first identified as an NK receptor. However, it is 
now well established that NKG2D is expressed also on CD8+ T cells, γδ T cells and 
subpopulations of CD4+ T cells (Zafirova et al. 2011). Ligands for this receptor are 
MICA, MICB and the ULBP molecules. The NKG2D ligands function as “stress”-
alerting molecules and are expressed on the cell surface after heat shock, injury, viral 
infection and tumor transformation (Raulet et al. 2013).  
The intracellular adhesion molecule ICAM-1 and the integrin LFA-1, which consists of 
the CD11a and the CD18 subunits, play an important role in the formation of the 
immunological synapse between T cells and APCs. Interaction of LFA-1 on the T cell 
with ICAM-1 on DCs highly increases antigen sensitivity of T cells (Bachmann et al. 
1997) and is necessary for the development of memory (Scholer et al. 2008). On the 
other side, T cell MHC-II triggering on naive B cells enhances LFA-1 “stickiness” on 
	  	  
 Introduction    
14	  
these cells, resulting in a very stable cell-cell contact that disfavours functional T cell 
activation and leads to the development of regulatory T cells (Gunzer et al. 2004). 
The SLAM family member CD48 is solely expressed on hematopoietic cells. Its 
receptor, 2B4, is expressed on NK and T lymphocytes and, according to the presence or 
the absence of the cytoplasmic adaptor SAP, can induce activatory or inhibitory signals 
(Parolini et al. 2000). 
Costimulatory receptors OX40 and 4-1BB of the TNF receptor superfamily play a 
substantial role in regulating effector T cell responses. Expression of both receptors is 
induced on T cells after TCR engagement (Croft 2009). OX40 promotes proliferation 
and survival of both CD4+ and CD8+ T cells, whereas 4-1BB preferentially promotes 
the expansion and survival of CD8+ T cells (Chen & Flies 2013). Ligands for these 
receptors are inducible on APCs (Croft 2009). Another member of the TNF receptor 
superfamily is the receptor CD40, an activatory receptor expressed by APCs including 
B cells. Its ligand, CD40-L, is expressed on CD4+ T helper cells reacting to TCR 
ligation. The interaction between CD40 and its ligand presented by helper T cells is 
essential for B cell activation and consecutive expansion and differentiation (see 
below). 
 
Family Ligand Receptor Functionality 
B7 family CD86 
 
PD-L1 
ICOS-L 
CD28 
CTLA-4 
PD-1 
ICOS 
+ 
- 
- 
+ 
NK receptors MICA/B 
ULBPs 
NKG2D 
NKG2D 
+ 
+ 
Integrin CD11a (LFA-1) ICAM-1 + 
Adhesion molecule ICAM-1 LFA-1 + 
SLAM family CD48 2B4 + 
TNF family 4-1BB-L 
OX40-L 
CD40-L 
4-1BB 
OX40 
CD40 
+ 
+ 
+ 
 
Table 1.2. List of activatory and inhibitory receptors playing a role in T cell activation and reactivity 
analyzed during this study. 
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1.7 B lymphocytes and the humoral immune response 
B lymphocytes recognize microbial antigens through the B-cell receptor (BCR). The 
BCR is composed by the pairing of two polypeptide chains, one of approximately 50 
kDa, called heavy or H chain, and a second one, the light or L chain, of 25 kDa. Two 
types of light chains can be produced, λ and κ. Each heavy chain is linked to a light 
chain by a disulfide bond, and the two heavy chains are likewise linked to each other by 
disulfide bonds. Like the TCR, the functional BCR genes are formed by somatic gene 
recombination. The light chain derives from V-J rearrangement, while the heavy chain 
derives from a V-D-J rearrangement. The light λ chain locus encodes 29 to 33 
functional Vλ gene segments and 4 or 5 Jλ genes. The number of Cλ genes presents 
variations between individuals. The κ locus has about 38 functional Vκ gene segments, 
5 Jκ genes and a single Cκ gene. The heavy chain can be encoded by 40 different VH 
segments, recombining with 23 DH genes and 6 JH genes, and has a 9 CH gene 
segments (Murphy 2011). 
Once a B cell encounters its antigen, the surface BCR-antigen complex is internalized, 
the antigen is degraded, and the derived peptides are loaded on MHC-II molecules. The 
peptides are presented on the B cell surface by MHC-II to specific CD4+ helper T cells 
that react to the TCR ligation by upregulating the CD40 ligand (CD40L). CD40L is 
bound by the receptor CD40 on the B cell. The recognition of the antigen (signal 1) and 
the engagement of the receptor CD40 (signal 2) synergize in driving B cell activation 
and inducing B cell proliferation, with formation of the germinal center, and 
differentiation. Activation of a B cell depends on the receiving of both these 
stimulatory signals (Graham et al. 2010). Nevertheless, maximal proliferation of B cells 
is achieved when the B cell receives an additional stimulation through pattern-
recognition receptors (PPR) such as Toll-like receptors (TLRs), recognizing microbial 
components like unmethylated CpG DNA or their mimics (signal 3) (Ruprecht & 
Lanzavecchia 2006). Upon activation, B cells differentiate to memory cells and plasma 
cells, which start producing high amounts of antibodies (immunoglobulins, Ig), the 
soluble version of their BCR. 
Igs are highly diverse and have diversified effector functions thanks to somatic 
hypermutation and class switching, modifications occurring in activated B cells. 
Somatic hypermutation further diversifies the rearranged V regions of the Ig genes by 
introducing mutational changes that may lead to a higher affinity to the antigen. Class 
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switching combines the same assembled V(D)J region – i. e. the same antigen 
specificity - with different C-region isotypes. Different classes of antibodies perform 
different functions. IgD and IgM are the first antibodies produced and are coexpressed 
on the surface of a naive B cell. Upon primary activation, B cells become IgM+IgD–. 
Once class-switching takes place, IgM is not produced anymore, but one of several 
other classes (IgG, IgA and IgE) will be produced. IgG are found in blood and in 
extracellular fluid where they bind to pathogens, neutralizing viruses, activating the 
complement and facilitating phagocytosis. IgA are the antibodies present in 
extracellular fluids within the body and in epithelial secretions. IgE resides below the 
body surfaces, mostly bound to IgE receptors on mast cells, and is accountable for 
allergic reactions (Murphy 2011).  
 
1.8 Epstein-Barr Virus 
Epstein-Barr virus (EBV) is a human gamma-1 herpesvirus with a preferred B cell 
tropism. EBV infects more than 95% of the adult population and, in healthy carriers, it 
persists in the form of a lifelong asymptomatic infection. The virus is mainly orally 
transmitted; in most cases primary infection occurs during childhood and is often 
asymptomatic or it can resemble a common cold or flu-like symptoms. If the first 
encounter with the virus occurs during adolescence or adulthood, acute infection with 
EBV can lead to infectious mononucleosis (IM), a self-limiting lymphoproliferative 
disease characterized by high fever, swollen lymph nodes, and general malaise lasting 
for several weeks (Rickinson et al. 2014).  
Persistent viruses are never completely cleared by the immune system. It is therefore of 
extreme importance for the host to develop an effective immune response able to 
continuously repress the reactivation of these viruses. Indeed, in healthy carriers, EBV 
infection is kept under control by a diverse repertoire of antigen-specific T cells (Hislop 
et al. 2007b). The consequences of the lack of proper control of EBV infection are seen 
in the reactivation of infection in immunosuppressed patient, such as patients after 
transplantation, who lack EBV-specific T cell responses and are prone to develop EBV-
associated lymphoproliferative disease, which is life-threatening and can be difficult to 
treat (Bollard et al. 2012). In these patients, transfer of EBV-specific T cells can be 
successfully used to treat EBV-associated diseases (Moosmann et al. 2010, 2012). As 
an oncovirus, EBV can also contribute to the development of several types of cancers 
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in immunocompetent patients, such as Burkitt lymphoma, nasopharyngeal carcinoma, 
EBV-associated gastric carcinoma and Hodgkin lymphoma (Rickinson 2014). 
 
1.8.1 The replication cycle of EBV 
After transmission, the virus establishes a lytic infection of epithelial cells and 
infiltrating B cells in the oropharynx, during which many viral proteins needed for the 
assembly and the release of new viral particles are expressed. From here, the virus 
colonizes the B cell compartment, establishing its growth programme (“latency III”) in 
B cells in lymphoid tissues. In “latency III”, several immunogenic EBV antigens, the 
latent membrane proteins (LMP1, -2A, -2B) and the Epstein-Barr nuclear antigens 
(EBNA1, -2, -3A, -3B, -3C, -LP), are expressed in EBV-infected B cells. This type of 
latency leads to intense cell proliferation and activation, and is found in vitro in EBV-
induced lymphoblastoid cell lines (LCLs) and in post-transplant lymphoproliferative 
disease (Brink et al. 1997). EBV-infected B cells in lymphoid organs during primary 
and persistent EBV infection (Tierney et al. 1994) lead to an amplification of EBV load 
through proliferation of infected cells (Hochberg et al. 2004; Young & Rickinson 
2004). Following the normal channels of B cell differentiation, the EBV-induced 
activated lymphoblastoid B cells enter the germinal center, where they gain access to 
the memory compartment, the site of long-term persistence (see below).  
Many of these proliferating B cells are detected and recognized by virus-specific T 
cells. However, some of them manage to escape from recognition and elimination by 
suppressing expression of most EBV antigens, resulting in “true latency” or the EBV 
“default program”. “True latency” or “Latency 0” characterizes quiescent infected 
memory B cells, without the expression of any viral protein (Babcock et al. 2000). 
“Latency 0” infected cells represent the virus reservoir in the immunocompetent host 
who has established an EBV-specific T cell and antibody response. During the “default 
program” (“latency I” and “latency II”), viral antigen expression is limited either to 
EBNA1, or to EBNA1 together with one or more LMPs (Young & Rickinson 2004). 
These latency types occur in Burkitt lymphoma (type I), nasopharyngeal carcinoma, 
gastric carcinoma (type I/II) and Hodgkin lymphoma (type II) (Rickinson 2014) and in 
centroblast and centrocytes, the proliferating and growing B cells forming the germinal 
centers (Babcock et al. 2000). Cells in “true” or “default” latency program express little 
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or no viral antigens and are, therefore, recognized by the immune response only with 
difficulty. 
Occasionally, EBV-infected memory B cells will re-enter the germinal center, where 
different stimuli will lead to activation of different latency programs and reinitiation of 
the EBV infection cycle. 
 
1.8.2 B cell activation by EBV: the role of LMP2A 
As mentioned, during type III latency, EBV induces activation and proliferation of the 
infected B cells. Two main mediators of these effects are the latent membrane proteins 
LMP2A and LMP1. These two viral proteins mimic the activatory signals induced by 
the BCR (signal 1) and by the receptor CD40 (signal 2), respectively. Both are 
transmembrane proteins, and each of them has a cytoplasmic domain containing 
various motifs functioning as docking sites for cellular kinases that lead to activation of 
several signaling pathways (Pang et al. 2009; Dawson et al. 2012).  
In B cells, LMP2A mimics the activatory signals of the B cell receptor (BCR) both in 
vitro and in a transgenic mouse model (Caldwell et al. 1998; Mancao & 
Hammerschmidt 2007), activating PI3K/Akt and ERK-MAPK signaling (Panousis & 
Rowe 1997; Fukuda & Longnecker 2004; Portis & Longnecker 2004; Anderson & 
Longnecker 2008). These signals promote B cell survival and inhibition of apoptosis. 
LMP2A was also shown to interfere with activation of EBV lytic cycle upon BCR 
engagement by preventing normal BCR activation (Miller et al. 1994a, b, 1995; 
Konishi et al. 2001; Merchant et al. 2001). In the absence of exogenous triggers of the 
lytic cycle, however, LMP2A supported basal levels of lytic cycle induction, suggesting 
a dual role of LMP2A in controlling EBV lytic cycle (Schaadt et al. 2005). 
However, the influence of LMP2A on human B cell proliferation and transformation 
has been controversial: while some studies did not identify a role of LMP2A in these 
processes (Longnecker et al. 1992, 1993a, b; Speck et al. 1999; Konishi et al. 2001) 
other reports indicated that LMP2A increases the efficiency of B cell proliferation and 
transformation (Brielmeier et al. 1996; Mancao & Hammerschmidt 2007), implying 
that LMP2A-deleted EBV has reduced capacity to transform B cells. 
LMP2A is one of few EBV latent antigens that are not only expressed in B cells in the 
transforming growth program (latency III), but also in tumors expressing the restricted 
antigen expression “default” programs such as Burkitt lymphoma, Hodgkin lymphoma, 
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nasopharyngeal carcinoma and gastric carcinoma (Rickinson 2014). Several studies in 
epithelial cells showed that LMP2A promotes survival, proliferation and transformation 
in these cells, implicating a role for LMP2A in the maintenance or in the progression of 
carcinomas. These reports showed that LMP2A enhances anchorage-independent 
growth (Fukuda & Longnecker 2007), inhibits differentiation (Scholle et al. 2000), 
interferes with the proapoptotic effects of TGFβ1 (Fukuda & Longnecker 2004) and 
induces the expression of the anti-apoptotic protein survivin (Hino et al. 2008). In 
addition, LMP2A enhances tumorigenesis in vivo (Scholle et al. 2000; Kong et al. 
2010).  
 
1.8.3 Cellular immunity in EBV infection 
Cell mediated responses are crucial both in acute and in persistent infection. In virus-
host interaction, both the adaptive and the innate immune response play fundamental 
role in the control of the infection. 
 
1.8.3.1 Humoral response in EBV infection 
The humoral immune response to active EBV infection shows an initial strong IgM 
production specific for the viral capsid antigen (VCA) and the development of IgG 
antibodies specific for the EBV early antigen (EA-D). While the antibody responses to 
these antigens rapidly decline after acute infection, the production of anti-VCA IgG 
antibodies rises slowly during acute infection and persists for life. In addition, IgG 
antibodies specific for the EBV nuclear antigen 1 (EBNA1) are produced and, as for 
the anti-VCA IgG antibodies, persist long-tern after the resolution of the infection. In 
seropositive hosts, viral reactivation can be indirectly detected by the presence of newly 
produced IgM antibodies (Klutts et al. 2004). 
 
1.8.3.2 NK cell response in EBV infection 
Several lines of evidence suggest an involvement of NK cells in the control of EBV 
infection, although a clear role for these cells in the control of EBV has not been 
established yet. First, male patients affected with X-liked lymphoproliferative disease 
(XLP), a fatal disease associated to mutations in the SAP gene, are prone to develop 
EBV-induced lymphomas (Nichols et al. 2005). Mutations in the adaptor protein SAP 
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lead to defective recognition of EBV-transformed B cells by NK cells (Benoit et al. 
2000). The fact that these patients cannot control EBV infection, suggests an important 
role for NK cells in EBV immunity. Second, expansion of NK cells is observed during 
infectious mononucleosis (Williams et al. 2005; Balfour et al. 2013). Third, several in 
vitro studies showed that NK cells can inhibit EBV-induced B cell transformation 
(Kaplan & Shope 1985; Wilson & Morgan 2002; Strowig et al. 2008; Lunemann et al. 
2013) or that NK cells can with some efficiency lyse lytically EBV-infected Burkitt 
lymphoma cells (Pappworth et al. 2007) and early EBV-infected B cells (Jochum et al. 
2012a). Interestingly, in the case of lytically EBV infected Burkitt cell lines, NK lysis 
was dependent on the downregulation of MHC molecules, ligands for NK inhibitory 
KIR receptors, and on the upregulation of ligands for the agonistic receptor NKG2D on 
the surface of infected cells (Pappworth et al. 2007). A recent study showed that in 
patients with genetic deficiencies in the magnesium transporter MAGT1, who are, like 
XLP patients, particularly susceptible to EBV infection and EBV+ lymphomas, 
NKG2D plays an important role in the control of EBV infection by NK and CD8+ T 
cells (Chaigne-Delalande et al. 2013), further supporting a role of NK cells in EBV 
immunity.  
 
1.8.3.3 T cell response in EBV infection  
The development and maintenance of an efficient adaptive immunity is extremely 
important in control of life-lasting infections, such EBV. During IM, a marked 
expansion of CD8+ T cells is observed. This population proved to be oligoclonal in the 
TCR repertoire (Annels et al. 2000), with reactivities for lytic cycle proteins usually 
dominant (Pudney et al. 2005). While these highly expanded responses to lytic cycle 
antigens are strongly culled after IM, the response to latent cycle proteins is smaller 
during acute infection, but is stably maintained or even increased after the resolution of 
IM (Catalina et al. 2001; Woodberry et al. 2005). In long-term asymptomatic EBV 
carriers, a significant fraction of circulating CD8+ T cells is devoted to the control of 
EBV, with individual epitope-specific populations reaching 1-2% of the total CD8+ T 
cell pool (Bihl et al. 2006). Despite the fact that even during asymptomatic infection, it 
is likely for EBV to sustain recurrent activation, most of the memory cells have a 
resting phenotype. Nevertheless, ex vivo EBV-specific T cells can be rapidly activated 
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upon challenge with peptide-loaded targets, EBV-transformed B cells, or other forms of 
antigen-specific stimuli (Hislop et al. 2001). 
A different role seems to be played by the response to EBV in the CD4+ T cell 
compartment. CD4+ T cells are not markedly expanded in IM, even though EBV-
specific CD4+ T cells are detected at this time (Long et al. 2013). Interestingly, in 
contrast to the CD8+ T cell response, the latent-specific CD4 T cell pool is larger that 
the one directed to the lytic antigens (Long et al. 2013). While CD4+ T cells specific 
for latent antigens are often incapable of recognizing EBV-infected cells such as LCLs, 
CD4+ T cells specific for late lytic antigens can sensitively recognize lytically 
produced EBV antigen, and can directly and efficiently kill target cells that present 
such antigens (Adhikary et al. 2006, 2007). Thus, CD8+ and CD4+ T cells appear to 
play complementary roles in control of EBV infection. 
 
1.8.3.4 γδ  T cell response in EBV infection 
In the context of EBV infection, less is known about the role of γδ T cells.  γδ T cells 
were shown to expand during acute infectious mononucleosis (De Paoli et al. 1990), to 
proliferate after contact with LCLs (Hacker et al. 1992; Orsini et al. 1993) and after 
contact with EBV-positive Burkitt lymphoma lines (Hacker et al. 1992; Orsini et al. 
1994; L'Faqihi et al. 1999). However, the literature gives controversial information 
regarding which population recognizes EBV-infected B cells (De Paoli et al. 1990; 
Lam et al. 1990; Qvigstad et al. 1990; Hacker et al. 1992; Orsini et al. 1993; Hyjek et 
al. 1997; Fujishima et al. 2007; Kong et al. 2009). In addition, after a number of studies 
were conducted early after the discovery of the γδ T cell population, less work has been 
done in recent years, and the knowledge about the role of γδ T cells in EBV infection 
has remained superficial. 
 
1.8.4 Mechanisms of EBV immune escape  
During lytic EBV replication, a majority of at least 70 viral proteins are co-expressed: 
in this situation, the virus would be extremely vulnerable to the immune system. Thus, 
a number of EBV proteins expressed in lytic cycle have been found to interfere with the 
display of viral antigens to CD8+ T cells. Among these, the BNLF2a protein 
diminishes the supply of peptide available in the ER for MHC class I antigen 
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presentation by inhibition of peptide translocation by the TAP transporter (Hislop et al. 
2007a). BILF1 directly associates with MHC class I molecules rapidly after their 
biosynthesis and induces their internalization and degradation in lysosomes (Zuo et al. 
2009). BGLF5 inhibits cellular protein biosynthesis thereby drastically reducing MHC-
I surface levels (Zuo et al. 2008). EBV IL-10 homolog BCRF1 (or v-IL10) was shown 
to reduce MHC-I levels by decreasing mRNA and protein levels of the TAP1 and the 
LMP2 proteins, two of the subunits forming the immunoproteasome (Zeidler et al. 
1997). Moreover, it has been described to block IFNγ release by CD8+ T cells 
(Swaminathan et al. 1993). 
In contrast, it is less clear how B cells expressing the EBV latency III  "growth 
program" manage to escape from recognition and elimination by virus-specific T cells. 
The sole known exception is EBNA1, which interferes in cis with its presentation to 
CD8+ T cells through its Gly-Ala repeat domain, which hampers the processing of 
EBNA1 by the proteasome, (Levitskaya et al. 1997) and prevents EBNA1 mRNA 
translation (Yin et al. 2003). The possibility of an involvement of LMP2A in the 
modulation of the immune response was suggested by the observation that LMP2A 
modulates signaling of type I/II interferon receptors in epithelial cells (Shah et al. 2009) 
and that the presence of LMP2A alters the expression of several immune-related genes 
(Portis et al. 2003). Beyond these hints, it is unclear whether the growth program uses 
other mechanisms to hamper T cell recognition of infected cells. 
 
1.8.5 EBV in cancer 
EBV is an oncovirus and is associated with numerous human malignancies, such as 
Burkitt lymphoma, nasopharyngeal carcinoma, EBV-associated gastric carcinoma and 
Hodgkin lymphoma (Rickinson 2014). Interestingly, although EBV has a preferential B 
cell tropism in vitro and, as far as is known, in healthy carriers in vivo, it is associated 
with tumors of both B and non-B cell origin. All EBV-positive B cell tumors present 
somatically mutated Ig genes, suggesting that at some point these cells have undergone 
a germinal center reaction. Non-B cell EBV-positive tumors arise from rare events in 
which the virus gains entry to a different host cell type. In both cases, EBV is present in 
these tumors expressing different sets of viral proteins. In Burkitt lymphoma, viral 
antigen expression is usually limited to EBNA1 (latency I) or to EBNA1 with low 
levels of one or more LMPs (latency I/II). This expression profile is common in non-B 
	  	  
 Introduction    
23	  
cell tumors (nasopharyngeal carcinoma, gastric carcinoma). In Hodgkin lymphoma 
both EBNA1 and the LMPs are expressed at high levels (latency II), while in 
lymphoproliferative disease, usually developed in immunocompromised patients, EBV 
present a latency III expression profile (Rickinson 2014). This latter mode of latency is 
more immunogenic, which makes it plausible that such tumors usually arise only in 
conditions of immunodeficiency. 
 
1.8.6 Immunotherapy  
The balance between EBV reactivation and control of the infection by the immune 
system can be disrupted after transplantation of solid organs or hematopoietic stem 
cells (HSCT). After solid organs transplantation, the cellular immune response of the 
patient is kept at bay by immunosuppressive drug administration for the prevention of 
graft rejection. In allogeneic HSCT, the host immune system is ablated and 
reconstitution of cellular immunity is a slow process, which can again be impaired by 
the administration of immunosuppressive drugs during the first months after 
transplantation. In both cases, the patients will lack the EBV-specific T cell responses 
necessary to control EBV reactivation. To treat the development of post-transplant 
lymphoproliferative disease (PTLD), guidelines suggest an initial reduction of immune 
suppression (Bollard et al. 2012). However, this solution is not always possible or 
successful. Monoclonal antibodies specific for B cells (Rituximab, a specific antibody 
against CD20, an antigen expressed solely on B cells) are often effective, either alone 
or in combination with chemotherapy (Kuehnle et al. 2000; Savoldo et al. 2005). 
However, the depletion of the complete B cell population that is a regular consequence 
of anti-CD20 application further increases the risk of other infections in patients after 
HSCT. In addition, PTLD often recurs because the cellular immunity is not restored. 
Thus, strategies to restore T cell immunity by transfer of EBV-specific T cells have 
been developed and successfully applied (Heslop et al. 2010; Moosmann et al. 2012). 
The majority of PTLD express a type III latency, while a minority presents a type II 
latency expression profile (Bollard et al. 2012). Therefore, it is necessary to transfer T 
cells specific for the relevant expressed antigens. In earlier times, transfer of 
unmanipulated donor lymphocytes in patients treated with allogeneic HSCT has shown 
good efficacy. However, this strategy often causes severe GvHD, because alloreactive 
T cells are costransferred (Heslop et al. 1994). For this reason, various strategies to 
	  	  
 Introduction    
24	  
expand ex vivo EBV-specific T cells have been tested. The use of LCLs as APCs to 
stimulate expansion of EBV-specific T cells was used with success; however, this 
strategy is laborious and time consuming (Heslop et al. 2010). Other strategies consist 
in the development of rapid ex vivo culture, for example by a single stimulation of T 
cells with DCs previously transfected with DNA plasmids encoding for EBV 
immunogenic proteins (Gerdemann et al. 2009). Another technique employs the use of 
tetrameric HLA-peptide constructs (tetramers) to select virus-specific T cell 
populations (Uhlin et al. 2010). Still another approach showed efficacy, in which virus-
specific T cells were selected by EBV peptide stimulation of PBMCs and subsequent 
isolation of IFN-γ secreting T cells (Moosmann et al. 2010). The last three approaches 
yield low absolute numbers of EBV-specific T cells, but these cells have the potential 
to expand in vivo, providing potent antiviral activity. Whereas experience with 
therapeutic transfer of EBV-specific αβ T cells (CD8+ and, sometimes, CD4+) has 
been promising, the potential of EBV-specific immunotherapy employing different 
types of effector cells, such as γδ T cells, has not been explored. 
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1.9 Aim of the study 
 
EBV efficiently infects B cells by taking advantage of the processes of normal B cell 
activation and differentiation. An important form of EBV infection in vivo is the 
"growth programme", also called latency III, which can be faithfully modeled in vitro 
by infection of primary B cells with EBV, resulting in generation of lymphoblastoid 
cell lines (LCLs). Latency III is also present in post-transplant lymphoproliferative 
disease. In the growth programme, EBV induces or mimics several cellular pathways of 
B cell activation, and thus drives B cell proliferation and its own amplification. 
However, it is unclear whether and how the virus modulates immunogenicity in this 
important form of infection. In principle, EBV-specific CD8+ T cells can recognize 
LCLs, but responses by some CD8+ and by CD4+ T cells appear to be blunted. 
Moreover, it has remained unclear whether γδ T cells can recognize this form of 
infection. The present study investigates different possibilities of how the virus controls 
and modifies the immunogenicity of B cells during latency III. One of the EBV latent 
viral proteins, LMP2A, triggers multiple signaling pathways, is expressed in latency III 
and also two other latency types (I and II), and is one of the few viral proteins 
expressed in most types of EBV-related malignancies. Therefore, LMP2A was a likely 
candidate to perform immunomodulatory functions during latent infection of EBV. The 
aim of the present study was to better understand what makes EBV one of the most 
successful persistent viruses, by addressing the following questions: 
I. How does EBV infection affect the immunophenotype of the B cell, and 
how does this differ from the phenotype induced by physiological B cell 
activation? Is there evidence for immunoevasion specifically induced by 
EBV in latency III B cells? 
II. Does LMP2A have immunomodulatory effect(s)? If yes, which 
immunological mechanisms are affected by the function of LMP2A? 
III. Which effector cells are affected by the immunomodulatory effects 
mediated by LMP2A?  
IV. Are γδ T cells involved in recognition of EBV-infected B cells? If yes, 
which γδ T cell subpopulation is active? 	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2 Materials 
2.1 Eukaryotic cells 
2.1.1 Primary cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from standard blood 
donations by anonymous healthy adult donors purchased in the form of buffy coats 
from the Institute for Transfusion Medicine, University of Ulm, Germany or from 
voluntary healthy adult blood donors providing written informed consent. All blood 
donors contributing to this work were anonymized. The institutional review board 
(Ethikkommission, Klinikum der Universität München, Grosshadern, Munich, 
Germany) approved this procedure. All work was conducted according to the principles 
expressed in the Helsinki Declaration. High- or low-resolution HLA types and virus 
carrier status of PBMC donors are listed in the following table: 
 
  
 
HLA-A HLA-B HLA-C EBV status HCMV status 
Donor 1 *0101 
*0201 
*3906 
*4402 
*0702 
*0704 
? (EBNA- 
VCA+) 
- 
Donor 2 *0101 
*2601 
*3501 
*5701 
*0401 
*0602 
- - 
Donor 3 *0301 
*6801 
*0702 
*3501 
*0401 
*0702 
+ - 
Donor 4 *0101 
*2402 
*0801 
*1402 
*0701 
*0802 
+ + 
Donor 5 *2402 
*2402 
*1302 
*1801 
*0602 
*1203 
+ + 
Donor 6 *110 
*3101 
*3503 
*4001 
*0304 
*1203 
+ - 
Donor 7 *0201 
*0301 
*1529 
*5101 
*1203 
*1402 
+ - 
Donor 8 *0201 
*6801 
*1501 
*4402 
*0102 
*0501 
+ + 
Donor 9 *0201 
*0201 
*0702 
*4002 
*0202 
*0702 
+ + 
Donor 10 *03 
*24 
*3501 
*4002 
*02 
*04 
+ - 
	  	  
 
Materials 
 
  
27	  
Donor 11 *0101 
*0201 
*1801 
*5101 
*0501 
*1502 
+ - 
Donor 12 *30 
*31 
*13 
*27 
*01 
*06 
+ - 
Donor 13 *3201 
*6601 
*4002 
*5101 
*0202 
*0202 
+ + 
Donor 14 *0201 
*2902 
*4402 
*4501 
*0602  
*0602 
+ + 
 
 
2.1.2 Cell lines 
B95.8 EBV B95.8 infected lymphoblastoid marmoset cell 
line 
(Miller et al. 
1972a; Miller & 
Lipman 1973) 
293/TR-2 EBV-packaging cell line based on the human 
embryonic kidney (HEK) 293 cell line stably 
transfected with p2114, TR- producer line  
(Delecluse et al. 
1999) 
293/2098 EBV-packaging cell line based on the human 
embryonic kidney (HEK) 293 cell line stably 
transfected with p2089, EBV WT 2089 producer line 
(Delecluse et al. 
1998) 
293/2525 EBV-packaging cell line based on the human 
embryonic kidney (HEK) 293 cell line stably 
transfected with p2525, ΔLMP2A EBV producer cell 
line 
(Mancao & 
Hammerschmidt 
2007) 
LL8 Mouse fibroblast cell line L929 stably transfected 
with human CD40L, for production of B-blasts 
Leah Schirrmann, 
Andreas 
Moosmann 
Daudi Burkitt’s lymphoma cell line, subcloned for EBV-
loss, MHC class I deficient 
(Klein et al. 1968) 
Raji Burkitt’s lymphoma cell line, EBV positive (PULVERTAFT 
1964) 
K562 Immortalized human chronic myelogenous leukemia 
cell line, MHC class I deficient 
(Lozzio & Lozzio 
1975) 
 
2.2 Plasmids 
p2670 Plasmid encoding the EBV glycoprotein 
BALF4/gp110 
(Neuhierl et al. 
2002) 
p509 Plasmid encoding the EBV lytic transactivator 
BZLF1 
(Delecluse et al. 
1999) 
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2.3 Oligonucleotides 
Oligonucleotides used in this work were ordered to and synthesized by Metabion 
(Munich, Germany). They are listed as follows in 5´→ 3´direction. 
Primers for standard PCR: 
PCR Primer 
name 
Sequence (5´→3´) Product 
size (bp) 
Annealing 
T (°C) 
LMP2A 
bridging 
L2BRC 
L2BRD 
GCTTCCTCGTGCTTTACGGTATC 
AAGAACTTTGACCTGTTGTCCCTG 
WT: - 
Δ: 481 
52 
LMP2A 
internal 
L2INA 
L2BRD 
CATTGCGGGTGGATAGCCTC 
AAGAACTTTGACCTGTTGTCCCTG 
WT: 831 
Δ: - 
55 
gp85 gp85c 
gp85d 
TGGTCAGCAGCAGATAGTGAACG 
TGTGGATGGGTTTCTTGGGC 
450 55 
TCR seq 
Vδ1 
Vδ1F2 
CδR3 
GAACAGAATGCAAAAAGTGGTC 
CACTTCAAAGTCAGTGGAGTGC 
variable 56 
TCR seq 
Vδ3 
Vδ3F3 
CδR3 
GGCGAGTGGCAGTGAGG 
CACTTCAAAGTCAGTGGAGTGC 
variable 56 
 
Primers for quantitative real-time PCR: 
Target Forward primer Reverse primer Product 
size 
Human 
IL-10 
GCAGGTGAAGAATGCCTTTA CCCTGATGTCTCAGTTTCGT 128 
BZLF1 -
unspliced 
GCACATCTGCTTCAACAGGA CCAAACATAAATGCCCCATC 104 
EBNA1 CGCAAGGAATATCAGGGAT-
G 
TCTCTCCTAGGCCATTTCCA 150 
gp350 TTGTGAAATTTCGCCATCCT CAAAACCCCGTGTACCTG 222 
BCRF1 
(vIL-10) 
ACCTTAGGTATGGAGCGAAG GGGAAAATTGTCACATTGGT 110 
EBNA3A TCCGCAGGTTTCCACTAG AT GGGATCCGAAAAACTGGT 
CT 
99 
LMP2 ATCGCTGGTGGCAGTATTTT GAGTATGCCAGCGACAATCA 105 
GUSB CGCCCTGCCTATCTGTATTC  TCCCCACAGGGAGTGTGTAG 91 
 
2.3.1 Peptides 
All peptides used in this study were synthesized by JPT (Berlin, Germany) to >70% 
purity, resuspended in 100% dimethyl sulfoxide (DMSO) at a final concentration of 10 
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mg/mL and stored at -20°C. In T cell assays, peptides were diluted to a final 
concentration of 2 µg/mL. 
Peptides used in this work are listed in the following table and are designated by their 
first three amino acids in one-letter code. 
Abbreviation Peptide sequence Antigen HLA-
restriction 
Source 
CLG CLGGLLTMV EBV, LMP2 A*0201 (Lee et al. 
1993) 
CRV CRVLCCYVL  HCMV, IE-1 C*0702 (Ameres et al. 
2013) 
FLY FLYALALLL  EBV, LMP2 A*0201 (Meij et al. 
2002; 
Lautscham et 
al. 2003) 
HPV HPVGEADYFEY EBV, EBNA1 B*3501 (Rickinson & 
Moss 1997) 
RAK RAKFKQLL EBV, BZLF1 B*0801 (Bogedain et 
al. 1995) 
RPP RPPIFIRRL EBV, 
EBNA3A 
B*0702 (Hill et al. 
1995) 
VLE VLEETSVML HCMV, IE-1 A*0201 (Khan et al. 
2002) 
YVL YVLDHLIVV EBV, BRLF1 A*0201 (Saulquin et 
al. 2000) 
 
2.4 Antibodies 
Antibodies used in this study are listed as follows. If not otherwise stated, all antibodies 
were made in mouse. 
 
specificity clone isotype labeling quantity company 
MICA 159227 IgG2b - 50 µg/mL R&D Systems 
MICB 236511 IgG2b - 50 µg/mL	   R&D Systems 
ULBP1 3F1 IgM - 50 µg/mL	   Santa Cruz 
ULBP1 170818 IgG2a - 50 µg/mL	   R&D Systems 
ULBP2-5-6 165903 IgG2a PE 12.5 µg/mL R&D Systems 
ULBP3 166510 IgG2a PE 12.5 µg/mL R&D Systems 
ULBP4 6E6 IgG2b - 50 µg/mL Santa Cruz 
CD48 BJ40 IgG1 PE 5 µg/mL BioLegend 
4-1BB-L (CD137L) 5F4 IgG1 PE 5 µg/mL BioLegend 
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OX40L (CD252) 11C3.1 IgG1 PE 5 µg/mL BioLegend 
CD11a G43-25B IgG2a PE 0.5 µL BD Bioscience 
ICOS-L (B7-H2) 2D3 IgG2b PE 2.5 µg/mL BioLegend 
PD-L1 (B7-H1) 29E.2A3 IgG2b APC 5 µg/mL BioLegend 
CD86 (B7-2) IT2.2 IgG2b APC 5 µg/mL BioLegend 
CD86 (B7-2) 37301 IgG1 PE 2.5 µg/mL R&D Systems 
CD54 (ICAM-1) HCD54 IgG1 PE 2.5 µg/mL BioLegend 
CD54 (ICAM-1) HCD54 IgG1 APC 2.5 µg/mL BioLegend 
TCR αβ IP26 IgG1 APC 4 µL BioLegend 
TCR γδ B1 IgG1 PE 1 µL BioLegend 
TCR Vδ2 B6 IgG1 PerCP 1 µL BioLegend 
TCR Vδ2 B6 IgG1 FITC 1 µL BioLegend 
TCR Vδ1 TS8.2 IgG1 FITC 2 µL Thermo Scientific 
TCR γ9 B3 IgG1 PE 1 µL BioLegend 
CD314 (NKG2D) 149810 IgG1 - 6.25 µg/mL R&D Systems 
CD314 (NKG2D) 1D11 IgG1 APC 7.5 µg/mL BioLegend 
CD314 (NKG2D) 1D11 IgG1 PE-Cy7 0.5 µL BioLegend 
CD159a (NKG2A) Z199 IgG2b APC 4 µL Beckman Coulter 
CD158b 
(KIR2DL2/3) 
CHL IgG2b PE 2 µL BD Pharmingen 
CD158e1 (KIR3DL1) DX9 IgG1 FITC 2 µL BioLegend 
CD158a (KIR2DL1) HP-3E4 IgM FITC 6 µL BD Bioscience 
CD56 (NCAM) 
N901 
(HLDA6) 
IgG1 PE 1 µL Beckman Coulter 
CD56 (NCAM) HCD55 IgG1 PE-Cy5 1 µL BioLegend 
CD56 (NCAM) HCD56 IgG1 BV421 1 µL BioLegend 
CD19 HIB19 IgG1 FITC 1.5 µL BioLegend 
CD19 HIB19 IgG1 PE 1.5 µL BioLegend 
CD19 HIB19 IgG1 APC 1.5 µL BioLegend 
CD3 HIT3a IgG2a PE-Cy5 1 µL BioLegend 
CD4 RPA-T3 IgG1 FITC 1 µL BioLegend 
CD4 RPA-T4 IgG1 PE 1 µL BioLegend 
CD4 RPA-T4 IgG1 PE-Cy5 1 µL BioLegend 
CD8 RPA-T8 IgG1 FITC 1 µL BD Pharmigen 
CD8 RPA-T8 IgG1 APC 1 µL BioLegend 
CD8 RPA-T8 IgG1 PB 1 µL BioLegend 
HLA-ABC W6/32 IgG2a APC 1-0.5 µL BioLegend 
CD80 2D10 IgG1 FITC 5 µg/mL BioLegend 
HLA-A2 BB7.2 IgG2b PE 3 µg/mL BioLegend 
HLA-B7 BB7.1 IgG1 PE 2 µL Millipore 
HLA-C/E DT9 IgG2b - - 
Veronique Braud, 
Nice, France 
HLA-A3 4i87 IgM - - US Biological 
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HLA-Bw6 REA143 
human 
IgG1 
PE - Miltenyi Biotec 
isotype control - 
human 
IgG1 
PE - SouthernBiotech 
isotype control 133304 IgG2a - - R&D Systems 
isotype control 
MOPC-
173 
IgG2a PE - BioLegend 
isotype control 
MOPC-
173 
IgG2a APC - BioLegend 
isotype control 133303 IgG2b - - R&D Systems 
isotype control 133303 IgG2b APC - R&D Systems 
isotype control MG2b-57 IgG2b PE - BioLegend 
isotype control MG2b-57 IgG2b APC - BioLegend 
isotype control 11711 IgG1 - - R&D Systems 
isotype control MOPC-21 IgG1 PE - BioLegend 
isotype control MOPC-21 IgG1 APC - BD Bioscience 
isotype control MM-30 IgM - - BioLegend 
Anti-mouse IgG Poly4053 Goat Ig APC 5 µg/mL BioLegend 
Anti-mouse IgG/IgM 
115-136-
068 
Goat Ig APC 5 µg/mL 
Jackson 
ImmunoResearch 
 
MHC-I:peptide pentamers for staining of EBV- and HCMV-specific CD8+ T cells 
were purchased by ProImmune, Oxford, England. 
 
CRV/HLA-C*0702 MHC-I:peptide monomers were generated and provided by Dr. 
Michael Neuenhahn and Prof. Dirck Busch (Institute for Medical Microbiology, 
Immunology and Hygiene, Technische Universität München). 
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2.5 Cell culture media and additives 
The following media and additives were used for cultivation of eukaryotic cell lines. 
Name Use Source 
RPMI 1640 Standard cell culture medium Gibco Invitrogen, 
Karlsruhe, Germany 
Opti-MEM Cell culture medium for transfection Gibco Invitrogen, 
Karlsruhe, Germany 
DMEM Cell culture medium for adherent cells 
(HEK293) 
Gibco Invitrogen, 
Karlsruhe, Germany 
Fetal calf serum (FCS) Nutritive substance Gibco Invitrogen, 
Karlsruhe, Germany 
Penicillin/streptomycin Antibiotics for inhibition of bacterial 
growth 
Gibco Invitrogen, 
Karlsruhe, Germany 
Sodium selenite Supplement of the essential element 
selenium 
ICN Biochemicals, 
Aurora, USA 
0.05% Trypsin-EDTA Detachment of adherent cells Gibco Invitrogen, 
Karlsruhe, Germany 
Cyclosporin A Immunosuppressant, inhibits T and NK 
cell growth during the establishment of 
EBV-infected B cell lines 
Novartis, Nürnberg, 
Germany 
Geneticine G-418 
sulphate 
Antibiotic for selection of eukaryotic cells Gibco Invitrogen, 
Karlsruhe, Germany 
Hygromycin B Antibiotic for selection of eukaryotic cells Gibco Invitrogen, 
Karlsruhe, Germany 
Polyethyleneimine 
(PEI) MW: 25000 
Mean for transfection of eukaryotic cells Sigma-Aldrich, St. 
Louis, USA 
αBCR F(ab´)2 
fragments 
F(ab´)2 fragments for BCR engagement for 
activation of B cells  
Jackson Immuno 
Research, West 
Grove, USA 
CpG DNA Ligand for TLR9 for activation of B cells (Iskra et al. 2010), 
Metabion, Germany 
 
The following cytokines were used for cultivation of specific cell types. 
Name Use Source 
Recombinant human IL-2 Cultivation of T cells Novartis, Nürnberg, 
Germany 
Recombinant human IL-4 Cultivation of CD40-
stimulated B cells 
R&D Systems, 
Minneapolis, USA 
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2.6 Commercial kits 
Human IFN-γ ELISA Kit (ALP) Mabtech, Nacka Strand, Sweden 
Human IL-10 ELISA Kit (ALP) Mabtech, Nacka Strand, Sweden 
MACS® IFN-γ secretion assay Miltenyi Biotec, Bergisch Gladbach, 
Germany 
MACS® Human B Cell Isolation Kit II  Miltenyi Biotec, Bergisch Gladbach, 
Germany 
MACS® TCR γ/δ+ T cell Isolation kit, 
human 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
RNeasy® Mini Kit  Qiagen, Hilden, Germany 
QIAamp® DNA Blood Mini Kit Qiagen, Hilden, Germany 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel, Düren, Germany 
QuantiTect® Reverse Transcription Kit Qiagen, Hilden, Germany 
SYBR Green LC480 Mix  Roche, Basel, Switzerland 
 
2.7 Enzymes 
Taq-DNA Polymerase  NewEngland BioLabs, Ipswich, USA 
Pfu-DNA Polymerase Thermo Fisher Scientific, Waltham, USA 
 
2.8 Chemicals, reagents, buffers 
10 mM dNTPs Thermo Fisher Scientific, Waltham, USA 
Biocoll Separating Solution Biochrom, Berlin, Germany 
Calcein acetoxymethylester (AM) Invitrogen, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Carl Roth GmbH, Karlsruhe, Germany 
DNA agarose Biozym, Hessisch Oldendorf, Germany 
DNA loading dye (6x) Fermentas, St. Leon-Rot, Germany 
Ethidium bromide Carl Roth GmbH, Karlsruhe, Germany 
FACS Flow/Clean/Rinse BD Biosciences, Heidelberg, Germany 
GeneRulerTM DNA Ladder Mix Fermentas, St. Leon-Rot, Germany 
Heparin-Natrium 25,000 Ratiopharm, Ulm, Germany 
NaOH (50 mM) Carl Roth GmbH, Karlsruhe, Germany 
Para-nitrophenyl phosphate (pNPP) Carl Roth GmbH, Karlsruhe, Germany 
PBS Dulbecco (w/o Mg2+) Biochrom, Berlin, Germany 
TAE (Tris, acetate, EDTA) Carl Roth GmbH, Karlsruhe, Germany 
Tris/HCl (1M) Carl Roth GmbH, Karlsruhe, Germany 
TritonTM X-100 Carl Roth GmbH, Karlsruhe, Germany 
Trypan blue Merck, Darmstadt, Germany 
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2.9 Consumables 
6-/12-/48-/96-well flat-bottom plates BD Biosciences, Heidelberg, Germany 
96-well round-bottom plates Nunc A/S, Roskilde, Denmark 
96-well V-bottom plates Hartenstein, Würzburg, Germany 
BD FalconTM cell strainer 100 µm BD Biosciences, Heidelberg, Germany 
BD FalconTM conical tubes 15mL, 50 mL BD Biosciences, Heidelberg, Germany 
BD FalconTM Polystyrene round-bottom 
tubes 5 mL 
BD Biosciences, Heidelberg, Germany 
Cell culture flasks (25/80/175 cm2) Nunc A/S, Roskilde, Denmark 
Cryo tube vials 1.8 mL Nunc A/S, Roskilde, Denmark 
Immunoplates MaxiSorp® 96-well flat 
bottom 
Nunc A/S, Roskilde, Denmark 
Infuject® 50 mL syringes and needles Dispomed Witt oHG, Gelnhausen, 
Germany 
PCR reaction tubes (0.2 µL single tubes, 
0.2 µL stips) 
Thermo Fisher Scientific, Waltham, USA 
Pipette tips (Diamond® TowerPackTM) 
(0.1-10 µL, 10-100 µL, 100-1000 µL) 
Gilson Inc. Middleton, USA 
Plastic pipettes (2 mL, 5 mL, 10 mL, 25 
mL) 
Greiner Bio-One, Kremsmünster, Austria 
Reaction tubes (0.5 mL, 1.5 mL, 2 mL) Eppendorf, Hamburg, Germany 
Single use Pasteur pipettes 3.2 mL Carl Roth GmbH, Karlsruhe, Germany 
Syringe filter Minisart® 0.2 µm Sartorius AG, Göttingen, Germany 
Syringe filter NalgeneTM 0.8 µm Nalge Company, Rochester, USA 
 
2.10 Laboratory equipment and devices 
Centrifuge “Centrifuge 5415 R” Eppendorf, Hamburg, Germany 
Centrifuge “Rotanta 460 R” Hettic AG, Bäch, Switzerland 
Centrifuge “Rotanta 46 RSC” Hettic AG, Bäch, Switzerland 
Centrifuge “Heraeus Pico 21” Thermo Fisher Scientific, Waltham, USA 
Cytofluorometer “FACS Calibur” BD Biosciences, Heidelberg, Germany 
Cytofluorometer “LS Fortessa” BD Biosciences, Heidelberg, Germany 
Freezer -20°C Liebherr, Bilberach an der Riss, Germany 
Freezer -80°C “Hera freeze” Heraeus Holding, Hanau, Germany 
Fridge Bosch, Gerlingen-Schillerhöhe, Germany 
Gel documentation system Vilber Lourmat, Eberhardzell, Germany 
Gel electrophoresis chambers Peqlab Biotechnologie, Erlangen, 
Germany 
Glassware Schott AG, Mainz, Germany 
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Irradiation device Gammacell 40 (Cs-137) Atomic Energy of Canada Limited, 
Ottawa, Canada 
Ice machine AF 200 Scottsman, Milan, Italy 
Incubator CO2 O2 control  Heraeus Holding, Hanau, Germany 
Binder, Tuttlingen, Germany 
Inverted microscope Axiovert 25 Zeiss, Jena, Germany 
Laminar flow hoods BDK, Sonnenbühl-Genkingen, Germany 
LightCycler 480  Roche, Basel, Swizerland 
Magnetic stirrer “IKAMag REO” IKA®-Werke GmbH, Staufen, Germany 
Microwave “compact microwave oven” Reston Lloyd, Sterling, USA 
Nanodrop ND-1000 spectrophotometer Peqlaq Biotechnologie, Erlangen, 
Germany 
Neubauer counting chamber Paul Marienfel, Lauda-Königshofen, 
Germany 
PCR-machine “Biometra® Tgradient” Biometra, Göttingen, Germany 
pH Tester (HI98108, pHep®) Hanna® Instruments, Smithfield, USA 
Pipetboy acu INTEGRA Biosciences, Fernwald, 
Germany 
Plasticware Brand, Wertheim, Germany 
PowerPac 200 power supply Bio-Rad, München, Germany 
Precision balance “SPB 55” Scaltec instruments, Göttingen, Germany 
Pipettes (0.1-2 µL 2-20 µL, 20-200 µL, 
100-1000 µL) 
Gilson, Mettmenstetten, Switzerland 
Thermomixer compact Eppendorf, Hamburg, Germany 
Transferpipette (2.5-25 µL, 20-200 µL) Brand, Wertheim, Germany 
Tumble roller mixer TRM-50 IDL GmbH, Nidderau, Germany 
Ultra pure water device “Aquintus” membraPure, Hennigsdorf, Germany 
Universal Microplate reader EL-800 BIO-TEK Instruments, Winooski, USA 
Vacuum pump Fröbel, Labortechnik, Lindau, Germany 
Vortex mixer, VM-300 NeoLab, Heidelberg, Germany 
Wallac Victor2 1420 Multilabel-Counter PerkinElmer, Waltham, USA 
Water baths GFL, Burgwedel, Germany 
 
2.11 Databases and software 
The IMGT database was used for this study for the identification of the CDR3 region of 
the sequenced δ chain of the TCR of γδ T cell clones (http://www.imgt.org/) 
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Software used for this study for designing experiments, data analysis and data 
illustration: 
Name Application Source 
Adobe® Illustrator® CS5 Illustration and graphic 
design 
Adobe System Inc., San 
José, USA 
Bookends 11.3.7 Reference management Sonny Software, Chevy 
Chase, USA 
Cell QuestTM Pro FACS analysis BD Biosciences, 
Heidelberg, Germany 
Diva Software FACS analysis BD Biosciences, 
Heidelberg, Germany 
FlowJo 9.4.11 FACS analysis TreeStar Inc., Ashland, 
USA 
KC4 ELISA measurement, 
calculation of standard 
curves 
TreeStar Inc., Ashland, 
USA 
LC480 Software Service 
Pack 3 
Relative quantification for 
quantitative PCR 
Roche, Basel, Switzerland 
MacVector 12.7.5 Nucleotide and protein 
sequence analysis and 
alignment 
MacVector Inc., Cary, 
USA 
Microsoft® Word 2011 Writing and work 
processing 
Microsoft, Redmond, USA 
Microsoft® Excel 2011 Data analysis  Microsoft, Redmond, USA 
 
2.12 Services 
The EBV and HCMV IgG serostatus of the blood donors was determined by the Max 
von Pettenkofer-Institute, München, Germany. 
High or low resolution HLA typing of blood donors was performed on PBMCs using 
PCR-based methods by IGMG/Labor Dr. Klein und Dr. Rost, Martinsried, Germany. 
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3 Methods 
3.1 Molecular biology methods 
3.1.1 Agarose gel electrophoresis 
PCR products were separated and visualized according to their size by agarose gel 
electrophoresis. 1-1.5% agarose gels were prepared in 1x TAE buffer. For 
visualization, ethidium bromide was added at the final concentration of 0.1 µg/mL. 1x 
TAE was used as running buffer. The nucleic acid was mixed with 6x loading dye 
(Fermentas) prior to loading onto the agarose gel. The molecular weight marker 
GeneRulerTM DNA Ladder Mix (Fermentas) was used to verify the size of the DNA 
fragments. Gels were documented by ultraviolet (UV) light irradiation (gel 
documentation system, Vilber Lourmat) 
 
3.1.2 Polymerase Chain Reaction (PCR) 
Polymerase chain reaction (PCR) was used to detect the presence of endogenous EBV 
in CD40L-stimulated B-blasts and in mutant LCLs. DNA extraction from these cells 
was performed with the aid of the DNA extraction kit QIAamp® DNA Blood Mini Kit 
(Qiagen). PCR reactions were carried on in 0.5 µL tubes in a total volume of 25 µL, 
using the Taq Polymerase (NewEngland BioLabs) with the supplied buffer. A standard 
reaction mix contained 100-150 ng DNA template, 2.5 µL of the 10x Taq Buffer, 10 
pmol of each primer, 0.5 µL dNTPs (10 mM, Fermentas) and 0.2 µL of the Taq 
Polymerase. Sterile water was added up to 25 µL of final the reaction volume. A 
standard PCR program included initial denaturation at 95°C for 45 seconds, followed 
by 40 cycles of (i) denaturation at 95°C for 45 seconds, (ii) annealing of the primers at 
the primer-specific temperature for 45 seconds, and (iii) product elongation at 68°C 
according to the expected product size (Taq polymerase elongates at 1000 bp/min). A 
final step of 5 minutes at 68°C was performed to enable the completion of abortive 
elongation reactions. 
The amplification of cDNA from γδ T cell clones to be sent for sequencing was 
performed in a similar fashion, but with the use of the Pfu DNA Polymerase (Thermo 
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Scientific) with the supplied buffer. Pfu DNA Polymerase is proof-reading and shows a 
reduced error rate. For the reaction mix, 1 µL of cDNA product, 4 µL of the 10x Pfu 
Buffer, 10 pmol of each primer, 0.5 µL dNTPs (10 mM, Fermentas) and 0.5 µL of the 
Pfu Polymerase were used. Sterile water was added up to 40 µL of the final the reaction 
volume. A standard PCR program included initial denaturation at 94°C for 2 minutes, 
followed by 40 cycles of (i) denaturation at 94°C for 30 seconds, (ii) annealing of the 
primers at the primer-specific temperature for 30 seconds, and (iii) product elongation 
at 72°C according to the expected product size (Pfu polymerase elongates at 500 
bp/min). A final step of 10 minutes at 72°C was performed to enable the completion of 
abortive elongation reactions. Out of this reaction, 10 µL were used to control the 
efficiency of the reaction by agarose gel electrophoresis and the remaining 30 µL were 
sent for DNA sequencing after purification with the kit NucleoSpin® Gel and PCR 
Clean-up (Qiagen). 
 
3.1.3 Reverse transcriptase-PCR 
Total RNA was extracted from LCLs or from γδ T cell clones with the aid of the 
RNeasy® Mini Kit (Quiagen) according to the manufacturer instructions. cDNA 
synthesis from RNA was performed by Quantiscript Reverse Transcriptase with the 
QuantiTect® Reverse Transcription Kit (Quiagen). Usually, 1 µg of RNA was used for 
reverse transcription.  
 
3.1.4 Quantitative PCR 
Quantitative PCR was performed on 96-well plates in a LightCycler 480 (Roche). PCR 
products were detected with the aid of SYBR Green LC480 Mix (Roche). SYBRGreen 
is an intercalating marker: intercalation into double-strand DNA results in fluorescence. 
Three technical replicates were performed for each sample, as well as for a negative 
control free of template to identify possible contaminations. Total reaction volume of 
10 µL contained 5 pmol of each primer, 2 µL of diluted cDNA template and 5 µL of 2x 
SYBRGreen reaction mix. cDNA stocks was diluted at least 5-fold with sterile water 
because of PCR efficiency. Relative mRNA expression of other genes was expressed in 
proportion to the housekeeping gene β-Glucuronidase (GUSB) (de Brouwer et al. 2006; 
Iskra et al. 2010). 
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A standard qPCR program included initial denaturation at 95°C for 10 minutes, 
followed by 45 cycles of (i) denaturation at 95°C for 10 seconds, (ii) annealing of the 
primers at 60°C for 10 seconds and acquisition of fluorescence, and (iii) product 
elongation at 72°C for 10 seconds. The 45 cycles were followed by 5 seconds at 95°C 
and 10 seconds at 65°C for the dissociation and annealing of the DNA strands before 
the quality control step. Afterwards, continuous heating to 95°C was performed with 
the acquisition of fluorescence (melting curve) to verify the amplification of only one 
DNA product. 
 
3.2 Cell culture methods 
3.2.1 Cell culture conditions 
All eukaryotic cells used in this study were cultivated in an incubator with humidified 
atmosphere at 37°C and 5% CO2. Handling of cells was carried out in laminar flow 
hoods. 
 
Standard cell culture medium was RPMI 1640 with 10% fetal calf serum (FCS), 100 
U/mL penicillin, 100 µg/mL streptomycin, and 100nM sodium selenite (ICN).  
 
Stimulator cell line LL8 stably expressing the human CD40 ligand was generated by 
stable transfection of L929 mouse fibroblasts with an expression plasmid for human 
CD40 ligand carrying a G418-selectable marker, followed by two rounds of single-cell 
cloning under selection. LL8 was cultivated until confluence and splitted once a week 
by washing twice with PBS and detachment with 0.5% Tryspin/EDTA for 7-10 minutes 
at room temperature. Detached cells were pelleted by centrifugation and replated at a 
25-50-fold lower cell number in fresh standard cell culture medium. 
 
Suspension cells (LCLs, K562, Daudi, Raji) were cultivated in flasks and expanded 
once or twice a week as necessary. 
 
293HEK-EBV derived lines were cultivated in standard cultivation medium with the 
addition of 100 µg/mL hygromycin B to preserve the stably transfected maxi-EBV 
plasmid. At confluence, cells were splitted once a week by washing twice with PBS. 
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Cells were detached with 0.5% Tryspin/EDTA for 7 minutes at 37°C. Detached cells 
were pelleted by centrifugation and expanded approximately 20-fold in fresh standard 
cell culture medium with the addition of hygromycin B. 
 
In general, cells were pelleted by centrifugation for 8-10 minutes at 12000 rpm at room 
temperature. 
 
Cell count was determined using a Neubauer counting chamber. Before counting, cell 
suspensions were diluted 2-10 fold with 0.5% trypan blue solution in order to visualize 
dead cells. Cells with intact cell membrane are not permeable to the negatively charged 
trypan blue. By contrast, dead cells and debris are stained by the dye and appear blue 
under the microscope. 
 
3.2.2 Cyopreservation of cells 
Long-term preservation of eukaryotic cells was achieved by storing the cells in the 
presence of dimethyl sulfoxide (DMSO) in the gas phase over liquid nitrogen. Cells 
were pelleted by centrifugation and resuspended in a cold solution containing 45% 
RPMI, 45% FCS and 10% DMSO. Cell suspensions were aliquoted in 1.8 mL 
cryovials, pre-cooled on ice and stored as soon as possible at -80°C. After a few days 
the aliquots were transferred to the liquid nitrogen tank. 
 
Frozen cells were thawed as quickly as possible by adding pre-warmed standard cell 
culture medium to the cryovial. The DMSO-containing solution was discarded by 
washing the cells once with 20-25 mL of medium. After centrifugation, the cell pellet 
was resuspended in the required medium and cells were taken into culture.  
 
3.2.3 Isolation of peripheral blood mononuclear cells 
Peripheral blood from healthy donors was collected and directly heparinized. A 
maximum of 25-30 mL of blood was distributed into 50 mL Falcon tube and diluted 
with sterile PBS until reaching 40 mL of volume. Slowly, 10 mL of Pancoll were added 
to the diluted blood by layering it at the bottom of the tube. Samples were centrifuged 
at 2000 rpm for 25 minutes without acceleration and without brake. The Pancoll 
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solution allows the separation of mononuclear cells (PBMCs) from red blood cells and 
granulocytes. During centrifugation, PBMCs collect at the interface between the 
Pancoll and the plasma. After discarding part of the plasma/PBS phase, PBMCs were 
carefully recovered avoiding the uptake of the Pancoll and transferred to a new 50 mL 
Falcon. Recovered PBMCs were washed 3-5x with sterile PBS, counted and 
resuspended in medium for further uses. 
 
3.2.4 Virus production 
Virus-producing cell lines for recombinant EBV 2089 (EBV WT), derived from EBV 
strain B95.8 (Delecluse et al. 1998), for its ΔLMP2A-deleted derivative EBV 2525 
(Mancao & Hammerschmidt 2007) and for the virus-like particle TR-EBV strain 
(Delecluse et al. 1999) were provided by Wolfgang Hammerschmidt . Virus-producing 
cell lines were cultured in 15-cm dishes and reached 70% density before replacing the 
standard cultivation medium with 13 mL Opti-MEM (Invitrogen). PEI diluted 1:1000 
(w/v) in sterile water was used for transfection and 120 µL PEI was diluted in 1 mL 
Opti-MEM, stirred vigorously, incubated for maximum 5 minutes at RT. Per 15-cm 
dish of 293HEK-derived EBV producer cell lines, the viral lytic cycle was induced by 
transient transfection of 10 µg each of the expression plasmids coding for transcription 
factor BZLF1 (p509) and glycoprotein gp110/BALF4 (p2670), diluted in 1 mL Opti-
MEM. The PEI/Opti-MEM solution was incubated with the DNA/Opti-MEM solution 
for 20 minutes at RT and applied dropwise to the cells. Incubation of the cells with the 
PEI/DNA solution was performed overnight or for at least 6 hours. On the following 
day, the cells were supplied with standard full RPMI media. EBV-containing 
supernatant was harvested three days later, centrifuged to reduce cellular debris, filtered 
(0.8 µM), and stored at 4°C. Titer of infectious virus was determined by infecting Raji 
cells for three days and quantifying GFP-positive cells by flow cytometry as described 
(Altmann & Hammerschmidt 2005). Infection of B cells was performed at 0.1 virus 
units per cell.   
The marmoset-derived lymphoblastoid cell line B95.8 spontaneously produces EBV in 
significant amount (Miller & Lipman 1973). Thus, virus containing supernatant was 
harvested from B95.8 cultures, cell debris were eliminated by centrifugation and 
filtration (0.8 µM), and virus containing supernatant was stored at 4°C. 
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3.2.5 Establishment of permanent B cell lines 
CD40-stimulated and lymphoblastoid cell lines (LCLs) were established from primary 
B cells purified from freshly isolated PBMCs. Untouched B cells were negatively 
isolated using Human B Cell Isolation Kit II (Miltenyi Biotec). Enrichment of B cells 
was verified by flow cytometry (anti-CD19 clone HIB19; anti-CD3 clone HIT3a) and 
was in the range of 95-98%. B cells were plated at 100.000 cells/well in 24-well plates 
on an adherent cell layer of irradiated (180 Gy) CD40 ligand-expressing LL8 cells in 
standard medium supplemented with 1 mg/mL cyclosporine A to inhibit possible 
residual T cell activity. Cyclosporin A was kept in the culture up to 4-5 weeks after 
infection/stimulation. In case of the establishment of CD40-stimulated B cell lines, IL-4 
was added to the culture at a concentration of 2.5 ng/mL, and cells were replated 
weekly onto a fresh layer of LL8 cells with expansion as necessary. For the 
establishment of LCLs, B cells were infected with 0.1 virus units per cell. Half of the 
culture supernatant was exchanged at day 1 post infection to diminish possible cell 
death due to toxicity of viral supernatant. Outgrowing cultures were transferred after 1-
2 weeks to a fresh plate, and further cultivated without LL8 cells. Presence of mutant 
EBV in the LCLs and absence of endogenous EBV wild type in the LCLs and CD40L-
stimulated B blasts were confirmed by PCR every few weeks. Proliferating lines were 
analyzed and used in T cell assays between 1.5 and 4 moths after establishment.  
 
3.3 T cell clones 
3.3.1 Generation of EBV-specific and HCMV-specific CD8+ T cells clones 
EBV-specific T cells were directly isolated from PBMCs of EBV-seropositive, HLA-
typed donors after stimulation with a matched peptide using the IFN-γ secretion assay 
(Miltenyi Biotec), according to the manufacturer instructions. For single T cell cloning, 
isolated IFN-γ-secreting cells were seeded into round-bottom 96-well plates at 0.7 or 
2.5 cells per well in 200 µL of medium supplemented with 1000 U/mL rIL-2, 105/mL 
irradiated (50 Gy) HLA-matched LCLs, and 1.5×106/mL of a mixture of irradiated (50 
Gy) allogeneic PBMCs from at least three different donors. Outgrowing T cell clones 
were expanded in round-bottom 96-well plates by restimulating every 2 weeks under 
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the same conditions. When necessary, cells were splitted and medium was exchange. 
Monoclonality of the cultures was tested by flow cytometry. 
3.3.2 Generation of monoclonal γδ  T cell lines 
Monoclonal γδ T cell lines were established using the limiting dilution method. Freshly 
isolated PBMCs were used to isolate γδ T cells with the aid of the TCRγ/δ+T cell 
Isolation Kit – human (Miltenyi Biotec) for purification of untouched γδ T cells. The 
instructions of the manufacturer were followed. Efficiency and purity of the separation 
was verified by flow cytometry and usually was above 95%. Subsequently, the purified 
γδ T cells were plated on a U-bottom 96-well plate at a concentration of 0.5 cells/well, 
together with irradiated (50 Gy) PBMCs from 3 different donors at a concentration of 
1x106 cells/mL, irradiated (50 Gy) LCLs from 3 different donors at a concentration of 
0.2x106 cells/mL and 500 U/mL IL-2, in order to stimulate γδ T cell growth. After two 
weeks, half of the medium was exchanged. Single cell clones started to outgrow after 3-
4 weeks after the first stimulation. Every 3 weeks, γδ T cell clones were restimulated 
under the same conditions. When necessary, cells were splitted and medium was 
exchange. Monoclonality of the cultures was tested by flow cytometry. 
 
3.4 Immunological methods 
3.4.1 ELISA for quantification of cytokine release 
For IFN-γ ELISA, effector cells (25.000 cells/well) and target cells (50.000 cells/well) 
were co-cultivated in 200 µl/well in a V-bottom 96-well plate at 37°C and 5% CO2. For 
IL-10 ELISA, LCLs were plated at a concentration 500.000 cells/mL in a 12-well plate 
or in a V-bottom 96-well plate and incubated at 37°C and 5% CO2. In both cases 
supernatants were harvested after 16-18 hours. ELISA was performed according to the 
manufacturer's instructions (Mabtech, Nacka, Sweden). Antibodies were diluted in 
sterile PBS w/o Mg2+ and added to the plates in 50 µL/well. Plates were rinsed 4-5 
times with PBS + 0.05% Tween. Unless otherwise noted, all incubation steps were 
carried out at room temperature. ELISA plates (Nunc MaxiSorp Immunoplates) were 
coated with a monoclonal „capture“ antibody (2 µg/mL) specific for the appropriate 
cytokine by overnight incubation at 4°C. The following day, plates were rinsed to wash 
away unbound antibody and unspecific binding sites were blocked by incubation with 
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200 µL standard culture medium for 30 minutes. After washing, 50 µL of the co-culture 
supernatant to be analyzed was applied to the plates for 2 hours, to allow cytokines to 
bind to the specific antibody. For quantification purposes, a cytokine standard was 
prepared and incubated in parallel on each plate. Plates were washed and incubated 
with a second cytokine-specific biotinylated antibody (1 µg/mL) for 1 hour. The 
antibody „sandwich“ was labeled by incubation for 1 hour with Streptavidin-ALP 
(diluted 1:1000), which binds to the antibody sandwich via biotin. Detection was 
achieved by applying 50 µL/well ALP substrate solution containing para-
nitrophenylphosphate (p-NPP). ALP catalyzes the hydrolysis of colorless p-NPP to the 
yellow p-nitrophenol. The ALP substrate solution was prepared immediately before use 
by 5-fold dilution in sterile water of the ALP stock solution (50% diethanolamine and 5 
mg/ml p-NPP in sterile water at pH 9.5) with the addition of the ALP cofactor Mg2+ 
(MgSO4) in final concentration of 0.8 mM. The presence of p-nitrophenol was detected 
with a spectrophotometer at 405 nm. The standard curve for the calculation of the 
concentration in each sample was performed with the KC4 software (TreeStar Inc.). 
 
3.4.2 Cytotoxicity assay 
The cytotoxic activity of γδ T cells against target cells was measured by calcein-release 
assay. Target cells (2x10^6 cells) were labeled with 5 µg/mL calcein 
acetoxymethylester (Invitrogen) in 1 mL medium. After incubation for 30 minutes at 
37°C, labeled cells were washed 3-4 times with sterile PBS in a 15 mL Falcon tube. 
Following, this 5000 target cells/well were plated in V-bottom 96-well plates (200 
µL/well). For each target cell type, spontaneous release (no effector cells, 0% lysis) and 
maximum release (addition of 0.5% of Triton-X 100, 100% lysis) was determined. 
Effector cells were counted, washed once and plated at the appropriate target:effector 
ratio (usually 1:10, see figure legends) and co-incubated with target cells for 3 hours at 
37°C and 5% CO2. Thereafter, 150 µl of supernatant were collected and transferred to 
a fresh flat bottom 96-well plate. Fluorescence intensity at 485/535 nm 
(excitation/emission) was measured in a Wallac Victor2 counter (Perkin-Elmer).  
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3.4.3 Blocking studies 
To evaluate the role of different receptors in CD8+ T cell and in γδ T cell effector 
function activities (cytokine release, cytotoxic lysis), the interaction between the given 
receptor and its ligand(s) was blocked by specific purified antibodies. Each antibody 
was added either to the target or to the effector cells at a pre-established concentration 
and incubated for 1 hour at 37 °C, 5% CO2 prior to the addition of the effector or target 
cells. As a control, matched isotype controls were used. 
 
Specificity Clone Isotype Purchased from Final conc 
NKG2D 
LEAF 
1D11 IgG1, mouse Biolegend, San Diego, USA 50 µg/ml 
isotype LEAF MOPC-21 IgG1, mouse Biolegend, San Diego, USA 50 µg/ml 
HLA-I LEAF W6/32 IgG2a, mouse Biolegend, San Diego, USA 100 µg/ml 
isotype MPC-11 IgG2a, mouse Biolegend, San Diego, USA 100 µg/ml 
γδ-TCR 
LEAF 
B1 IgG1, mouse Biolegend, San Diego, USA 50 µg/ml 
isotype LEAF MOPC-21 IgG1, mouse Biolegend, San Diego, USA 50 µg/ml 
IL-10R 3F9 IgG2a, mouse Biolegend, San Diego, USA 20 µg/ml 
isotype RTK2758 IgG2a, mouse Biolegend, San Diego, USA 20 µg/ml  
Il-10 JES3-9D7 IgG1, mouse Biolegend, San Diego, USA 20 µg/ml  
isotype RTK2071 IgG1, mouse Biolegend, San Diego, USA 20 µg/ml  
HLA-A2 BB7.2 IgG2b, mouse Biolegend, San Diego, USA 50 µg/ml 
isotype MPC-11 IgG2b, mouse Biolegend, San Diego, USA 50 µg/ml 
 
LEAF indicates low-endotoxin, azide-free 
 
3.5 Phenotypical analysis of cells by flow cytometry 
3.5.1 Staining of cell surface antigens 
To measure the expression of different surface molecules, cells were stained with 
specific antibodies. Generally, between 100.000 and 200.000 cells were stained in a V-
bottom 96-well plate or in a 1.5 mL reaction tube (Eppndorf). All centrifugation steps 
were carried out in a centrifuge suitable for 96-well plates at 1200 rpm for 5 minutes at 
4°C or in a table centrifuge at 3200 rpm for 4 minutes at 4°C. Pre-cooled buffer (PBS + 
2% FCS) was used as washing buffer. If not stated otherwise, incubation with the 
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antibody diluted in buffer was always carried out in a final volume of 20 µl. Each 
antibody was used at the appropriate concentration, according to manufacturer´s 
instructions or previous titration analysis. Then, cells were incubated for 20 minutes on 
ice, washed (twice with 200 µL buffer in case of the V-bottom 96-well plate, once with 
1.5 mL buffer for the 1.5 mL tube), resuspended with the suitable volume of buffer, 
usually 100 µL, and directly analyzed. In case the sample was to be analyzed during the 
following days, cells were resuspended in fixing solution (PBS + 1% 
Paraformaldehyde). Fixed samples were stored in the refrigerator at 4-6°C for up to one 
week. 
 
In the case of unlabeled antibodies, cells were first stained with the unlabeled antibody 
by incubation for 20 minutes on ice, followed by a washing step (three times with 200 
µL buffer in case of the V-bottom 96-well plate, twice with 1 mL buffer for the 1.5 mL 
tube). The sample was then incubated again for 20 minutes on ice with a labeled 
secondary antibody specific for the Fc part of the primary antibody. If necessary, 
following the washing step (three times with 200 µL buffer in case of the 96-well plate, 
twice with 1 mL buffer for the 1.5 mL tube), the sample was incubated for a third step 
with a mix of labeled antibodies specific for other antigens. This last incubation step 
was followed by another washing step (twice with 200µL buffer in case of the 96-well 
plate, once with 1.5 mL buffer for the 1.5 mL tube) and the resuspension in a suitable 
volume of buffer. Cells were analyzed on a BD Bioscience FACS Calibur or on a LS 
Fortessa flow cytometer (BD Biosciences). Data analysis was performed using the 
FlowJo software (TreeStar Inc.).  
 
3.5.2 Peptide/HLA class I multimer staining  
Monoclonality of EBV- and HCMV-specific CD8+ T cells was confirmed ex vivo 
using the MHC class I multimer technology. This method uses the natural ligand for a 
given TCR, the MHC-I:peptide complex, to stain T cells and evaluate their epitope 
specificity. To increase the avidity of this interaction, multimerization of MHC-
I:peptide complexes to tetramers or pentamers is used. 
200.000-300.000 T cells were first stained with 1 µL unlabeled multimer for 10 
minutes at room temperature in a final volume of 30 µl in a V-bottom 96-well plate. 
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After two rounds of washing with 200 µL staining buffer (PBS+2%FCS), cells were 
incubated with Fluorotag-PE for 20 minutes on ice in a volume of 30 µl, followed by 
two times washing with 200 µL buffer. In case cells were to be stained with labeled 
antibodies, the sample was then incubated with the mix of labeled antibodies in 20 µL 
volume for 20 minutes on ice. The sample was washed once with 200 µL buffer and 
resuspended in a suitable amount of buffer for analysis. 
CRV-specific CD8+ T cells were stained using an MHC-StrepTactin multimer reagent 
(Streptamer) as described (Knabel et al. 2002). CRV/HLA-C*0702 MHC-I:peptide 
monomers were generated and provided by Dr. Michael Neuenhahn and Prof. Dirck 
Busch (Institute for Medical Microbiology, Immunology and Hygiene, Technische 
Universität München). Multimerization of the streptamer complexes for stabilization of 
the interaction between the streptamer and the TCRs was achieved by incubating the 
monomers with PE-labeled Streptactin for 45 minutes on ice at molar ratios of MHC 
molecule/StrepTactin molecule 1:1. Cells were incubated with an aliquot of the 
assembled multimer containing 2.5 µg CRV/HLA-C*0702 monomer in a total volume 
of 30 µL staining buffer for 20 minutes on ice. In case cells were to be stained with 
labeled antibodies, the sample was incubated at the same time with the multimer and 
with the mix of labeled antibodies for 20 minutes on ice. The sample was washed once 
with 200 µL buffer and resuspended in a suitable amount of buffer for analysis. 
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4 Results 
4.1 Modulation of the immunophenotype of B cells in cellular 
activation and EBV infection 
Infection with a virus induces numerous changes in a cell. Once cells are infected, they 
alert the immune system of the infection and support the recognition and the 
elimination of the infected cells in various fashions. One way to signal the threat by 
infection is the modification of the cell surface levels of immunomodulatory molecules. 
On the other hand, viruses strive to reduce infection-related alterations that could be 
detected by the immune system. EBV represents an extreme case, because it triggers B 
cell activation pathways that usually render a B cell highly immunogenic, and it is only 
incompletely known whether it interferes with some of the signals that trigger 
responses of immune effector cells. Therefore, I investigated the immunophenotypic 
changes induced in B cells early after EBV infection (Figure 4.1). Freshly isolated 
peripheral blood mononuclear cells (PBMCs) were infected with the recombinant EBV 
"wild type" strain 2089 (Delecluse et al. 1998) (WT, Figure 4.1A and B) or with its 
parental EBV wild type strain B95.8 (Miller et al. 1972b) (WT, Figure 4.1C), and 
surface expression of immune effector molecules was analyzed by flow cytometry after 
staining with specific antibodies. Already at day 3 after infection, EBV-infected B cells 
upregulated the B7 family member CD86, ligand for the costimulatory receptor CD28 
on T cells, and the adhesion molecule ICAM-1, important in the formation of the 
immunological synapse (Figure 4.1A). A stable increase of the surface expression of 
these two molecules was observed during the whole duration of the experiment. 
Surface expression of MICB, one of the ligands for the coactivatory receptor NKG2D 
on T and NK cells, reached its peak already at day 3 after infection, and was constant 
for all later time points (Figure 4.1A). Figure 1B and 1C show the surface expression at 
day 7 of the complete panel of analyzed molecules. Day 7 was chosen as representative 
of EBV-induced modifications, because at this time a dominant population of EBV-
transformed/activated cells was present in the culture, as evidenced by cell enlargement 
and increased scatter in flow cytometry (Iskra et al. 2010). Infection with EBV was 
compared to pseudo-infection with virus-like particles (TR-) and to non-infected cells 
(Figure 4.1B), or only to non-infected cells (Figure 4.1C). The EBV mutant "TR-" 
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lacks the packaging signals (Terminal Repeats) (Delecluse et al. 1999), and upon 
induction of the lytic cycle of the packaging cell line, virus-like particles devoid of the 
viral DNA genome are produced. Of notice, the virus-like particles still contain some 
viral and cellular mRNAs (Jochum et al. 2012b). At day 7, we detected upregulation of 
the coinhibitory B7 molecule PD-L1, and downregulation of the costimulatory 
molecules ICOS-L, another B7 family member, and of CD48, ligand of the SLAM 
family member 2B4. However, surface expression of CD48 was decreased not only on 
EBV-infected cells but also on uninfected cells on day 7. I did not detect modification 
of surface expression of CD11a, a component of the integrin LFA-1, its counterpart  
Figure 4.1. Induction of the surface expression of immunomodulatory molecules on B cells by EBV 
infection. (A) PBMCs (donor 2) were infected with recombinant EBV wild-type strain 2089 (WT), and 
expression of the indicated surface molecules on B cells was determined by flow cytometry after staining 
with specific monoclonal antibodies. Expression of the indicated surface molecules was determined at 
day 0, 3, 7, 9, 11, 13 and 17 after infection. (B, C) PBMCs (donor 2) were infected with EBV 
recombinant 2089 (WT in panel B) or native recombinant strain B95.8 (WT in panel C), EBV virus-like 
particles (TR-), or cultivated without EBV (Not Inf). Expression of the indicated surface molecules on B 
cells was determined at day 7 after infection by flow cytometry after staining with specific monoclonal 
antibodies and compared to expression at day 0 on untouched B cells. The multiplicity of mean 
fluorescence intensity (mMFI) was determined by dividing MFI of specific antibody staining by MFI of 
isotype control. 
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ICAM-1, or the coactivating members of the TNF superfamily OX40-L and 4-1BB-L. 
Interestingly, at later time points (day 9) I detected upregulation of the NKG2D ligand 
ULBP4 (Figure 4.1A). Expression of other NKG2D ligands, ULBP1, 2, 3, 5 and 6 was 
not detected, even at late time points (data not shown). With the exception of changes 
in CD48 expression, none of these modifications could be detected in non-infected cells 
or in cells infected with virus-like particles, suggesting that active EBV infection was 
responsible for the modification of the surface levels of these immunomodulatory 
molecules. 
A number of recent reports suggested that EBV infection induces upregulation of 
ligands for the receptor NKG2D, which is important as a coactivator on T and NK cells 
(Pappworth et al. 2007; Kong et al. 2009; Wiesmayr et al. 2012; Chaigne-Delalande et 
al. 2013). Therefore, I analyzed the surface expression of all NKG2D ligands in a 
tighter time frame directly after infection, to determine the kinetics of regulation of 
these molecules (Figure 4.2).  EBV infection of B cells induced upregulation of MICB 
already at day 1 after infection, and a moderate upregulation of ULBP1 at later time 
points. I could not observed upregulation of ULBP4, probably because the time points 
analyzed in this experiment were too early for its detection.  
Subsequently, to determine whether the modifications observed in the surface 
expression of immunomodulatory molecules was specifically induced by EBV, I 
compared EBV infection to “classical” B cell activation. B cell activation through the 
BCR was achieved with F(ab´)2 fragments specific for human IgA, IgG and IgM 
Figure 4.2. Surface expression of NKG2D ligands on B cells early after infection with EBV. PBMCs 
(donor 6) were infected with EBV wild type strain 2089 (WT EBV) or left untouched (Not Infected), and 
expression of the indicated NKG2D ligands on B cells was determined by flow cytometry after staining 
with specific monoclonal antibodies. Expression of the indicated molecules was determined at day 0, 1, 
2, 3, 6 and 8 after infection. The multiplicity of mean fluorescence intensity (mMFI) was determined by 
dividing MFI of specific antibody staining by MFI of isotype control. 
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(αBCR, signal 1) (Ruprecht & Lanzavecchia 2006); coactivation by helper T cells was 
mimicked by plating B cells on a layer of murine fibroblasts overexpressing human 
CD40 ligand (CD40L) together with the addition of IL-4 (CD40L/IL-4, signal 2) 
(Wiesner et al. 2008); unmethylated CpG DNA oligonucleotide 2006 was added in 
 
Figure 4.3. Induction of surface expression of agonistic or antagonistic molecules on B cells after B 
cell activation. PBMCs (donor 6) were activated with F(ab´)2 fragments specific for human IgA, IgG 
and IgM to activate the BCR receptor (αBCR, signal 1 in B cell activation), with mouse L929 cells 
stably expressing human CD40L plus IL-4 (CD40L/IL-4, signal 2 in B cell activation), with CpG DNA 
to activate TLR9 (CpG, signal 3 in B cell activation), or with all possible combinations of these stimuli. 
These conditions were compared with infection with EBV WT strain 2089 or with cultivation of 
untouched, uninfected cells in standard medium alone (Not Infected). Expression of the indicated surface 
molecules on B cells was determined by flow cytometry after staining with monoclonal antibodies. Flow 
cytometric analyses were performed on day 0, 1, 2, 3, 6 and 8 after activation/infection. The multiplicity 
of mean fluorescence intensity (mMFI) was determined by dividing MFI of specific antibody staining by MFI 
of isotype control. 
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soluble form to activate toll-like receptor 9 (TLR9), a PRR receptor (CpG, signal 3) 
(Hartmann & Krieg 2000). These stimuli were used alone or in all possible 
combinations and were compared to infection with EBV WT 2089 (WT EBV) or to 
uninfected cells (Not Infected). Stimulation of B cells through the activation of 
different cellular mechanisms, induced upregulation of several immune effector 
molecules on the B cell surface. The NKG2D ligand MICB was most efficiently 
upregulated by CD40L/IL-4 alone, or by combinations of at least two stimuli (Figure 
4.3A). The highest induction of this ligand was obtained on B cells stimulated with all 
three compounds. Induction was transient, reaching its maximum at day 2 after 
stimulation, and going back to near-basal levels later. I could not observe upregulation 
of any other NKG2D ligands (Figure 4.3A and data not shown). Activation of B cells 
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also induced a fast but transient expression of the inhibitory B7 family molecule PD-L1 
(Figure 4.3B). Interestingly, to observe upregulation of this molecule, at least two 
stimuli were needed. Again, strongest expression was obtained when all three 
stimulatory signals were combined. It appeared that αBCR+CpG were more important 
for PD-L1 induction than CD40L/IL-4. In contrast, the stimulatory B7 molecule CD86 
was induced by CD40L/IL-4 activation, while αBCR or CpG alone had no effect on the 
expression of this molecule. CD86 expression reached its maximum surface expression 
level at the last day of analysis, especially by combining CD40L/IL-4 with CpG 
stimulation (Figure 4.3C). In this case, combination of the three stimuli still resulted in 
upregulation of CD86, but the surface expression level reached for this molecule was 
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comparable to the induction by CD40L/IL-4 alone, suggesting that activation of the 
BCR partially counteracted the upregulation of this molecule induced by CD40L/IL-
4+CpG. It is noteworthy that induction of CD86 by EBV is slightly lower during the 
first few days after infection, but reached levels similar to those during CD40L/IL-
4+CpG stimulation at the last analyzed time point, day 8. For the other B7 molecule 
analyzed in this experiment, ICOS-L, I could not detect any relevant changes in its 
expression (Figure 4.3B). 
In contrast to what was seen with EBV (Figure 4.1, Figure 4.3B), activated B cells 
showed upregulation of the integrin CD11a, which was delayed relative to most other 
induced markers. CD11a seemed to be induced in particular by CD40L/IL-4 or by the 
combinatory activation of two or more B-cell activatory pathways. The expression of 
its interaction partner, ICAM-1, followed a pattern of expression similar to PD-L1 
(Figure 4.3C). Upregulation of ICAM-1 was strongly marked at day 1 after activation, 
but it was transient and quickly compressed already at day 2. In this case, strongest 
induction was observed by CD40L/IL-4 alone or in combination with αBCR, although 
the contribution of αBCR was small. EBV infection, on the other end, did not cause 
early induction of ICAM-1, but led to a slow progressive upregulation of this molecule. 
Expression of the SLAM family member CD48 showed only small changes after any 
kind of stimulus, with a small peak of expression on day 2 followed by a slow but 
stable decrease (Figure 4.3B). Modulation of OX40-L and 4-1BB-L expression levels 
was not observed (data not shown). Untouched B cells did not show any modulation of 
expression for any of the molecules analyzed in this experiment. It is interesting to 
notice that the stimulus that had the strongest effects on the largest number of 
immunomodulatory molecules was CD40L/IL-4. These results show that “classical” B 
cell activation induces the upregulation of a variety of immunomodulatory molecules 
often in a pattern different from EBV infection. Although there are several similarities 
in the expression patterns, EBV infection of B cells does not simply mimic cellular 
activation pathways, but induces in early-infected B cells a specific, virus-induced 
immunophenotype. In particular, suppression of MICB and ICAM-1 peak expression 
and induction of sustained PD-L1 expression are hallmarks of EBV infection compared 
to normal B cell activation. This observation is consistent with the hypothesis that EBV 
must modify the standard activation-induced gene expression program in infected cells 
in order to avoid being eliminated by immune effector cells. 
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4.2 LMP2A decreases recognition of infected cells by CD8+ T cells 
To investigate the influence of LMP2A on the interaction between EBV-infected cells 
and cellular immunity, I established EBV-transformed B cell lines (LCLs) with a 
mutant EBV virus deleted for LMP2A (Mancao & Hammerschmidt 2007). This virus is 
deleted for the promoter and the first exon of LMP2A on the background of the EBV 
strain B95.8. Expression of LMP2B is still possible in this mutant. B cells were purified 
from freshly isolated PBMCs (Figure 4.4) and infected with the LMP2A-deficient virus 
(ΔLMP2A) and with the parental LMP2A-expressing virus, the wild type strain 2089 
(WT). In line with previous findings (Brielmeier et al. 1996; Mancao & 
Hammerschmidt 2007), I found that the ΔLMP2A virus had reduced efficiency of B 
cell transformation (data not shown). From now on, all LCLs designated "WT" had 
been established with the recombinant 2089 strain that carries the complete B95.8 wild-
type EBV genome. To facilitate the establishment of LMP2A-deficient LCLs, I 
infected primary B cells with both WT and mutant EBV in the presence of LL8 
fibroblasts that overexpress human CD40L. Outgrowing B cell cultures were further 
expanded in the absence of these stimulator cells. Established LCLs were regularly 
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Figure 4.4. Purification of peripheral B cells. The flow cytometry plots show examples of the 
efficiency of B cell purification from PBMCs from two donors by immunomagnetic depletion of non-B 
cells (B Cell Isolation Kit II, Miltenyi Biotec). Mononuclear cells were identified in the SSC/FCS graph 
and gated to eliminate debris and dead cells. Within the lymphocyte population, B cells were identified 
as CD19+/CD3-. Purity of the purified B cell population reached always 95-99%. Before: PBMCs before 
purification; After: B cell fraction after purification. FSC, forward scatter; SSC, side scatter. 
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Figure 4.5. ΔLMP2A LCLs were tested by PCR for the presence of endogenous wild-type EBV. 
ΔLMP2A LCLs (Δ, in this example established from donor 9) were tested by PCR every few weeks to 
detect the presence/reactivation of endogenous EBV. LMP2A bridging PCR was performed using 
primers binding conserved sites flanking the LMP2A deletion; a 481 bp product was expected only in the 
presence of the mutant EBV genome. Efficient generation of a PCR product from WT genomes was not 
expected due to its large size. LMP2A internal PCR was performed using one primer binding in a region 
present in both the WT and ΔLMP2A genomes together with a primer binding inside the genome 
fragment deleted in the mutant. Therefore, a product of 831 bp would be expected only in the presence of 
wild-type EBV. DNA preparations from WT LCLs (WT) and from the packaging cell line (pΔ) for the 
ΔLMP2A strain (LMP2A- 2525 293HEK) were used as controls, together with a PCR reaction performed 
without added DNA (∅). 
examined for the presence of the LMP2A deletion and for the absence of endogenous 
wild type EBV (Figure 4.5). Under these conditions, LCLs transformed with the WT or 
with the ΔLMP2A virus could be established with similar efficiency and did not exhibit 
differences in proliferation, cell density, survival, or longevity in culture (data not 
shown). This observation suggested that the presence of LMP2A was crucial for the 
proper establishment of EBV latent infection in vitro, but it was not essential for the 
growth of established LCLs.  
I analyzed the reactivity of EBV-specific CD8+ T cells in response to WT and 
ΔLMP2A LCLs  (Figure 4.6). Interestingly, CD8+ T cell clones specific for epitopes 
from all tested EBV latent antigens (EBNA1, EBNA3A, LMP2) showed a higher IFN-γ 
release in response to ΔLMP2A LCLs than to WT LCLs (Figure 4.6A). CD8+ T cells 
specific for the LMP2 epitope CLG recognized ΔLMP2A LCLs, as expected, because 
the CLG peptide is derived from a transmembrane region shared between LMP2A and 
LMP2B. In contrast, CD8+ T cell clones specific for lytic-cycle antigens (BRLF1, 
BZLF1) showed weak recognition of LCLs, and no difference in IFN-γ release could be 
detected after contact with WT or ΔLMP2A LCLs (Figure 4.6B). This is in accordance 
LMP2A Bridging LMP2A Internal
WT :6 p6M 6 WT :6 p6M 6
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with long-standing observations showing that LCLs express low to undetectable 
amounts of lytic-cycle genes (Pudney et al. 2005). Thus, LMP2A interfered with CD8+ 
T cell recognition of various EBV latent antigens, but was not able to detectably 
modulate the recognition of EBV lytic-cycle antigens by CD8+ T cells due to their low 
baseline level of recognition. 
 
Figure 4.6. Recognition of EBV-transformed B cells by CD8+ T cells in the presence or absence of 
LMP2A. (A, B) CD8+ T cell clones specific for epitopes from EBV latent antigens (A) or EBV lytic-cycle 
antigens (B) were coincubated with HLA-matched LCLs that were infected with EBV expressing LMP2A 
(WT) or deleted for LMP2A (ΔLMP2A). After 16 hours, IFNγ release in the supernatant was quantified by 
ELISA. EBV epitope peptides are designated by their first three amino acids in one-letter code. “D”, donor; 
“pep”, WT LCLs exogenously loaded with corresponding peptide; “∅t”, T cells alone. Data are represented as 
mean + standard error of the mean (SEM) for three replicates. Data are representative for two or more 
independent experiments performed for each T cell clone. 
	  	  
 
Results 
 
  
58	  
 
Figure 4.7.	  mRNA expression of EBV latent and lytic-cycle genes in LCLs in the presence or absence of 
LMP2A. Transcript levels of LMP2, EBNA1, EBNA3A (latent genes), BZLF1 and gp350 (lytic-cycle genes) 
were measured by quantitative RT-PCR in LCLs established with WT or ΔLMP2A EBV (donors 1, 3, 7, 9). 
Expression relative to transcript levels of the housekeeping gene β-glucuronidase (GUSB) is represented. Each 
dot represents a single measurement for a single cell line. Per condition, six to nine independently established 
LCLs from 4 different donors were analyzed. The horizontal line indicates the median. Statistical analysis was 
performed with the Mann-Whitney test.	  
 
Now I tested whether the observed difference in cell recognition could be related to 
mere differences in antigen expression between WT and ΔLMP2A LCLs. I 
quantitatively analyzed transcript levels of various latent and lytic EBV antigens in WT 
and ΔLMP2A LCLs from different donors (Figure 4.7). Independently generated LCLs 
showed some variation between each other in their expression of EBV transcripts, even 
though established with the same virus. On average, transcript levels of several EBV 
latent antigens (EBNA1, EBNA3A, LMP2) appeared to be increased in ΔLMP2A 
LCLs. However, this effect reached p < 0.05 only for EBNA1. No difference between 
WT and ΔLMP2A LCLs was seen for median expression of the lytic-cycle genes 
BZLF1 and gp350. These results suggest that LMP2A downmodulates the expression 
of latent antigens in EBV-infected B cells, in particular EBNA1. This effect may 
contribute to the reduced presentation of these antigens to CD8+ T cells. However, at 
least for latent antigens other than EBNA1, modulation of T cell recognition (Figure 
4.6) appeared too intense to be likely explained by differences in antigen expression 
alone. 
To investigate whether the differential reactivity of CD8+ T cells against B cells 
infected with WT or ΔLMP2A was mediated by mechanisms beyond availability of 
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EBV antigens, I exogenously loaded WT and ΔLMP2A LCLs with peptides from the 
human cytomegalovirus (HCMV) protein IE-1 (CRV and VLE), and I analyzed the 
recognition of peptide-loaded LCLs by HCMV-specific CD8+ T cell clones (Figure 
4.8). CD8+ T cells specific for the two analyzed HCMV peptides showed a better 
recognition of peptide-loaded ΔLMP2A LCLs than peptide-loaded WT LCLs. These 
data demonstrate that endogenous levels of antigen expression, or a potential 
interference of LMP2A with antigen processing, cannot be the only factors accountable 
for the difference in recognition of mutant LCLs to WT LCLs. This suggested that 
LCL-expressed surface or secreted molecules contributed to the differences in CD8+ T 
cell recognition.  
To identify other factors playing a possible role in CD8+ T cell reactivity, I 
investigated soluble and cell surface molecules that may influence the interaction 
between EBV-infected cells and CD8+ T cells. EBV codes for a homologue of the 
human anti-inflammatory cytokine IL-10, and LMP2A was shown to increase IL-10 
production in infected B cells (Incrocci et al. 2013). This possibility is intriguing 
because IL-10 is known to reduce antiviral activity of various immune effector cells 
(Zeidler et al. 1997; Bejarano & Masucci 1998; Jochum et al. 2012a). Therefore, I 
analyzed the release into the supernatant of IL-10 by WT and ΔLMP2A LCLs. Higher 
amounts of IL-10 were secreted by WT LCLs than LCLs lacking LMP2A (Figure 
4.9A). In contrast, transcription levels for human and viral IL-10 did not mirror levels 
of secreted IL-10, and for human IL-10 there was even an opposite trend (Figure 4.9B). 
This suggests an effect of LMP2A on post-transcriptional regulation of IL-10. To 
determine whether differences in IL-10 release could influence the reactivity of CD8+ 
Figure 4.8. CD8+ T cell recognition of heterologous peptides on LCLs in the presence or absence of 
LMP2A. WT and ΔLMP2A LCLs (donor 9) were loaded with titrated peptides CRV and VLE from the 
HCMV antigen protein IE-1, and were coincubated for 16 hours with antigen-specific CD8+ T cell clones. 
IFNγ release by CD8+ T cells into the supernatant was quantified by ELISA. “∅t”, T cells alone. 
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T cell clones, I used specific antibodies to neutralize IL-10 in the supernatant (Figure 
4.9D), or to block IL-10 receptor on CD8+ T cells (Figure 4.9C). In both cases, I did 
not detect an increase of recognition for WT or ΔLMP2A LCLs. These data suggest 
that, even though ΔLMP2A LCLs produce lower amounts of IL-10, this does not affect 
the ability of CD8+ T cells to recognize EBV-infected B cells.  
 
Figure 4.9. Role of LCL-secreted IL-10 in CD8+ T cell recognition in the presence or absence of 
LMP2A. (A) WT and ΔLMP2A LCLs (donors 1, 3, 7, 8, 9) were incubated at 0.5x106 cells/ml for 18 hours, 
and released IL-10 was evaluated in ELISA. Each dot represents the mean of quadruplicates for a single 
independently established cell line. Shown data are representative for three independent experiments. LCLs 
established from 5 different donors were analyzed. The horizontal line indicates the median. Statistical analysis 
was performed with the Mann-Whitney test. (B) mRNA levels for human IL-10 and BCRF1 (viral IL-10) 
were measured by quantitative RT-PCR in WT and ΔLMP2A LCLs (donors 1, 3, 7, 9) and are displayed 
relative to transcript levels of the housekeeping gene β-glucuronidase (GUSB). Each dot represents a single 
measurement for a single cell line. LCLs established from 4 different donors were analyzed. Shown data are 
representative for two independent experiments. The horizontal line indicates the median. Statistical analysis 
was performed with the Mann-Whitney test. (C, D) Reactivity of EBV-specific CD8+ T cell clones against 
WT or ΔLMP2A LCLs (donor 9) was determined after blocking the IL-10 receptor on the T cells (C) or in the 
presence of neutralizing IL-10-specific antibody (D). For both conditions, matched isotype control antibodies 
were used as control where indicated ("iso"). T cells had been pre-treated with the antibodies for 1 hour before 
incubation with LCLs. After 16 hours, IFNγ release in the supernatant was quantified by ELISA. Mean and 
range of duplicates are shown. 
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Figure 4.10. Expression of MHC class I on the surface of LCLs in the presence or absence of LMP2A. 
WT and ΔLMP2A LCLs were stained with antibodies specific for total HLA class I (“HLA-I”) or individual 
allotypes as indicated. Stained cells were analyzed by flow cytometry. Each dot represents a single 
measurement for a single independently established cell line. Lines established from 5 different donors were 
analyzed. Shown data are representative for three independent experiments. MFI: mean fluorescent intensity. 
The horizontal line indicates the median. Statistical analysis was performed with the Mann-Whitney test. 
 
Now I analyzed surface molecules involved in the interactions between CD8+ T cells 
and LCLs. First, I asked whether the absence of LMP2A could affect the surface levels 
of MHC class I molecules. To this end, I stained ΔLMP2A and WT LCLs with specific 
antibodies for total MHC class I and for individual MHC class I allotypes, and analyzed 
the cells by flow cytometry (Figure 4.10). Total MHC class I levels were moderately 
but significantly (p=0.0046) increased in LCLs deleted for LMP2A as compared with 
WT LCLs. A similar tendency was observed for some of the individual MHC allotypes, 
but this did not reach p < 0.05. Thus, LMP2A moderately reduces MHC-I levels in 
LCLs, which may contribute to the reduced recognition by CD8+ T cells. 
Antigen-specific activation of CD8+ T cells can be modulated by a variety of surface 
molecules on the antigen-presenting cell. Thus, I examined the expression on the 
surface of LCLs of relevant immunomodulatory molecules, for which an upregulation 
was seen early after EBV infection (Figure 4.1), and tested whether their expression 
was altered in the absence of LMP2A (Figure 4.11). Indeed, I found strong differences 
in expression for some such molecules. Contrary to what might have been expected, the 
coinhibitory B7 family molecule PD-L1 (B7-H1) was strongly induced in ΔLMP2A 
LCLs, whereas there was no difference in the expression of the B7 molecule CD86. 
Also counter-intuitively, the integrin CD11a was strongly downregulated in the absence 
of LMP2A, while its interaction partner ICAM-1 showed no differences in ΔLMP2A 
versus WT LCLs. So far, these alterations could not explain the increased susceptibility 
of ΔLMP2A cells, but rather would suggest the contrary. When I examined surface 
expression of NKG2D ligands, interestingly I found that latent EBV infection induced 
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the expression of MICA, MICB and ULBP4. As shown above in Figures 4.1, 4.2 and 
4.3, these molecules were not expressed on primary B cells and early EBV infection 
induced upregulation of MICB and, at later time points of ULBP4, but not of MICA 
(Figure 4.1, 4.2 and 4.3). This demonstrates that MICA induction is a slow process in 
EBV infection that becomes apparent only at later times than those tested above (days 
0–8). While expression of MICB did not differ between mutant and WT LCLs, a 
marked increase for MICA and ULBP4 was detected on ΔLMP2A LCLs as compared 
to WT LCLs (Figure 4.11). Similarly to early EBV infection, WT or ΔLMP2A LCLs 
did not express the other five NKG2D ligands (ULBP1, 2, 3, 5, 6) on their surface (data 
not shown). This phenotypic analysis identified NKG2D ligands as effector molecules 
that potentially contributed to increased recognition of ΔLMP2A LCLs by CD8+ T 
cells.    
 
Figure 4.11. Immunophenotype of EBV-infected B cells in the presence or absence of LMP2A. 
Expression of the indicated antigens on the surface of WT and ΔLMP2A LCLs (donors 2, 3, 4, 9) was 
determined by flow cytometry after staining with monoclonal antibodies. The multiplicity of mean 
fluorescence intensity (mMFI) was determined by dividing MFI of specific antibody staining by MFI of 
isotype control. Each dot represents a single analysis of an independently generated LCLs. LCLs from 4 
donors were analyzed. The horizontal line indicates the median. Statistical analysis was performed with the 
Mann-Whitney test. 
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Figure 4.12. Effect of NKG2D blocking on CD8+ T cell recognition of LCLs in the presence or absence 
of LMP2A. (A) CD8+ T cell clones specific for epitopes from EBV latent antigens EBNA3A  (RPP) and 
LMP2 (FLY) were coincubated with WT and ΔLMP2A LCLs in the presence of an anti-NKG2D antibody or 
matched isotype control where indicated. T cells had been pre-treated with the antibodies for 1 hour before 
incubation with LCLs. After 16 hours, release of IFNγ into the supernatant was evaluated by ELISA. “pep”, 
WT LCLs exogenously loaded with corresponding peptide; “∅t”, T cells alone. Mean and range of duplicates 
are shown. (B) WT and ΔLMP2A LCLs were loaded with peptides CRV and VLE from the HCMV antigen 
protein IE-1, and were coincubated for 16 hours with antigen-specific CD8+ T cell clones. Treatment with 
anti-NKG2D or isotype control antibodies and determination of IFNγ release were done as before. “∅t”, T 
cells alone. Data are representative for two or more independent experiments performed for each T cell clone. 
Mean and range of duplicates are shown. 
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To assess the functional relevance of NKG2D ligands, I analyzed the reactivity of 
CD8+ T cell clones against WT or ΔLMP2A LCLs after blocking the receptor NKG2D 
on the effector cells with a specific antibody (Figure 4.12). NKG2D blocking 
consistently decreased the IFN-γ release by EBV-specific CD8+ T cells after contact 
with EBV-infected cells (Figure 4.12A). A reduction was found in the reactivity of 
CD8+ T cells to both WT and mutant LCLs, but in absolute terms the reduction was 
higher for ΔLMP2A LCLs as compared to WT LCLs. Likewise, NKG2D blocking on 
HCMV-specific CD8+ T cell clones recognizing peptide-loaded LCLs also led to a 
reduction of IFN-γ release (Figure 4.12B). Thus, NKG2D ligands on LCLs contribute 
to their recognition by CD8+ T cells, irrespective of the antigen specificity of the CD8+ 
T cells. Thus, LMP2A reduces CD8+ T cell recognition of EBV-infected B cells, 
among other mechanisms, by reducing the expression of NKG2D ligands. 
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4.3 Evidence for a role of  γδ  T cells in control of EBV infection  
To elucidate the involvement of γδ T cells in the immunity against EBV, I incubated 
freshly isolated PBMCs from different donors with autologous or allogeneic LCLs, and 
analyzed the resulting expansion of γδ T cells (Figure 4.13). In the majority of the 
stimulation reactions (6 out of 8), contact with LCLs induced expansion of γδ T cells. 
Both the δ2+ and the δ2– subpopulations contributed to expansion (Figure 4.13B).  
Higher average expansion was observed for δ2– T cells than for δ2+ cells (Figure 
4.13A), and the proportion of cultures in which any expansion was observed was also 
 
Figure 4.13. Expansion of γδ  T cells after contact with LCLs. PBMCs from donors 3, 4, 6, 9, 13 and 
14 were stimulated with matched (donor 3) or mismatched LCLs (all other stimulation reactions). 
Expansion of γδ T cells, δ2+ T cells or δ2- T cells (determined as γδ+/δ2-) was determined by flow 
cytometry after staining with specific monoclonal antibodies. (A) Fold expansion of γδ T cell, δ2+ T 
cells or δ2- T cells is calculated as the ratio between the percentage identified by flow cytometry of the 
indicated population present at the last day of analysis (day 13, 14 or 21) and the percentage present in 
the culture at day 0, multiplied by total expansion of the culture. The horizontal lines indicate the 
median. (B) Kinetics of expansion for each stimulation. Cell numbers were calculated from percentages 
of each cell type and the total expansion rate reached at each time point of analysis (day 0, 7 or 8 and day 
13, 14 or 21) in the culture are shown. 
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Figure 4.14. Purification of peripheral γδ  T cells for the establishment of single cell clones. Flow 
cytometry graphs show examples of the efficiency of γδ T cells purification from PBMCs from three 
donors (Before: before purification; After: after purification). Lymphocytes were identified in the 
SSC/FSC graph and gated to eliminate debris and dead cells. In the lymphocyte population, γδ T cells 
were identified as γδ+/CD3+. Purity of the purified γδ cell population reached 90-95% in each case. 
higher for δ2– than for δ2+ cells. These results showed that both of the major γδ T cell 
subpopulations can react against EBV infected cells, but suggested that the role of δ2– 
T cells may be more important.  
I decided to establish single γδ T cell clones, in order to address which population was 
actively involved in the immunity against EBV. γδ T cells were purified from freshly 
isolated PBMCs (Figure 4.14), plated at a density of 0.7 cells/well, and stimulated with 
a mixture of irradiated PBMCs and LCLs coming from at least three allogeneic donors. 
Interestingly, different types of γδ T cells could be established as single cell clones 
(Table 4.1). Figure 4.15 shows examples of the single cell clones established. In total, I 
established 317 clones from five different donors. A majority of these clones were  
	  
N° γδ 
clones δ1+ δ2+ 
γ9+ 
δ1+ 
γ9+ 
δ2+ 
γ9+ 
δ1–
δ2– 
δ1– 
δ2– 
Donor 1 107 14 55 nd nd nd 3 
Donor 4 81 45 18 nd nd nd 6 
Donor 8 28 2 17 2 17 1 1 
Donor 9 22 14 2 3 2 0 0 
Donor 14 79 29 36 nd nd nd 2 
 
Table 4.1.	  Summary of the T-cell receptor phenotype of established γδ  T cell clones from 5 donors. 
γδ	  T cells purified from freshly isolated PBMCs were plated at a density of 0.7 cells/well and stimulated 
with a mixture of irradiated PBMCs and LCLs coming from at least three allogeneic donors. Individual 
outgrowing T cell cultures were analyzed by flow cytometry for expression of different TCR chains. The 
table summarizes the results of these analyses. Not all clones were analyzed with the whole set of 
antibodies; therefore, the total number of clones will not always matched the identified γδ	   T cell 
subpopulations. Nd: not determined. 
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Table 4.2. Phenotypic analysis of the 
established γδ  T cell clones from 5 donors.  
γδ	  T cells purified from freshly isolated PBMCs 
were plated at a density of 0.7 cells/well and 
stimulated with a mixture of irradiated PBMCs 
and LCLs coming from at least three allogeneic 
donors. The tables show the results of these 
stimulations. γδ	   T cell subpopulations were 
determined by flow cytometry after staining 
with specific monoclonal antibodies. Clones 
that showed a combined γδ+/αβ+ low-
expression phenotype were marked as αβ+? 
The tables also indicate for which of the T cell 
clones it was possible to perform at least one 
cellular cytotoxicity (lysis) assay (#). For γδ-
specific staining, which showed a wider range 
of staining intensities, +/++/+++ indicates 
positive staining, with low/intermediate/bright 
intensity.  For the other antibodies, a + sign 
indicates positive staining. -: negative staining, 
nd: not determined, smear: variable degree of 
positivity within one clone, αβ+?: γδ+/αβ+ low 
phenotype, #: lysis assay was performed. 
 
Donor 1 γδ δ1 δ2 CD56 lysis 
1 ++ - + + nd 
2 ++ - + + nd 
3 ++ - - + # 
5 ++ - + + nd 
7 ++ - + + nd 
8 +++ + - + # 
9 + - + + nd 
10 ++ - + + nd 
11 +++ - - + nd 
12 ++ - + smear nd 
13 + - + + nd 
14 ++ - + + nd 
15 ++ - + + nd 
16 ++ - + smear nd 
17 ++ - + smear # 
18 ++ - + + nd 
19 ++ - + + nd 
20 + - + smear nd 
21 +++ + - + # 
22 + - + + nd 
23 ++ + - smear # 
24 + - + + nd 
25 ++ - + + nd 
26 ++ - + + nd 
27 ++ - + smear nd 
28 ++ - + + nd 
29 ++ - + smear nd 
30 ++ - + smear nd 
31 ++ - + + nd 
32 +++ + - + # 
33 ++ - + + nd 
34 ++ + - smear # 
35 ++ - + + nd 
36 ++ - + + nd 
37 ++ - + + nd 
38 ++ - + smear nd 
39 + - + + nd 
40 ++ - + smear # 
41 ++ - + smear nd 
42 ++ - + + nd 
43 ++ - + + nd 
44 ++ - + + nd 
45 ++ - + + nd 
46 ++ - - smear # 
47 ++ + - smear # 
48 ++ - + + nd 
49 + - + + nd 
50 ++ - + + nd 
51 + - + + nd 
52 ++ - + + # 
53 ++ - + + nd 
54 ++ - + + nd 
55 ++ - + smear # 
56 +++ + - smear # 
57 + - + nd nd 
59 ++ - + + nd 
60 ++ - + + nd 
61 ++ - + + nd 
63 ++ - nd smear nd 
64 +++ - nd smear nd 
65 ++ - + + nd 
66 ++ - + + nd 
67 ++ - + + nd 
68 ++ - + + nd 
69 ++ - + + nd 
70 + - + + nd 
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71 ++ - + smear nd 
72 ++ - nd + nd 
73 ++ - nd + nd 
75 ++ - nd + nd 
76 ++ - nd + nd 
80 ++ - nd + nd 
81 ++ - nd + nd 
82 ++ - nd + nd 
83 +++ + nd smear nd 
84 ++ - nd + nd 
85 ++ - nd + nd 
86 ++ - nd + nd 
91 + - nd + nd 
92 ++ - nd smear nd 
93 ++ - nd + nd 
95 +++ + nd + # 
96 ++ - nd + nd 
97 ++ - nd + nd 
99 ++ - nd + nd 
100 ++ - nd + nd 
102 ++ - nd + nd 
104 ++ - nd + nd 
105 +++ + nd + nd 
106 ++ - nd + nd 
107 ++ - nd + nd 
108 ++ - nd + nd 
109 ++ - nd + nd 
110 ++ - nd + nd 
112 ++ - nd + nd 
113 ++ - nd + nd 
115 ++ - nd + nd 
116 ++ - nd + nd 
117 ++ - nd + nd 
118 ++ - nd smear nd 
120 ++ - nd + nd 
122 ++ - nd + nd 
123 ++ - nd + nd 
119 
/αβ+? +++ + nd smear # 
58 
/αβ+? +++ + - smear nd 
62 
/αβ+? +++ + - smear # 
94 
/αβ+? +++ + nd smear # 
 
 
Donor 4 γδ δ1 δ2 CD56 lysis 
1 +++ - - + # 
2 ++ - + + # 
3 +++ + - smear # 
4 +++ + - smear # 
5 +++ + - smear # 
6 ++ + - + # 
7 +++ + - smear nd 
8 ++ - + + nd 
9 +++ + - smear # 
10 +++ + - smear # 
11 ++ - + + nd 
12 ++ + - smear # 
13 +++ + - smear # 
14 +++ + - + nd 
15 ++ - + + nd 
16 +++ + - smear # 
17 ++ - + smear nd 
18 ++ - + + nd 
19 ++ - + smear nd 
20 +++ + - smear # 
21 +++ + - smear # 
22 +++ + - smear nd 
23 +++ + - smear nd 
25 ++ - + smear nd 
26 ++ + - + # 
27 +++ + - smear # 
28 ++ - - smear nd 
29 ++ + - smear # 
30 ++ - + smear nd 
31 +++ + - smear # 
32 +++ + - smear # 
33 ++ - - smear # 
34 +++ + - smear # 
35 ++ - + + nd 
36 ++ + - smear # 
37 ++ - - smear # 
38 +++ + - smear # 
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39 ++ - + + nd 
40 +++ + - smear # 
43 + - + smear nd 
44 +++ + - smear # 
46 +++ + - smear # 
47 +++ + - smear # 
48 +++ + - smear # 
49 +++ + - smear # 
50 +++ + - smear # 
51 +++ + - smear # 
52 + - + + nd 
53 ++ - + smear nd 
54 +++ + nd smear # 
55 ++ - nd + nd 
56 +++ + - smear # 
57 ++ - nd + nd 
58 ++ - nd smear nd 
59 ++ - nd + nd 
60 ++ - nd smear nd 
61 ++ - nd + nd 
62 +++ + nd smear # 
63 +++ + nd smear # 
64 ++ - nd + nd 
65 ++ - nd + nd 
66 ++ - + + # 
67 +++ - nd + nd 
68 ++ - nd + nd 
69 ++ - nd + nd 
70 ++ - + smear nd 
71 ++ + - smear # 
73 +++ + nd smear # 
75 +++ + nd smear # 
76 +++ + - smear # 
77 +++ + nd smear # 
78 +++ - nd + nd 
79 +++ + nd smear # 
80 +++ + nd smear nd 
89 +++ + - smear # 
92 ++ - + smear nd 
94 ++ - + smear # 
95 ++ - - smear # 
96 +++ - - smear # 
42/αβ+? ++ + - + # 
45/αβ+? ++ + - smear nd 
 
 
Donor 8 γ9 δ2 δ1 Lysis 
A4 + nd - nd 
B1 + + - nd 
B5 + + - nd 
B6 + + - nd 
B8 + bright + - # 
C1 + bright nd - nd 
C2 + bright + - nd 
C11 + bright - - # 
C3 + + - nd 
C4 + + - nd 
C9 + + - nd 
D1 + dim nd - # 
D3 + dim nd - nd 
D6 + + - nd 
E5 + + - nd 
F2 + nd - nd 
F7 + nd + # 
G11 + + - nd 
G5 + + - nd 
G9 + + - nd 
H1 + dim nd - nd 
H2 + + - nd 
H6 + dim + - nd 
H7 + nd + # 
I1 + nd - nd 
I4 + + - # 
I6 + dim nd - nd 
I7 + bright + - # 
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Donor 14 γδ δ1 δ2 CD56 Lysis 
1 ++ + - + # 
2 + - + + # 
3 ++ - + + nd 
4 + - + + nd 
6 +++ - - + # 
7 ++ + - + # 
8 ++ - + + nd 
9 +++ - - + # 
11 ++ - + + nd 
12 ++ + - + # 
13 ++ - + + nd 
14 ++ + - + # 
15 ++ - + + nd 
16 ++ - + + nd 
17 ++ - + + nd 
18 ++ + - smear # 
19 ++ - + + nd 
20 + - + + nd 
21 ++ - + + nd 
22 ++ + - smear # 
23 ++ - + + nd 
24 ++ - + + nd 
25 + - + + nd 
26 ++ - + + nd 
27 + - + smear nd 
28 ++ - + + nd 
29 + - + + nd 
30 ++ + - + # 
32 + - + + nd 
33 ++ + - + # 
34 ++ - + + nd 
35 ++ - + + nd 
37 ++ + - + # 
38 + - + + nd 
39 ++ + - + # 
40 ++ + - + nd 
41 ++ - + + nd 
42 ++ - + + nd 
43 ++ - + + nd 
44 ++ - + + nd 
45 ++ - + + nd 
46 ++ + - + # 
47 +++ + - + # 
48 ++ - + + nd 
49 ++ - + + nd 
51 + - + + nd 
52 ++ + - smear # 
54 ++ - nd + # 
55 + + nd + nd 
56 ++ - nd + nd 
57 ++ - nd + nd 
58 + + nd + # 
59 ++ - nd + nd 
61 + + nd + # 
62 ++ - nd + nd 
66 + + nd + nd 
69 +++ - nd + nd 
70 ++ + nd + nd 
71 + + nd + nd 
76 ++ + nd + nd 
78 ++ + nd + # 
79 ++ + nd + # 
81 ++ - + + nd 
82 + - + + nd 
83 ++ + nd + nd 
84 ++ - nd + nd 
85 ++ - nd + nd 
86 ++ + nd + # 
87 ++ + - + nd 
88 + - + + nd 
89 ++ + - + # 
91 +++ - nd + nd 
92 +++ + - + # 
93 ++ - + + nd 
94 ++ - + + nd 
95 +++ - nd + nd 
96 ++ - nd + nd 
36/αβ+? ++ + - smear nd 
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Donor 9 γ9 δ2 δ1 KIR NKG2A Lysis 
A3 - - + - - # 
A4 - nd - nd nd nd 
A5 - nd + nd nd nd 
A6 - nd + nd nd nd 
A7 + nd + nd nd # 
B1 - - + - + # 
B2 - nd - nd nd nd 
B4 - - + - smear # 
B6 - - + 2DL2/3+ 3DL1+ - # 
B7 + nd + nd nd # 
B8 - nd + nd nd # 
C3 - nd + nd nd nd 
C5 - nd - nd nd nd 
C6 - nd + nd nd nd 
C8 + nd - nd nd # 
D2 - - + - - # 
D3 - - + - - # 
D5 + + - nd nd # 
D8 + + - nd nd # 
E1 + - + nd nd # 
E2 - - + - - # 
E6 - - + - + # 
 
analyzed for their TCR phenotype by flow cytometry (Table 4.2). From each of the 
donors, I obtained both δ2+ and δ2– clones, although with different efficiencies for 
each TCR expression phenotype. From donor 8, nearly all of the outgrowing clones 
were δ2+ T cell clones, except for two clones expressing a γ9δ1+ TCR and another 
with a γ9+/δ1–/δ2– TCR (Table 4.2, donor 8). From donor 1, only 13% of the 
established clones possessed a δ1 chain, while for the other three donors (4, 9, 14), 
about half of the clones were δ1+ and the other half were δ2+ (also identified as δ1–). It 
is of notice that I could establish clones presenting a rare phenotype of γ9δ1+ TCR, and 
clones that were δ1–/2–, and therefore expressing another of the available but less 
frequently expressed delta chains. Some rare clones showed a peculiar and unexpected 
γδ+/αβ+low phenotype (Table 4.2). All γδ T cell clones expressed the receptor NKG2D 
with similar intensity (examples in Figure 4.16) and the marker CD56, although there 
was sometimes a broad CD56 intensity distribution within a clone (Table 4.2). Table 
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4.2 also indicates for which T 
cell clones it was possible to 
perform at least one lysis 
assay against EBV-infected 
cells. This series of 
experiments showed that 
stimulation of γδ+ T cells with 
irradiated PBMCs and LCLs is 
an efficient method to obtain 
γδ+ single cell clones, even 
from infrequent γδ 
subpopulations.  
To identify whether γδ T cells 
could specifically recognize 
EBV-infected cells, I 
performed lysis assays, in 
which γδ T cell clones were 
challenged with autologous 
LCLs or autologous B-blasts 
(Figure 4.17, and data not 
shown). Indeed, some of the 
clones analyzed lysed EBV-
infected B cells with different 
degrees of efficiency, but not 
activated B-blasts. Thus, some γδ T cell clones may recognize a molecular marker 
related to EBV infection but not to endogenous B cell activation. Interestingly, the 
opposite case was found for some of the γδ T cell clones (Figure 4.17), which indicates 
that there are some antigenic determinants that are induced by standard B cell 
activation pathways, but suppressed in EBV infection.   
The γδ T cell clones were further analyzed by performing lysis assays with autologous 
or allogeneic LCLs, with other EBV-positive or EBV-negative B cell lines (Raji and 
Daudi, respectively), and with a known, broadly recognized target for NK cells (K562, 
a CML cell line) (Figure 4.18). Interestingly, γ9δ2+ T cell clones had no or very low 
Figure 4.15. Flow cytometry staining of γδ  T cell clones. TCR 
expression and clonal phenotype of cloned γδ T cells was 
analyzed by flow cytometry with the aid of specific monoclonal 
antibodies recognizing the αβ TCR, the γδ TCR, δ1, δ2 or γ9 
chains. In the established cultures, I identified clones with a δ1–
/ δ2– TCR (clone 1), with δ1+ TCR (clone 2), and with a δ2+ 
TCR (clone 3). Taking into account the γ chain as well, clones 
were identified with a γ9δ2+ TCR (clone 4), with a γ9+/ δ1–
/ δ2– TCR (clone 5) and with a γ9δ1+ TCR (clone 6). Examples 
of 317 clones established from five different donors are shown 
(see Table 4.1). 
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reactivity against EBV-
infected B cells, but did 
recognize the other cell lines 
with different degrees of 
intensity (Figure 4.18B and 
data not shown). 
Meanwhile, δ1+ T cells 
generally recognized and 
induced lysis of at least one 
LCL line and showed low 
recognition of the B cell 
lines Raji and Daudi, but 
different intensities of lysis 
of the CML line K562. 
These data suggest that the 
major population playing a 
role in the control of EBV 
infection is the δ1+ T cell 
population. It is of interest 
that some δ1+ T cell clones 
recognized autologous 
LCLs, while others 
recognized only allogeneic 
targets. This observation 
suggests that δ1+ T cells 
recognize LCLs in different 
ways, possibly by 
recognizing different 
molecular targets on these 
cells.  
 
 
Figure 4.16. Expression of NK receptors by γδ  T cell clones. 
The expression of several NK receptors (KIR and NKG2 group 
receptors) was analyzed on γδ T cell clones by flow cytometry 
after staining with specific monoclonal antibodies. The clones 
analyzed were from donor 9. 
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Figure 4.18. Recognition of autologous or allogeneic EBV-infected cells by γδ  T cell clones. γδ T cell 
clones from donors 8 and 9 were challenged in a lysis assay with autologous or allogeneic LCLs and, 
where indicated, with the cell lines Daudi, K562 and Raji at a target:effector ratio of 1:5/10/20. Mean 
and standard error of the mean (SEM) of four replicates are shown. 
 
Figure 4.17. Recognition of autologous B-blasts or EBV-infected cells by γδ  T cell clones. γδ T cell clones 
from donors 1, 4 and 9 were challenged in a lysis assay with autologous B-blasts or autologous LCLs at a 
target:effector ratio of 1:10. Mean and standard error of the mean (SEM) of four replicates are shown. 
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Clone 
V-gene 
segment 
V-region 
AA NDN J-region AA 
J-gene 
segment 
D1 #8 TRDV1*01 CALGE RTSLIYWGFNV TAQLFF TRDJ2*01 
D1 #21 TRDV1*01 CALGE RTSLIYWGFNV TAQLFF TRDJ2*01 
D1 #94 TRDV1*01 CALGE FRAYLGGYVRLK YTDKLIF TRDJ1*01 
D1 #95 TRDV1*01 CALG HSVLLPWGIRD TDKLIF TRDJ1*01 
D4 #04 TRDV1*01 CALGE AFARLRRGDTRL YTDKLIF TRDJ1*01 
D4 #20 TRDV1*01 CALGEL LSTGG YTDKLIF TRDJ1*01 
D4 #29 TRDV1*01 CALGE PVGSWIPDNAD TDKLIF TRDJ1*01 
D4 #36 TRDV1*01 CALGEL NSPTGNTGGYFVGSN TDKLIF TRDJ1*01 
D9 #3A TRDV1*01 CALGE QLPILPEVWGIKGD DKLIF TRDJ1*01 
D14 #14 TRDV1*01 CALGE SAFPTTGGST YTDKLIF TRDJ1*01 
D14 #22 TRDV1*01 CALGE SAFPTTGGST YTDKLIF TRDJ1*01 
D4 #1 TRDV3*01 CAF REIHVLG TDKLIF TRDJ1*01 F 
D14 #6 TRDV3*01 CAF SALQ YTDKLIF TRDJ1*01 F 
D14 #9 TRDV3*01 CAF SALQ YTDKLIF TRDJ1*01 F 
 
Table 4.3 Sequences of the δ  TCR chain for some γδ  T cell clones. mRNA was extracted from γδ T 
cell clones, cDNA synthesized, the δ TCR cDNA was amplified by PCR and sent for sequencing. 
Primers for the δ TCR were positioned in the V-gene segment and in the C-gene segment to amplify the 
CDR3 region. The sequences are aligned according to their usage of V and J regions. The table indicates 
the amino acid composition of the CDR3 region for each clone, specifying the amino acids encoded by 
the V-segment and the J-segment. Underlined amino acids are homologues to the D-gene segments. The 
IMGT online tool was used to facilitate allocation of amino acid sequences to the individual gene 
segments (www.imgt.cines.fr) {Lefranc et al., 1999, #30971}. TCR nomenclature according to 
{Giudicelli and Lefranc, 1999, #871} was used. 
To assess whether there was a correlation of TCR primary structure with reactivity of 
the γδ T cells, I analyzed the TCR sequences of the δ TCR chain of some δ2-negative T 
cell clones (Table 4.3). The mRNA was extracted from γδ T cell clones, cDNA was 
synthesized, the δ TCR cDNA was amplified by PCR and commercially sequenced. 
Primers for the δ TCR were positioned in the V-gene segment and in the C-gene 
segment, bridging the hypervariable region (CDR3 region). In Table 4.3, the CDR3 
sequences are arranged according to their expression of different V and J gene 
segments. Interestingly, sequences obtained from clones from 4 different donors 
showed a large heterogeneity in their CDR3 sequences. Only in the case of three pairs 
of clones that came from the same donor, identical δ-CDR3 sequences were found. 
Thus, δ2– γδ T cell clones with different specificities carry different γδ TCRs. Thus, the 
sequences identified here could be used in the future as molecular markers for 
identification of EBV-specific γδ T cells across donors.  
To further clarify how γδ T cells mediate the lysis of EBV-infected B cells, I performed 
a lysis assay with an antibody specific for the receptor NKG2D, blocking the 
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interaction with its ligands on the target cells. As shown in figure 4.19A, blocking of 
NKG2D partially reduced the efficiency of LCL lysis by the analyzed γδ T cell clones. 
Interestingly, clone 6B from donor 9 showed a reactivity pattern that appeared to be 
related to its expression of inhibitory NK receptors (Figure 4.16). It is interesting to 
notice that a dominant cell population within this clone – if it is in fact a single-cell 
clone – co-expressed at least two inhibitory KIR receptors that are specific for HLA 
class I molecules, KIR2DL1 and KIR2DL2/3 (Figure 4.16). When I blocked the 
interaction between KIRs present on the T cell clone and their ligands with a specific 
antibody targeting HLA class I molecules, lysis was increased (Figure 4.19B), which is 
in accordance with the idea that the reactivity of clone 6B is at least partially regulated 
by inhibitory KIRs. For another clone expressing the inhibitory molecule NKG2A but 
no other inhibitory KIR receptors (Figure 4.16), I could not see any differences in its 
functions (Figure 4.19B). NKG2A is inhibited by the nonpolymorphic MHC molecule 
HLA-E, which is also bound by the anti-HLA antibody. However, it has been observed 
before that LCLs express comparatively small amounts of HLA-E (Braud et al. 1997; 
Corrah et al. 2011), so a lack of regulation of this T cell clone through the 
NKG2A/HLA-E axis in this experiment can be easily explained. For the third clone 
Figure 4.19. Effect of NKG2D and HLA class I blocking on lysis efficiency of LCLs by γδ T cell 
clones. γδ T cell clones from donor 9 were challenged in a lysis assay with autologous (clone 3A) or 
allogeneic (clones 6B and 1B) LCLs at a target:effector ratio of 1:10 in the presence of an anti-NKG2D 
(A) or anti-HLA-I antibody (B) or matched isotype control where indicated. Means and range of 
duplicates are shown. 
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analyzed, in contrast to expectation, I observed a reduction of recognition when its 
interaction with HLA-I molecules was blocked (figure 4.19B). I investigated this clone 
in more detail, and analyzed its recognition of autologous, partially matched or 
mismatched LCLs (Figure 4.20). Patterns of lysis of several LCLs from different 
donors confirmed that the reactivity of this clone was associated with the presence of 
the HLA-A2 molecule on the target cell. Indeed, when I performed blocking 
experiments with specific antibodies targeting only the HLA-A2 molecule, I observed a 
clear reduction of the reactivity of this clone to autologous LCLs (Figure 4.21). 
Recognition of LCLs by this clone was also dependent on the γδ TCR, as shown by 
blocking (Figure 4.21). In addition, this experiment confirmed the involvement of the 
receptor NKG2D in the recognition of EBV-infected cells. Taken together, these results 
show that the δ1+ γδ T cell population contains different types of effector cells that 
specifically kill EBV-infected cells through recognition of different determinants, and 
some of these effector cells have HLA-I-restricted reactivity.  
To investigate the effect of LMP2A on the effector activity of δ1+ T cells, we 
performed a lysis assay challenging δ1+ T cell clones with WT or ΔLMP2A LCLs 
Figure 4.20. Recognition of matched, 
partially matched or mismatched LCLs by 
the δ1+ T cell clone 3A from donor 9. This 
δ1+ T cell clone was challenged in a lysis 
assay with autologous CD40-stimulated B 
blasts, autologous LCLs, and partially HLA-
matched (HLA-A*0201+) or fully mismatched 
(A2–) LCLs, at a target:effector ratio of 1:10. 
Mean and standard error of the mean (SEM) of 
four replicates is shown. 
Figure 4.21. Effect of γδ TCR, NKG2D and 
HLA-A2 blocking on the lysis efficiency of the 
δ1+ T cell clone 3A from donor 9. The δ1+ T 
cell clone 3A from donor 1 was challenged in a 
lysis assay with autologous LCLs at a 
target:effector ratio of 1:10, in the presence of an 
anti-γδ TCR, anti-NKG2D or anti-HLA-A2 
antibody or matched isotype control where 
indicated. Mean and range of duplicates are 
shown. 
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(Figure 4.22). Interestingly, recognition of cells infected with the mutant virus showed 
a decreased recognition by δ1+ T cell clones. Thus, the presence of LMP2A favors 
recognition of EBV-infected cells by γδ T cells, but hampers recognition of infected 
cells by CD8+ T cells as examined above. This suggests that CD8+ T cells and γδ T 
cells are predominantly triggered by different determinants or coactivators on LCLs. It 
appears that the immunomodulatory properties of LMP2A have evolved to strike a 
balance between prevention of control by CD8+ T cells and by γδ T cells.   
 
 
Figure 4.22. Recognition of WT and ΔLMP2A LCLs by δ1+ T cell clones. Five different δ1+ T cell 
clones from donor 4 were challenged in a lysis assay with autologous WT and ΔLMP2A LCLs, and with 
allogeneic LCLs or B-blasts at a target:effector ratio of 1:10. Means and standard error of the mean 
(SEM) of four replicates are shown. 
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5 Discussion 
Epstein-Barr virus has a deep and intricate impact on the human immune system. Two 
processes come to mind that vividly illustrate this effect: the remarkable efficiency of 
transformation of normal human B cells by EBV in vitro (Pope et al. 1968), and the 
capability of EBV to induce strong virus-specific T cell responses in virus carriers for a 
lifetime (Hislop et al. 2007b). The discovery of Epstein-Barr virus (EPSTEIN et al. 
1964), the first identified human tumor virus, even preceded the insight that 
lymphocytes can be divided into subsets with different functions, B and T cells (Miller 
& Mitchell 1967; Mitchell & Miller 1968). Thus, it is not surprising that the concepts 
of how EBV interacts with the immune system were only gradually developed, in 
parallel to the elucidation of the principles of immune function.  
When EBV transforms normal human B cells, B-"lymphoblastoid" cells are formed that 
closely resemble B lymphoblasts. The latter are B cells that have been activated by 
executing their capacity to recognize antigen (signal 1), receiving T cell help (signal 2), 
or detecting invariant microbial components (signal 3). All of these signals are 
important elements for the mobilization of a B cell response against pathogens, and 
exert the strongest effect if present in combination (Ruprecht & Lanzavecchia 2006). 
Many of the viral functions that mediate B cell transformation have been characterized 
in close detail (Young & Rickinson 2004), including the functions of LMP2A, which 
mimics signal 1 (Merchant et al. 2001), and of LMP1, which mimics signal 2 (Graham 
et al. 2010). However, the apparent close similarity of lymphoblasts and 
lymphoblastoid cells, and the compelling analogy of viral transforming molecules with 
cellular activation pathways, have lead to a view of EBV infection of B cells that has 
neglected an important distinguishing aspect: while physiological mechanisms of B cell 
activation are designed to elicit and sustain immune responses, EBV has necessarily 
evolved to evade immune responses that are mobilized against the virus. Thus, it can be 
predicted that B cell activation by EBV infection on one hand, and by physiological 
triggers of signals 1, 2, and 3 on the other hand, produce B cells with important 
functional differences regarding their capability to interact with other cells of the 
immune system. Strikingly, not much is known so far on mechanisms employed by 
EBV that limit the immunogenicity of EBV-transformed B cells. To the contrary, the 
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focus of research has mainly been on the immune-stimulatory capacity of EBV-
transformed lymphoblastoid cells. This is understandable because EBV LCLs have 
proven their suitability as a tool to expand EBV-specific T cells for scientific and also 
for immunotherapeutic use (Wallace et al. 1982; Rickinson & Moss 1997; Adhikary et 
al. 2007; Bollard et al. 2012). Moreover, a number of immunomodulatory EBV genes 
has been identified that reduce T cell recognition of infected cells in lytic cycle, but 
these immunomodulators are not active in latently infected cells (Hislop et al. 2007a; 
Zuo et al. 2008, 2009; Jochum et al. 2012a).  
Therefore, the goal of my work presented in this thesis was to identify factors that 
modulate the interaction of EBV-infected B cells with antiviral immune cells. In the 
first part of my experiments, I comparatively analyzed changes in the 
immunophenotype that are triggered by EBV infection versus non-viral triggers of 
signals 1, 2, and 3, and identify immune effector molecules that are differentially 
regulated in lymphoblastoid cells and lymphoblasts. In the second part, I describe that 
latent membrane protein LMP2A counteracts CD8+ T cell recognition of latently 
infected cells. In the third part, I show that γδ T cells can specifically recognize EBV-
infected cells, and describe that their recognition of LCLs appears to follow different 
rules than recognition by CD8+ T cells.  
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5.1 Effect of EBV infection and non-viral B cell activation on 
immunophenotype 
In the first part of the present work, I present a detailed analysis of the modulation of 
the expression of relevant immunomodulatory molecules in the context of EBV-
mediated and non-viral B cell activation. It is now appreciated that costimulatory and 
coinhibitory molecules have a crucial role in regulating activation, effector function, 
subset differentiation and survival of T cells (Welten et al. 2013). Therefore, the 
modulation of the surface expression of these molecules is relevant to understand how a 
virus such as EBV can influence the cellular immune response of the host. 
EBV is known to induce activation of B cells through its viral proteins LMP1 and 
LMP2A (Dawson et al. 2012). In B cells, LMP2A mimics signal 1, the activatory signal 
of the B cell receptor (BCR) both in vitro and in a transgenic mouse model (Caldwell et 
al. 1998; Mancao & Hammerschmidt 2007). LMP2A promotes B cell survival and 
inhibition of apoptosis by activating the PI3K/Akt and ERK-MAPK signaling pathways 
(Panousis & Rowe 1997; Fukuda & Longnecker 2004; Portis & Longnecker 2004; 
Anderson & Longnecker 2008). 
LMP1 acts as a functional mimic of signal 2, T helper cell–mediated CD40 ligation on 
B cells, but in comparison to the receptor CD40, LMP1 does so in a constitutive, 
dysregulated manner (Graham et al. 2010). Studies regarding the activatory functions 
of LMP1 have been mainly performed in epithelial cells, fibroblasts or HEK293 cells 
and showed that LMP1 activates the canonical and non-canonical NF-κB and PI3K/Akt 
pathways (Dawson et al. 2003; Eliopoulos et al. 2003; Luftig et al. 2004; Thornburg & 
Raab-Traub 2007; Kung & Raab-Traub 2010) and leads to the activation of the ERK 
and JNK kinases (Kieser et al. 1997; Roberts & Cooper 1998). The activation by LMP1 
of these cellular pathways positively affects cell proliferation, survival and 
transformation. Since EBV mimics B cell activation and takes advantage of the same 
cellular pathways as physiological B cell activation, EBV-induced B cell activation is 
often compared to non-viral B cell activation: identifying similarities and differences is 
useful to gain information on how EBV influences the molecular changes induced by 
these pathways. Indeed, my data show that early EBV infection induces the 
upregulation of the B7 molecules CD86 and PD-L1, of the integrin ICAM-1 and of the 
NKG2D ligands MICB and ULBP4.  
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The surface molecule CD86 is upregulated on APCs upon activation. It can bind to the 
co-stimulatory receptor CD28 or to the inhibitory receptor CTLA-4 on T cells, but it 
was shown that CD28 binds CD86 more effectively in comparison to CTLA-4 (Collins 
et al. 2002). This observation suggests a predominantly stimulatory rather than 
inhibitory function for CD86. CD28 is constitutively expressed on naive CD8+ and 
CD4+ T cells, for which it serves as positive stimulator of cell growth and cell survival 
(Acuto & Michel 2003). CD28 is also expressed on γδ T cells; however, for these cells 
its role is still controversial (Ribot et al. 2011). CD28 ligation itself does not trigger 
activation of its own cellular pathways, except in the special case of "CD28 
superagonists" (Mikami & Sakaguchi 2014), but it rather amplifies TCR signaling, 
which makes the difference between T cell activation or T cell death especially in the 
event of weak TCR signals (Acuto & Michel 2003).  Priming of virus-specific CD4+ T 
cells is strongly reduced in CD28 knock-out mice, but requirement of CD28 co-
stimulation for CD8+ T cell activation was shown to be variable in several viral 
infection models (Salek-Ardakani et al. 2009). Our data show that B cell activation and 
EBV infection induced a similar extent of CD86 upregulation, suggesting that EBV-
induced activation and B cell activation through BCR/CD40/TLR engagement were 
comparable in regard to this parameter. Expression of CD86 was variable in latently 
EBV infected cells, but showed a downward trend as compared to early infection. In 
the context of B cell activation, upregulation of CD86 may help the activation and 
priming of T cells. In return, this signal leads to induction of CD40L on the T cell, 
supporting B-cell-mediated humoral responses (Acuto & Michel 2003). It is difficult, 
however, to predict the role of the upregulation of this molecule especially in the 
context of EBV infection, since there is no knowledge on whether CD86 is involved in 
the priming of EBV-specific T cells or in the support of recognition of EBV-infected 
cells.  
Another B7 family member whose surface expression is influenced by B cell activation 
is PD-L1. The ligand PD-L1 is expressed on both lymphoid and non-lymphoid cells. 
Increasing evidence suggests that PD-L1 expression on non-lymphoid cells prevents 
tissue destruction by suppressing autoreactive lymphocytes (Okazaki & Honjo 2006).  
Its receptor PD-1 is found on activated T cells, and its engagement induces T cell 
inactivation or anergy (Okazaki & Honjo 2006). PD-1 interferes with activatory TCR 
signaling by recruiting negative regulators to the site of the immunological synapse 
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(Kulpa et al. 2013). Interestingly, blocking of the interaction between PD-1 and PD-L1 
was demonstrated to restore T cell function in various contexts (Okazaki & Honjo 
2006), for example in a model of chronic viral infection (Barber et al. 2006). Several 
reports showed the presence of PD-1 on EBV-specific CD8+ T cells, especially during 
and after IM (Sauce et al. 2009; Greenough et al. 2010), and blocking of PD-1/PD-L1 
interactions between NK or T cells and EBV-infected B cells was recently shown to 
increase NK and T cell reactivity (Durand-Panteix et al. 2012). In accordance with 
these findings, I found that EBV stably induced PD-L1 expression, both in early and in 
established latent infection. The induction of expression of PD-L1 by EBV, especially 
early after infection, may support the escape of EBV-infected cells and help establish 
infection. The induction or maintenance of PD-L1 expression to promote immune 
escape or T cell exhaustion has been already demonstrated in the context of other viral 
infections (Kirchberger et al. 2005; Benedict et al. 2008; Kulpa et al. 2013). Inhibition 
of T cell activity during the early phase of infection establishment may provide enough 
time for EBV to build up an EBV-carrying B cell population and establish sustained 
latent infection in its host. Thus, it will be interesting to investigate to what extent the 
blocking of the interaction between PD-1 and PD-L1 influences recognition by T cells 
of early EBV-infected B cells.  
The expression of PD-L1 on B cells after non-viral activation followed completely 
different kinetics. On these cells, PD-L1 expression was first induced and then 
downregulated within 48 hours after stimulation, while EBV-infection induced a slower 
increase to a level that remained stable already after 48 hours. While upregulation of 
PD-L1 by EBV could be a mechanism designed to avoid detection of infection, the 
rapid induction of PD-L1 upon B cell activation might be of importance in T cell 
activation control. In this regard, it is interesting to notice that PD-L1 surface 
expression is maximal when all three B cell activatory stimuli are combined but, in 
contrast to the expression of other immune effector molecules studied here, 
upregulation of PD-L1 appears to be mainly driven by the combination of BCR and 
TLR9 signaling. CD40L alone or in combination with only one other stimulus was not 
a good inducer of PD-L1. However, CD40L further increased PD-L1 expression by 
anti-BCR combined with CpG. It would be interesting to investigate whether and how 
the differences in PD-L1 expression after different types of stimulation could affect T 
cell functions. 
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Upregulation of the adhesion molecule ICAM-1 on non-virally activated B cells 
followed a kinetic similar to PD-L1 expression. Detection of ICAM-1 was highly 
increased 24 hours after stimulation, but showed a drastic decrease of expression 
already at 48 hours post-stimulation. As components of the immunological synapse, the 
integrin LFA-1 on the T cell side and its ligand ICAM-1 on the target cell side play an 
important role in stabilizing interaction between T cell and target cell, and in promoting 
T cell activation (Wulfing et al. 1998). Additionally, LFA-1 can be expressed by 
antigen-presenting cells, and ICAM-1 by T cells. Anti-LFA-1 antibodies inhibit CD4+ 
T cell proliferation, cytokine production, and induction of activation antigens. These 
observations support a model in which blocking of LFA-1/ICAM-1 interaction prevents 
TCR-mediated signaling events, such as upregulation of the activation antigen IL-2Rα 
(Hathcock et al. 1994). It is however interesting to note that the highest surface 
expression level detected for ICAM-1 upon B cell activation was observed with 
CD40L/IL-4 activation alone or in combination with BCR activation, whereas the 
addition of CpG had no major effects on ICAM-1 expression. This provides an example 
of a partial division of labor among different physiological B cell stimuli: whereas TLR 
signaling triggered by CpG DNA preferentially influences the expression of molecules 
such as PD-L1 as described above, the induction of ICAM-1 was largely driven by 
CD40 and BCR stimulation, but not supported by CpG stimulation. It is possible that 
rapid downregulation of ICAM-1 after B cell activation may positively influence the 
functional outcome of B cell:T cell contacts, because it was shown that transient 
contacts of a T cell with an APC are typical for the interaction of T cells with dendritic 
cells, which leads to the differentiation of effector T cells, whereas overly prolonged 
contacts of a T cell with an APC may render T cells anergic, or favor their 
differentiation to regulatory T cells (Reichardt et al. 2007). In contrast to B cell 
activation, EBV infected B cells showed a slow induction of ICAM-1 expression, and 
expression of this molecule was maintained in latently infected B cells.  
On the other hand, the expression of CD11a, the α chain of the integrin LFA-1, the 
interacting counterpart of ICAM-1, was only influenced by non-viral B cell activation. 
In non-viral B cell activation, CD11a showed a slow upregulation during the late stages 
of B cell activation (day 6, day 8 after stimulation). LFA-1 is thought to help in 
formation and stability of the immunological synapse. Indeed, supporting this 
hypothesis, it was shown that T cell MHC-II triggering on naive B cells enhances LFA-
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1 “stickiness” on these cells, resulting in a very stable cell-cell contact (Gunzer et al. 
2004). Moreover, activation of B cells mediated by follicular DCs is dependent on the 
presence of integrins such as LFA-1 (Koopman et al. 1991). LFA-1 was shown to form 
a ring around clusters of BCR molecules, stabilizing the cell:cell contact and reducing 
the threshold of antigen required by B cell for activation (Koopman et al. 1991). In 
addition, interaction between LFA-1 and ICAM-1, expressed on the B cell and on the 
APC respectively, prevents apoptosis of the B cell in the germinal center (Arana et al. 
2008). This mechanism becomes of particular importance in the case of a limited 
amount of antigen for B cell activation. The differential expression of the two intergins 
ICAM-1 and CD11a during B cell activation may reflect the different roles of these 
molecules in providing an anchor for B cell–T cell or B cell–APC interactions. If we 
compare early and latent EBV infection of B cells in regard to CD11a surface 
expression levels, it appears that EBV does not modulate the expression of this 
molecule after early infection, but its levels are stably maintained throughout EBV 
infection. A more comprehensive series of measurements over a longer time will 
provide an even better insight into the effect of EBV on CD11a surface expression. 
We also analyzed upregulation of NKG2D ligands after non-viral and EBV infection-
mediated B cell activation. NKG2D is an agonistic receptor present on T and NK cells, 
which recognizes a variety of “stress-induced” ligands that are upregulated on the cell 
surface in conditions such as malignant transformation, viral infection or heat shock. 
Increased expression of NKG2D ligands after EBV infection was described earlier 
(Pappworth et al. 2007; Kong et al. 2009; Zhang et al. 2012; Chaigne-Delalande et al. 
2013), but a comprehensive analysis of NKG2D ligand expression on EBV-infected B 
cells was still missing. Our analysis of the eight known NKG2D ligands showed that 
early EBV infection induced the expression of two of them (MICB, ULBP4) and the 
transient but moderate upregulation of a third NKG2D ligand, ULBP1. MICB and 
ULBP4 were also expressed on the surface of latently EBV infected B cells, MICB 
higher than ULBP4. Interestingly, in latently infected B cells a third NKG2D ligand, 
MICA, was also upregulated. After non-viral B cell activation, I observed only a 
transient expression of MICB, but no expression of any other NKG2D ligand. If we 
compare the expression of NKG2D ligands between EBV infection and B cell 
activation, a few differences become apparent. First, EBV induces not only MICB but 
also transient ULBP1 expression and ULBP4 upregulation, even though at later time 
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points. Second, EBV slowly induced and maintained the expression of MICB on the 
cell surface, while activated B cells presented a transient expression of this molecule. 
Could the expression of MICB on activated B cells play a role in attracting help from 
NKG2D+ T helper cells? While the role of NKG2D on cytotoxic T and NK cells is 
well established (Zafirova et al. 2011), not so much is known about the role of this 
activatory receptor on CD4+ T cells. What is known is that NKG2D+ CD4+ T cells are 
a rare subpopulation in healthy humans (Groh et al. 2003; Alonso-Arias et al. 2011). In 
contrast, NKG2D+ CD4+ T cells have been isolated in different malignancies (Garcia-
Chagollan et al. 2013; Romero et al. 2014; Yu et al. 2014) and in chronic inflammatory 
disease (Camus et al. 2014). Interestingly, a population of virus-specific NKG2D+ 
CD4+ T cells has been identified in carriers of the herpesvirus HCMV (Saez-Borderias 
et al. 2006). Therefore, it cannot be ruled out that EBV-specific CD4+ T cells with this 
phenotype may exist in EBV carriers, and that MICB may play a role in priming or 
activation of these cells. 
B cell activation, but not EBV-induced activation, also influenced the expression of the 
SLAM family member CD48. CD48 surface expression was slightly upregulated 24 
hours after B cell stimulation. Induction of the expression of this molecule was rapidly 
reversed and it was followed by a slow reduction of its expression. CD48 is a molecule 
solely expressed on hematopoietic cells. Its receptor, 2B4, is expressed on NK and T 
lymphocytes and it can induce both activatory and inhibitory signals, accordingly to the 
presence or the absence of the cellular mediator SAP (Parolini et al. 2000). Activation 
of T and NK cells by 2B4 and other SAP-interacting receptors is fundamental for 
efficient control of EBV-infection. In fact, male patients affected with X-linked 
lymphoproliferative disease (XLP), a fatal disease caused by mutations in the SAP 
gene, are prone to develop life-threatening EBV-induced lymphomas (Nichols et al. 
2005). This suggests a relevant role for this receptor-ligand pair in the recognition and 
clearance of EBV-transformed B cells by NK cells (Benoit et al. 2000). It has been 
recently appreciated that SAP also play a role in the generation and maintenance of 
humoral immunity. Mutations in SAP impair the ability of CD4+ T cells to interact 
with B cells, leading to a shortage of adequate T cell contact-dependent help for B cells 
(Qi et al. 2008). Like for CD11a, early or latent EBV infection of B cells did not show 
strong effects on the surface expression of CD48. Comparing CD48 expression levels 
between early EBV infection of B cells and LCLs, it appears that CD48 might be 
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slowly upregulated upon EBV infection. Further experiments with a longer kinetic 
would be necessary to reach a conclusive answer. 
When we directly compare these results on non-virally activated B cells and EBV-
infected B cells, we need to keep in mind that EBV infection is expected to act more 
slowly on B cells on a population level in vitro due to the experimental conditions that 
are available. Stimulation with CD40L-expressing cells (Wiesner et al. 2008) or with 
CpG DNA (Hartmann & Krieg 2000; Ruprecht & Lanzavecchia 2006) is rapid and 
efficient in vitro, because these stimuli are applied in a form that quickly targets most 
or all B cells that are present in the culture. In contrast, EBV infection of primary B 
cells is quantitatively less efficient, because only a fraction of the B cells can be 
functionally infected with EBV in vitro (Iskra et al. 2010), which has several reasons. 
Although different B cell subsets (naive and memory) can be infected by EBV in vitro 
with similar efficiency (Heath et al. 2012), only a fraction of EBV bound to the B cell 
surface can reach the cell nucleus and initiate viral gene expression (Shannon-Lowe et 
al. 2005). After EBV reaches the nucleus, intracellular expression of viral B-cell–
activatory molecules first needs to be turned on before they can initiate changes in 
expression of cellular immune effector molecules on the cell surface, a process that can 
take hours to days (Iskra et al. 2010; Jochum et al. 2012b). Within this time window, a 
proportion of B cells undergo apoptosis, because they apparently do not receive 
sufficient survival signals under in vitro culture conditions. EBV counteracts this 
tendency by early expression of two antiapoptotic molecules that are functionally 
homologous to Bcl-2 (Altmann & Hammerschmidt 2005), but their efficiency is not 
absolute, and therefore apoptosis is prominent in EBV-infected B cell cultures around 
2–6 days after initiation of culture (Altmann & Hammerschmidt 2005; Iskra et al. 
2010). It follows that B cell immunophenotypes after EBV infection and non-viral 
stimulation should be compared qualitatively rather than quantitatively.  
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5.2 Role of LMP2A in evading recognition of latently EBV-infected 
cells by CD8+ T cells  
In the second part of my experiments for this thesis, I analyzed the role of the EBV 
latent membrane protein LMP2A in modulating the immunophenotype of infected B 
cells and in altering their recognition by immune effector cells. These studies were 
made possible by my identification of a method to generate LMP2A-deleted LCLs with 
high efficiency. In this method, primary B cells are infected with LMP2A-deleted EBV 
in the presence of CD40L-expressing stimulator cells, but further expanded without 
such an exogenous stimulus. My analyses showed for the first time that LMP2A 
interferes with CD8+ T cell recognition of latently infected B cells (LCLs), and I could 
identify several mechanisms that contribute to this immunoevasive function of LMP2A. 
First, LMP2A lowered the amount of antigen available for CD8+ T cell recognition by 
decreasing mRNA expression levels of EBV latent antigens targeted by CD8+ T cells, 
in particular EBNA1. Second, LMP2A downregulated MHC class I molecules on the 
cell surface to a certain degree. Third and perhaps most important, two ligands of the 
coactivatory receptor NKG2D were strongly upregulated in LMP2A-deficient LCLs. I 
could demonstrate that blocking of NKG2D reduced T cell recognition of infected 
cells, and this reduction was particularly strong in LMP2A-deleted LCLs. These results 
show that LMP2A hampers CD8+ T cell recognition of infected cells by combining a 
variety of mechanisms, and establish the importance of NKG2D ligands in CD8+ T cell 
recognition of EBV-infected B cells. 
LMP2A is part of the latent protein repertoire of EBV. Much of the protein is 
embedded in cell membranes, because it contains twelve transmembrane regions that 
follow each other closely. Its N-terminal cytoplasmic tail contains various motifs 
functioning as docking sites for cellular kinases that lead to activation of intracellular 
signaling pathways (Pang et al. 2009; Dawson et al. 2012). As mentioned above, 
LMP2A promotes B cell survival and inhibition of apoptosis by mimicking the 
activatory signals of the BCR (Caldwell et al. 1998; Mancao & Hammerschmidt 2007), 
and by activating the PI3K/Akt and ERK-MAPK pathways (Konishi et al. 2001; Portis 
& Longnecker 2004; Anderson & Longnecker 2008). In addition, by preventing normal 
BCR activation, LMP2A was shown to interfere with BCR-induced activation of the 
EBV lytic cycle (Miller et al. 1994a, b, 1995; Konishi et al. 2001). However, in the 
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absence of exogenous triggers of lytic cycle, LMP2A supported the induction of basal 
levels of lytic cycle gene expression. This suggests a dual role of LMP2A in controlling 
EBV lytic cycle (Schaadt et al. 2005). 
The influence of LMP2A on human B cell proliferation and transformation has been 
controversial: while some studies did not identify a role of LMP2A in these processes 
(Longnecker et al. 1992, 1993a, b; Speck et al. 1999; Konishi et al. 2001), other reports 
indicated that LMP2A increases the efficiency of B cell proliferation and 
transformation (Brielmeier et al. 1996; Mancao & Hammerschmidt 2007). My 
experience with establishing LCLs with an EBV mutant deleted for LMP2A confirmed 
that LMP2A is indeed important for establishment of EBV latent infection in vitro, 
because the outgrowth of LCLs from EBV-infected primary B cell cultures was 
strongly impaired when the virus was deleted for LMP2A. However, if an additional 
stimulus such as CD40 activation was provided, LCLs deleted for LMP2A could be 
efficiently generated, and were then maintained autonomously. This showed that 
LMP2A is not essential for maintenance and proliferation of established LCLs, as long 
as the B cell receptor is expressed in the transformed B cells (Mancao & 
Hammerschmidt 2007).  
In hindsight, the immunomodulatory effects of LMP2A may also have contributed to 
the differential outgrowth of WT and ΔLMP2A EBV-infected B cells in culture that I 
observed. Although I performed EBV infection with B cells purified from PBMCs, the 
purity of the B cells was obviously not absolute, but in the range of 95–98%, and some 
T and NK cells were necessarily still present. Some of these T cells, with potential 
support by NK cells, may have selectively prevented outgrowth of ΔLMP2A LCLs, due 
to their higher potential to activate T cells. It is known that immune effector cells in 
PBMCs can abolish outgrowth of B cells infected with EBV in vitro. In fact, this 
phenomenon of outgrowth regression first demonstrated the existence of EBV-specific 
cellular immunity (Moss et al. 1978), and forms the basis of a simple assay to 
quantitate EBV-specific T cell immunity in bulk (Frisan et al. 2001). Later, it was 
shown that EBV antigen-specific cytotoxic CD8+ T cells, and cytotoxic CD4+ T cell 
populations that target unknown antigens expressed on LCLs, both contribute to 
regression of EBV-infected B cells (Nikiforow et al. 2001; Gudgeon et al. 2005). In 
accordance with standard methods (Roskrow et al. 1998; Moosmann et al. 2002), I used 
cyclosporin A in our EBV infection cultures to prevent activation of residual effector T 
	  	  
 
Discussion 
 
  
90	  
cells against outgrowing EBV-infected B cells. However, the experience of our and 
other laboratories shows that the effect of cyclosporin A in culture is not an absolute 
one, and occasionally the outgrowth of EBV-transformed B cells from infected cultures 
is prevented by T cells in spite of the presence of cyclosporin A, a problem that can be 
circumvented by establishing multiple parallel EBV-infected microcultures from each 
donor (Roskrow et al. 1998; Moosmann et al. 2002). Thus, it can be easily imagined 
that ΔLMP2A LCLs are more susceptible to attack by T cells than WT LCLs, and this 
difference may also have contributed to reduce outgrowth of LMP2A-deleted LCLs 
observed earlier (Brielmeier et al. 1996). Whether this hypothesis is true remains to be 
verified in more detailed regression assays with precisely defined numbers of admixed 
primary T cells.  
LMP2A is not only expressed in B cells expressing the transforming “growth” program 
or latency III program, but also in EBV-positive tumors expressing an even more 
restricted panel of viral antigens, such as Burkitt lymphoma, Hodgkin lymphoma, 
nasopharyngeal carcinoma, and gastric carcinoma (Rickinson 2014). By enhancing 
anchorage-independent growth (Fukuda & Longnecker 2007), inhibiting differentiation 
(Scholle et al. 2000), interfering with the proapoptotic effects of TGFβ1 (Fukuda & 
Longnecker 2004) and inducing the anti-apoptotic protein survivin (Hino et al. 2008), 
LMP2A promotes survival, proliferation and transformation in epithelial cells. In 
addition, LMP2A was shown to enhance tumorigenesis in vivo (Scholle et al. 2000; 
Kong et al. 2010)), strongly suggesting a role for LMP2A in the maintenance or in the 
progression of LMP2A-expressing malignancies. 
While a number of EBV-encoded immunoevasins that operate in lytic cycle have been 
identified as discussed above (Hislop et al. 2007a; Rowe et al. 2007; Zuo et al. 2009), 
only one EBV antigen expressed in latently infected cells, EBNA1, was shown to 
interfere with antigen presentation to CD8+ T cells. Importantly, EBNA1 does not 
generally interfere with antigen presentation, but specifically inhibits its own 
processing in cis by blocking proteasomal processing (Levitskaya et al. 1997). It has 
been unknown whether other latent EBV antigens can affect recognition by T cells. An 
immunomodulatory role of LMP2A was previously suggested by reports showing that 
the presence of LMP2A alters the expression of several genes related to immunity 
(Portis et al. 2003), and demonstrated an interference of LMP2A with signaling of type 
I/II interferon receptors (Shah et al. 2009). My data demonstrated that the presence of 
	  	  
 
Discussion 
 
  
91	  
LMP2A markedly reduced the reactivity by EBV-specific CD8+ T cells against LCLs. 
Notably, this was true for all the latent viral antigens investigated (LMP2, EBNA1, 
EBNA3A). In contrast, for the tested lytic antigens, BZLF1 and BRLF1, I could not 
identify differences in recognition by CD8+ T cells. This absence of a detectable effect 
of LMP2A on recognition of lytic antigens is due to the negative or very low baseline 
expression of these antigens in LCLs (Pudney et al. 2005; Hislop et al. 2007b), which 
means that latently WT EBV-infected B cells are unreliably or not at all recognized by 
CD8+ T cells specific for lytic-cycle antigens, as my data confirm. Thus, LMP2A is the 
first EBV latency antigen for which an in-trans interference with recognition of infected 
cells by EBV-specific CD8+ T cells has been demonstrated, independent of the identity 
of the antigen recognized. 
Interestingly, the latent antigens targeted by the CD8+ T cells analyzed in our 
experiments are processed in the infected cells by different pathways for their 
presentation: the CLG and FLY epitopes are TAP-independent epitopes, with FLY 
being immunoproteasome-dependent (Lautscham et al. 2001, 2003), while the RPP and 
HPV epitopes are TAP-dependent (Tellam et al. 2004). In addition, a reduction in 
CD8+ T cell reactivity was mediated by LMP2A in the context of different HLA 
allotypes (HLA A*0201, B*0702, B*3501 and HLA A*0201, C*0702 for the peptide-
loading experiments). By demonstrating effects of LMP2A on specific CD8+ T cell 
recognition of LCLs that were exogenously loaded with peptides derived from CMV, I 
further showed that LMP2A has immunomodulatory effects that are independent of a 
specific antigen or MHC-I allotype, and are mediated by secreted molecules and cell 
surface molecules including NKG2D ligands. 
However, LMP2A influenced antigen-specific T cell recognition at different levels. 
Besides the antigen-processing machinery, other factors can influence the successful 
presentation of an antigen, such as antigen availability and levels of MHC class I 
molecules. An effect of LMP2A on these processes was observed in our experiments, 
showing that LMP2A had a tendency to reduce mRNA expression of several EBV 
latent genes as well as MHC-I surface levels. Both aspects could be causally related, 
because an increased supply of peptides available for loading on MHC class I may 
increase the overall levels of MHC-I present at the cell surface. 
Nontheless, some of the effects of LMP2A on the EBV-infected B cell appear to 
preferentially affect particular antigens. This was suggested by my observation that 
	  	  
 
Discussion 
 
  
92	  
LMP2A differentially affected the mRNA levels of other latent-cycle antigens, and 
mRNA coding for the nuclear antigen EBNA1 was downregulated more strongly than 
other viral latency mRNAs. This is particularly interesting, because in several EBV-
associated malignancies of EBV latency II type, such as nasopharyngeal carcinoma and 
Hodgkin lymphoma, LMP2A and EBNA1 are often the only two EBV protein-coding 
genes expressed in the tumor cells (Herbst et al. 1991; Deacon et al. 1993; Bell et al. 
2006). Thus, LMP2A may interfere with presentation of EBNA1-derived peptides not 
only in the LCL model studied here, but also in latency II type tumors, which could 
have important effects on the overall visibility of these tumors for the immune system.  
I also addressed the question whether cytokines could mediate part of the effects of 
LMP2A on LCLs by CD8+ T cells. In this regard, IL-10 was an interesting candidate, 
because it is an immunomodulatory cytokine (Ng et al. 2013) that is constitutively 
produced at high levels by EBV-transformed B cells (Finke et al. 1993), and a recent 
report showed that LMP2A increased IL-10 production in Burkitt lymphoma lines 
(Incrocci et al. 2013). EBV encodes a viral homologue of human IL-10 also known as 
viral IL10 (vIL-10), which is encoded by the early lytic gene BCRF1 (Hsu et al. 1990). 
Both human and viral IL-10 have been shown to interfere with EBV immunity at 
various levels. vIL-10 was shown to reduce IFN-γ release by PBMCs after contact with 
LCLs in which the lytic cycle was artificially induced (Swaminathan et al. 1993) and to 
inhibit, when added exogenously, the control of EBV-infected B cell outgrowth by T 
cells (Bejarano & Masucci 1998). vIL-10 contributes to downregulation of the 
transporter of antigen processing 1 (TAP1) and MHC-I in the early phase of B cell 
infection (Zeidler et al. 1997), although recognition of early-infected B cells by EBV-
specific CD8+ T cells was not increased in the absence of vIL-10 (Jochum et al. 
2012a). However, the presence of vIL-10 impaired NK cell reactivity (Jochum et al. 
2012a).  
Our data showed that LCLs lacking LMP2A released lower amounts of IL-10 
compared to WT LCLs, which was not associated with reduced IL-10 mRNA levels. 
IL-10 mRNA present multiple copies of potential mRNA destabilizing motifs, and 
previous reports showed that IL-10 transcription and secretion can be widely divergent 
(Powell et al. 2000; Nemeth et al. 2005). Thus, IL-10 secretion is strongly modulated 
by post-transcriptional processes. Importantly, in my experiments I found that the 
difference in IL-10 production did not affect the reactivity of CD8+ T cell clones 
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against infected B cells, as shown by blocking and neutralizing experiments. This is 
compatible with the observation of Jochum et al. that WT EBV and vIL-10-deleted 
EBV are equally recognized by CD8+ T cells in the early phase of infection (Jochum et 
al. 2012a).  Nonetheless, my finding does not exclude an indirect influence of altered 
IL-10 secretion on T cell recognition of LCLs. Indeed, human and viral IL-10 have 
been shown to downregulate MHC-I surface expression on freshly infected B cells and 
monocytes, and to interfere with the expression of other surface molecules on 
monocytes (Zeidler et al. 1997; Salek-Ardakani et al. 2002). Therefore, LCL-secreted 
IL-10 may act back on the LCLs, reducing in a downregulation of MHC-I molecules 
observed for WT LCLs as compared to ΔLMP2A LCLs that translates later into a 
differential recognition by CD8+ T cells, although there is no direct impact of IL-10 
levels on the T cells themselves. 
CD8+ T cells recognize their targets through the specific interaction of the TCR with 
the peptide:MHC-I complex. As explained above, the intensity and quality of antigen 
recognition by CD8+ T cells depend on their interaction with costimulatory receptors 
(Greaves & Gribben 2013) and adhesion molecules (Springer & Dustin 2012) on the 
surface of the antigen-presenting cell. Thus, I analyzed the influence of LMP2A on 
surface expression of the B7 molecules PD-L1 and CD86, of the integrin CD11a and 
the adhesion molecule ICAM-1, of ligands for the receptor NKG2D, and of the SLAM 
family member CD48. 
As mentioned, the inhibitory receptor PD-1 is found on activated T cells or on virus-
specific T cells in chronic infection (Barber et al. 2006) and on EBV-specific CD8+ T 
cells during and after IM (Sauce et al. 2009; Greenough et al. 2010). Interestingly, 
surface expression of PD-L1, PD-1 ligand, is increased on LCLs and on EBV-positive 
PTLD (Kim et al. 2008; Durand-Panteix et al. 2012; Green et al. 2012). Notably, it was 
recently shown that blocking of PD-1/PD-L1 interactions could increase cytotoxic 
activity of T and NK cells against EBV-infected B cells (Durand-Panteix et al. 2012). 
PD-L1 expression may additionally mediate toxic effects to EBV-infected cells because 
it was shown that cross-linking of PD-L1 by a specific antibody induced their apoptosis 
(Kim et al. 2008). Counter-intuitively, we found PD-L1 to be downregulated in LCLs 
in the presence of LMP2A. Thus, it is very unlikely that differential PD-L1 expression 
contributed to increased T cell reactivity to ΔLMP2A LCLs. However, it would be 
interesting to investigate in the future whether PD-L1 can decrease recognition of WT 
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and ΔLMP2A LCLs. Hypothetically, because of higher PD-L1 expression in ΔLMP2A 
LCLs, blocking of PD-L1, or of PD-1 on the side of the T cell, may even increase the 
difference in reactivity of T cells against WT versus ΔLMP2A LCLs. 
As mentioned before, the receptor-ligand pair ICAM-1 and LFA-1 plays an important 
role in promoting T and B cell activation and interaction between T cell and antigen-
presenting cell (Wulfing et al. 1998; Arana et al. 2008). Our analyses showed that the 
levels of ICAM-1 were equally high on the surface of WT and ΔLMP2A LCLs, 
suggesting a similar capability of these LCL variants to interact with LFA-1 on T cells 
and thereby stabilize T cell recognition. Of interest, the expression of CD11a, the alpha 
chain of LFA-1, on LCLs itself was strongly decreased in the absence of LMP2A. 
Although LFA-1 on B cells is important for their BCR-mediated activation upon 
contact with antigen (Carrasco et al. 2004), it seems unclear whether an "inverse" 
interaction of LFA-1 on B cells and ICAM-1 on T cells could influence T cell-mediated 
recognition of EBV-infected B cells. However, in a very speculative model B-cell-
expressed LFA-1 could compete in cis or in trans for B-cell expressed ICAM-1 with 
LFA-1 expressed by effector T cells. Thus, we cannot rule out that the decreased levels 
of LFA-1 on ΔLMP2A LCLs contribute to their increased recognition by EBV-specific 
T cells.   
EBV infection was described to increased expression of NKG2D ligands (Pappworth et 
al. 2007; Kong et al. 2009; Wiesmayr et al. 2012; Chaigne-Delalande et al. 2013). Our 
analysis of the eight NKG2D ligands showed that latent EBV infection indeed induced 
the expression of three of them (MICA, MICB, ULBP4) and that induction of MICA 
and ULBP4 was further increased in the absence of LMP2A. In addition, we 
demonstrated that blocking of NKG2D on CD8+ T cells distinctly affected the 
recognition of LCLs by these effector cells. A recent study has shown that in patients 
with genetic deficiencies in the magnesium transporter MAGT1, who are particularly 
susceptible to EBV infection and EBV+ lymphomas, NKG2D plays an important role 
in the control of EBV infection by NK and CD8+ T cells (Chaigne-Delalande et al. 
2013). 
A role for NKG2D in control of EBV-associated cancer has been further illustrated in a 
mouse model of LMP1-induced cancer, which could be therapeutically targeted 
through NKG2D (Zhang et al. 2012). Targeting of the NKG2D ligand MICB by an 
EBV-encoded miRNA may decrease susceptibility of EBV-infected B cells to lysis by 
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NK cells (Nachmani et al. 2009). Thus, NKG2D ligands represent important coagonists 
for EBV-specific adaptive or innate immunity, and it appears an efficient strategy for 
the virus to decrease surface expression of NKG2D ligands through the action of 
LMP2A.  
Taken together, I describe here for the first time an immunomodulatory function of the 
EBV protein LMP2A, and show that LMP2A affects escape of infected B cells from 
recognition by CD8+ T cells. A broad range of immunoevasive mechanisms is 
mediated by LMP2A in EBV-infected B cells. Thus, it will be urgent to determine the 
role played by LMP2A in evasion from T and NK cell recognition in different types of 
EBV-associated lymphoproliferative and malignant disease. Because LMP2A decreases 
T cell recognition independent from the identity of the antigen and the MHC allotype, 
an important function of LMP2A could be to shield the spectrum of mutated cellular 
antigens in malignantly transformed cells from recognition by T cells.  
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5.3 γδ  T cells in the control of EBV infection 
In the third part of this thesis, I studied the reactivity of γδ T cells against EBV-infected 
B cells. I demonstrated that γδ T cells efficiently recognize and exert cytotoxicity 
against EBV infected cells. I found that the γδ cells mediating this effect carry a T cell 
receptor containing the Vδ1 chain. Some cells within this subpopulation could 
recognize EBV-infected B cells in an apparently EBV-specific fashion. Moreover, I 
identified one δ1+ T cell clone that specifically recognized autologous EBV-infected B 
cells in an HLA-A2-restricted manner. 
In the context of EBV infection, not much is known about the role of γδ T cells.  γδ T 
cells were shown to expand during acute infectious mononucleosis (De Paoli et al. 
1990), to proliferate after contact with LCLs (Hacker et al. 1992; Orsini et al. 1993) and 
after contact with EBV-positive Burkitt lymphoma cells (Hacker et al. 1992; Orsini et 
al. 1994; L'Faqihi et al. 1999). However, the literature gives controversial information 
regarding which population recognizes EBV-infected B cells. In some studies, the 
population showing major expansion was the δ1+ T cell population (Hacker et al. 1992; 
Orsini et al. 1993), while others reported expansion of other γδ T cell populations (De 
Paoli et al. 1990; Qvigstad et al. 1990). Various groups also reported lysis of LCLs by 
the δ1+ T cell population (Mami-Chouaib et al. 1990; Qvigstad et al. 1990; Hyjek et al. 
1997; Fujishima et al. 2007), by δ2+ T cells (Kong et al. 2009) and by polyclonal lines 
(Lam et al. 1990), or production of IFNγ after contact with LCLs in bulk short-term 
cultures (Bhaduri-McIntosh et al. 2008). It is interesting to notice that expansion of γδ 
T cells was also observed in cytotoxic lymphocyte cultures (CTL) stimulated with 
LCLs prior infusion to treat EBV-positive post-transplant lymphoproliferative diseases, 
reaching even 30% of the total culture mix (Comoli et al. 2001; Savoldo et al. 2006). In 
one of the treated patients, the CTL status was analyzed again 15 weeks after CTL 
infusion and it was observed that the γδ T cell population remained present in 
frequencies that were very close to those present in the pre-infusion CTL mix (Comoli 
et al. 2001). This evidence suggests an involvement of γδ T cells in the control of EBV 
infection. 
By stimulating freshly isolated PBMCs with LCLs, I confirmed that γδ T cells regularly 
expand in the presence of EBV-infected cells, and that both δ2+ and δ2– 
subpopulations were expanded after contact with LCLs. The δ2– subpopulation showed 
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a higher average expansion than the δ2+ subpopulation. Interestingly, there were 
differences in the expansion efficiency between different donors. For two donors the 
expansion of γδ T cells was minimal (Donor 3 and 13). In these cases, I suggest that the 
overall stimulatory reaction may be composed of a compression of irrelevant γδ T cells 
and an expansion of a subpopulation of “EBV-specific” γδ T cells. In these two cases, it 
would have been interesting to continue the analysis for a longer time frame. 
All donor analyzed were EBV-seropositive, and four out of six donors were also CMV-
seropositive. The CMV status is relevant, because CMV-seropositive donors present 
higher numbers of δ2– T cells in peripheral blood than CMV-negative donors 
(Dechanet et al. 1999; Pitard et al. 2008). However, CMV serostatus did not appear to 
influence the expansion of γδ T cells after contact with LCLs. We also compared 
stimulation efficiencies by different LCLs. PBMCs from two donors (donors 4 and 14) 
were stimulated in two separate reactions with two different allogeneic LCLs. For one 
donor, the kinetic of the expansion was similar in the two stimulatory reactions, even 
though one LCL was slightly more efficient in inducing γδ T cell expansion. For the 
second donor, instead, the expansion of γδ T cell, and especially of δ2– T cell 
population, was strongly increased in one of the two reactions. This suggests that 
heterogeneity between LCLs used for γδ T cell stimulation can strongly affect 
expansion efficiency of these effector cells, and that specific interactions between γδ T 
cells and donor-specific alloantigens on LCLs might affect the selective expansion of a 
desired γδ T cell subpopulation.  
To further investigate which γδ T cell population mediates an effector function in the 
control of EBV infection, I established γδ single T cell clones. From all donors 
examined, I could obtain δ2+ and δ2– clones, although with different efficiencies in 
different donors. From one donor almost all clones established presented a δ2+ TCR. 
From a second donor, only 13% of the established clones were δ1+ T cells, while for 
the other three donors the δ2+ and δ2– clones were present in similar proportions. It is 
noteworthy that I could also establish clones that are rarely found in peripheral blood, 
presenting a γ9δ1+ TCR or, in another case, a δ1–/δ2– TCR, which therefore expressed 
another of the available but less frequently used delta chains (Casorati et al. 1989). I 
also identified some rare clones that presented a peculiar and unexpected low affinity 
interaction with a αβTCR-specific antibody, in addition to staining with γδ-specific 
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antibodies. αβ+ T cell clones presenting a Vδ1 chain have been already identified 
(Ueno et al. 2003). However, in that case the TCR composition showed an occurred 
recombination between the Vδ1 gene segment with a Jα gene segment. In my case, 
TCR sequencing for one of these peculiar clones (clone 94, donor 1) showed the 
presence of a classic Vδ1-Jδ1 chain. All the clones analyzed, irrespective for their TCR 
composition, expressed high levels of the agonistic receptor NKG2D and expressed 
variable levels of CD56, a marker for NK cells that is also found in subpopulations of 
CD8+ T cells. In contrast, only a few clones between those analyzed showed 
expression of other NK receptors. These data confirm that stimulation of γδ+ T cells 
with LCLs is an efficient method to obtain γδ+ single cell clones, even from infrequent 
γδ subpopulations.  
Subsequently, I investigated whether these clones could mediate cytotoxicity of EBV-
infected B cells. My results demonstrated that the population performing higher and 
broader LCL cytotoxicity was the δ1+ T cell population. In contrast, δ2+ T cell clones 
showed no or low levels of cytotoxicity when challenged with LCLs. γ9δ1+ and δ1/2– 
T cell clones had variable effector activity against LCLs. Different δ1+ T cell clones 
had different specificities, as shown by their different degree of recognition of 
allogeneic or autologous LCLs. Importantly, several clones appeared to specifically 
recognize autologous LCLs, but not activated autologous CD40-activated B 
lymphoblasts, suggesting recognition of an EBV antigen or a specifically EBV-induced 
antigen. The different patterns of recognition of EBV-infected B cells by different 
clones confirm the idea that γδ+ T cells are highly heterogeneous, further supporting 
the hypothesis that this T cell population can recognize a variety of molecular targets. 
In order to obtain more precise data regarding the specificity mediated by different 
types of γδ T cell receptors, I analyzed the TCR sequences of some of the clones that 
had an effector activity against EBV-infected B cells. These data showed that, even 
though the recognition of EBV-infected cells appears to be mostly related to the 
presence of the δ1 TCR chain, the CDR3 regions of the analyzed δ1 chains are highly 
variable both in length and in their amino acid sequence. In three cases, I identified two 
clones from the same donor that had identical CDR3 regions. Generally, however, the 
variability of TCR sequences of clones from the same donor and between donors was 
high, supporting the idea that they recognize different molecular targets. High 
variability in the length, and in the amino acid and nucleotide sequence was also 
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observed in the TCRs from γδ T cells after infection with HCMV, another herpesvirus 
(Dechanet et al. 1999). The only feature that appeared more frequent in γδ T cells after 
infection with HCMV than in the absence of HCMV infection was the presence of 
phenylalanine and tryptophan, two apolar aromatic bulky residues, in positions P3 and 
P6 of the δ1 chain of the TCR (Dechanet et al. 1999). In the sequences obtained from 
EBV-specific δ1+ T cells in my work, no conserved motifs were identified, further 
supporting the idea of the recognition of different molecular targets by these cells. 
Generally, information regarding the TCR sequences for δ1+ T cells, but also for other 
γδ subpopulation, is limited, and the correlation between TCR sequence and specificity 
of the γδ T cells has rarely been investigated, most likely because only a few γδ T cell-
specific ligands have been identified so far (Chien & Konigshofer 2007). Therefore, 
these data are a good starting point for further analysis focusing on the correlation 
between TCR sequences and reactivity of γδ T cells.   
Interestingly, when further investigating the mechanism of recognition for three δ1+ T 
cell clones, I found that for all of them, the costimulatory receptor NKG2D was a 
mediator of cytotoxicity against LCLs, as shown by anti-NKG2D blocking studies. 
This is of particular interest, because in the case of the herpesvirus HCMV the receptor 
NKG2D was not involved in the recognition of HCMV-infected cells by γδ+ T cells 
(Halary et al. 2005). A possible reason for this could be that HCMV uses several 
immunoevasive strategies to downregulate the surface expression of NKG2D ligands 
during infection (Muller et al. 2010). My evidence further supports the hypothesis that 
NKG2D ligand expression on LCLs is an important factor for recognition of EBV-
infected cells by T cells of different types. 
One γδ T cell clone, which expressed the inhibitory KIR receptors KIR2DL2/3 and 
KIR3DL1, presented a high increase in its cytotoxic activity against EBV-infected B 
cells upon antibody blocking of MHC-I, the ligand of these inhibitory KIRs. These data 
support the hypothesis that γδ+ T cells expressing NK receptors can have an NK-like 
behavior (Rothenfusser et al. 2002). Moreover, these observations suggest that the co-
receptor repertoire of γδ+ T cells can strongly affect the effector functions of these 
cells, possibly much more than for αβ+ T cells. Therefore, this characteristic of γδ+ T 
cells needs to be considered when analyzing the functionality of these cells. 
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Another γδ T cell clone showed the opposite behaviour, resulting in a surprising 
decrease of the lysis of LCLs after blocking with anti-MHC-I antibody, suggesting an 
MHC-dependent mechanism of recognition of EBV-infected cells. The hypothesis of 
HLA-restricted γδ T cells is not new. Several groups investigated this hypothesis, 
especially early after the discovery of γδ T cells, but the evidence gathered to support 
or discard this hypothesis appeared to be contradictory at that time. A number of 
different reactivity patterns of γδ T cells were described. For some γδ T cells, 
alloreactive MHC-dependent activity was found (Matis et al. 1987). Some authors did 
not find classical MHC-restricted reactivity (Borst et al. 1987; Lam et al. 1990; 
Maccario et al. 1993), whereas others identified γδ T cells that recognized polymorphic 
determinants of MHC molecules (Ciccone et al. 1989; Matis et al. 1989; Flament et al. 
1994)}.  Later, when it became accepted that γδ T cells followed different rules of 
antigen recognition than αβ T cells, the hypothesis of HLA-restricted reactivity of γδ T 
cells was abandoned by most researchers, and research efforts focused on the 
identification of alternative molecules serving as molecular targets (Pardoll et al. 1987; 
Janeway et al. 1988; Constant et al. 1994). Nevertheless, the idea that some γδ T cells 
may be HLA-restricted has not been abandoned (Knutson & Disis 2002). My data show 
a possible resolution of these apparent contradictions, showing that δ1+ T cells are a 
heterogeneous group of cells with different specificities and modes of regulation. 
By testing the MHC-dependent γδ T cell clone against a panel of HLA-matched and 
mismatched LCLs, I found that recognition correlated with expression of HLA-A2 on 
the LCLs. Blocking experiments with HLA-A2-specific antibody confirmed this 
finding. Recognition of LCLs by this clone was γδ TCR-dependent, and receptor 
NKG2D was also involved in the recognition of EBV-infected B cells.  
Interestingly, when the reactivity of δ1+ T cell clones against WT LCLs was compared 
to the reactivity against LCLs lacking LMP2A, δ1+ T cells showed a decreased 
recognition of ΔLMP2A LCLs. Therefore, the presence of LMP2A in EBV-infected 
cells favors the recognition of LCLs by δ1+ T cells but hampers the recognition of the 
same cells by CD8+ T cells. This observation implies that these two subsets of effector 
cells interact differently with their target and suggests that CD8+ T cell and γδ T cell 
reactivity is triggered by different determinants and, possibly, by different coactivators. 
In addition, it underlines the balance that is established between the need by EBV to 
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evolve escape mechanisms to hide from immune recognition and the need by the host 
to develop efficient strategies for the control of EBV infection. 
Taken together, these results show that δ1+ T cells represent the γδ T cell 
subpopulation mediating an immune response against EBV and that different γδ T cells 
have different anti-viral properties. Moreover, we identified a clone that specifically 
recognizes EBV-infected B cells in an HLA-restricted manner. 
There have been many hints in the literature that γδ T cells are involved in recognition 
of EBV-infected cells. However, it has remained unclear and controversial which types 
of γδ T cells are involved in EBV-specific recognition, and which receptors and 
mechanisms are responsible for it. The results of my analyses do not comprehensively 
answer these questions, but they clearly show that specific interaction of γδ T cells and 
EBV-infected B cells takes place, and leads to killing of EBV-infected B cells. Thus, it 
is likely that γδ T cells have a role in control of EBV in vivo. My findings provide a 
solid starting point for more intense investigations of this question in the future, and 
indicate which lines of research will be most promising.  
My use of a large panel of single-cell clones has allowed me to clearly distinguish the 
reactivity of different types of γδ T cells. First, I showed that certain δ1+ T cells 
specifically recognize EBV-infected lymphoblastoid cells, whereas such recognition 
was never found for δ2+ T cells, the major γδ T cell population in peripheral blood.  
Thus, if δ2+ T cells are sometimes found to be expanded in the presence of EBV in 
vitro or in vivo (De Paoli et al. 1990; Kong et al. 2009), my results suggest that this is 
unlikely to be driven by direct recognition of EBV+ lymphoblastoid cells. Second, I 
found that only specific subsets of δ1+ T cells recognize EBV-infected B cells from the 
autologous host, while sparing EBV-negative or allogeneic B cells, and I identified 
examples of specific δ1+ TCR sequences that are involved in this recognition. Thus, γδ 
T cells with these or closely related TCRs should be specifically studied in a larger 
panel of healthy donors and patients. Third, I confirmed the earlier finding that certain 
γδ T cells specifically react with certain allogeneic B cells. It will be very important for 
future immunotherapeutic applications of γδ T cells, for example after stem cell 
transplantation (Scheper et al. 2013), that potentially protective and potentially 
pathogenic γδ T cells are precisely distinguished and separately analyzed. Fourth, I 
identified an example of an EBV-specific δ1+ T cell that only recognized HLA-A2-
positive EBV-infected targets, and is most likely an HLA-restricted γδ T cell. This 
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refutes the notion that γδ T cells can never be HLA-restricted (Lam et al. 1990; 
Maccario et al. 1993). HLA-restricted γδ T cells may be a very important antiviral 
effector population, and should be more intensely investigated in the future. Although 
γδ T cells are sometimes considered to be "innate-like" immune effectors due to the 
supposedly small diversity of their T cell receptor repertoire, my data clearly argue that 
γδ TCRs are highly diverse, and that apparently subtle differences in their TCR primary 
structure lead to distinctly different reactivities. Although some γδ T cells show a 
pattern of reactivity reminiscent of natural killer cells, there are good arguments to 
consider γδ T cells part of the adaptive immune system, at least the δ1+ subset. The 
exact principles that guide their antiviral activity, and their potential in 
immunotherapeutic application, remain to be fully explored in the future.  
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6 Abbreviations 
α- anti-, antibody specific for 
Akt protein kinase B 
Allo allogeneic 
ALP alkaline phosphatase 
AM acetoxymethylester  
APC Antigen-presenting cell 
APC allophycocyanin 
ATP adenosine triphosphate 
Auto autologous 
β2m β2-microglobulin 
B7-H1 B7 homolog 1 
BCR B-cell receptor 
BV421 brillant violet 421 
CD cluster of differentiation 
cDNA complementary DNA 
CDR complementarity-determining region 
CML chronic myeloid leukemia 
conc concentration 
CTL cytotoxic T lymphocyte 
CTLA-4 cytotoxic T-lymphocyte antigen 4 
D donor 
DNA deoxyribonucleic acid 
DC dendritic cell 
ΔLMP2A LMP2A deleted 
DMEM Dulbecco’s modified Eagle Medium (cell culture medium) 
DMSO dimethyl sulfoxide  
dNTP deoxynucleotide triphosphate 
EBNA Epstein-Barr nuclear antigen 
EBV Epstein-Barr virus 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
ER endoplasmic reticulum 
ERAPs ER aminopeptidases  
ERK extracellular-signal-regulated kinase 
FACS fluorescence-activated cell sorting 
FCS fetal calf serum  
FITC fluorescein isothiocyanate 
FSC forward scatter 
gp glycoprotein 
GUSB β-glucuronidase  
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GvHD graft versus host disease 
HCMV human cytomegalovirus 
HEK human embryonic kidney 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HMBPP hydromethyl-but-2-enyl-pyrophosphate  
HSCT hematopoietic stem cell transplantation 
HSV herpes simplex virus 
ICAM-1 intracellular adhesion molecule 1 
ICOS inducible costimulator 
ICOS-L inducible costimulator ligand 
IE-1 immediate early protein 1 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
IM infecious mononucleosis 
IPP isopentenyl pyrophosphate  
iso isotype control 
ITAM immunpreceptor tyrosine-based activation motif 
kDa kilodalton 
KIR killer cell immunoglobulin-like receptor 
KLR killer C-type lectin-like receptors  
L ligand 
LCL lymphoblastoid cell line 
LEAF low-endotoxin, azide-free 
LFA-1 lymphocyte function-associated antigen 1 
LIR/ILT receptor of the leucocytes immunoglobulin-like receptor/immunoglobulin-like transcript family 
LMP latent membrane protein 
MAGT magnesium transporter 
MAPK mitogen-activated protein kinase 
MEP methylerythritol 4-phosphate  
MFI mean fluorescence intensity 
MHC major histocompatibility complex 
MHC-I MHC class I 
MHC-II MHC class II 
MIC MHC class-I polypeptide-related sequence 
mMFI multiplicity of mean fluorescence intensity 
mRNA messenger RNA 
NCAM neural cell adhesion molecule 
NCR natural cytotoxicity receptor 
nd not determined 
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells 
NK natural killer 
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NKG2A natural killer group 2 A 
NKG2D natural killer group 2 D 
No Ab no antibody 
Not Inf not infected 
Opti-
MEM 
reduced serum media Eagle’s Minimum Essential Medim 
(cell culture medium) 
PB pacific blue 
PBMCs peripheral blood mononuclear cells 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
pΔ packaging cell line 
PD-1 programmed death-1 
PD-L1 programmed death-ligand 1 
PE phycoerythrin 
PE-Cy5 phycoerythrin-cyanine 5 
PEI polyethyleneimine 
pep peptide 
PerCP peridinin chlorophyll 
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase 
pNPP para-nitrophenyl phosphate  
PRRs pattern recognition receptors 
PTLD post-transplant lymphoproliferative disease 
R receptor 
RNA ribonucleic acid 
RPMI Roswell Park Memorial Institute (cell culture medium) 
RT-PCR real time PCR 
SAP Signaling lympocytic activation molecule-associated protein 
SEM standard error of the mean 
SLAM signaling lymphocyte activation molecule 
SSC side scatter 
TAE Tris, acetate, EDTA 
TAP transporter associated with antigen processing 
TCR T-cell receptor 
TGF trasforming growth factor 
TLR toll-like receptor 
TNF tumor necrosis factor 
TR terminal repeats 
ULBP UL-16-binding protein 
UV ultraviolet 
v viral 
VCA virus capsid antigen 
WT wild type 
XLP X-linked lymphoproliferative disease  
∅t no target 
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